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           Abstract  
Ras proteins are small GTP binding and hydrolysing proteins (GTPases) that 
regulate various signalling pathways responsible for cell proliferation, 
differentiation, migration and survival. Ras proteins are found to be mutated in 
30% of all human cancers. Mutations in Ras or their regulators such as GTPase 
activating proteins (GAPs) or guanine nucleotide exchange factors (GEFs) 
render Ras proteins to be in persistently active GTP bound state leading to 
uncontrolled cell growth and proliferation.  
Despite three decades of extensive research, no pharmacological inhibitors of 
Ras have reached the market. Targeting Ras proteins directly has been 
challenging process because of lack of deep binding pockets for small 
molecules to bind to with high affinity and specificity. A novel approach of using 
non-antibody scaffolds for development of Ras inhibitors has shown great 
promise. This is being illustrated by recent increase in antibody mimetics 
targeting Ras such as Intrabodies, Monobodies and DARPins. In this thesis the 
Affimer, a novel binding protein based on a consensus cystatin scaffold has 
been used to inhibit KRas, which is most mutated Ras isoform. 
The project aims to identify Affimers that are potent inhibitors of KRas function. 
Three KRas binding Affimers have been identified via phage display that have 
shown to inhibit KRas activity by inhibiting nucleotide exchange activity.  Out of 
three Affimers, Affimer K3 was identified to exhibit dual mode of inhibition i.e. 
inhibit nucleotide exchange as well as Ras-Raf interaction. To further 
understand the binding and inhibition of KRas by K3 Affimer, pulldown assays 
and nucleotide exchange assays identified that both variable regions of Affimer 
K3 are important for binding and inhibition of KRas. Furthermore, molecular 
details of Affimer K3 in complex with KRas revealed a novel Ras conformation 
with generation of pocket between Switch II and α3 helix. The pocket created 
by hydrophobic interactions is stabilised by the W44 indole side chain of K3, 
orienting itself to form hydrogen bonds with H95 present in α-3 helix. Mutation 
of KRas specific residue H95 has shown preferential specificity of Affimer K3 
towards KRas, as compared to HRas and NRas. The work presented in this 
thesis shows Affimer K3 can be used as valuable tool to study KRas function 
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Chapter 1                      
                                             Introduction 
 
1.1 A brief history, classification and post translational modifications of 
Ras GTPases  
 
1.1.1 The discovery of Ras  
RAS genes were identified from the studies of “tumour-inducing” retroviruses 
isolated from rats, cats, cows and other animals (Harvey., 1964; Kirsten and 
Mayer., 1967) (Coffin et al., 1997). Early research dates back to the 1900s when 
Peyton Rous discovered transmissible leukaemia and solid tumours in chickens 
(Rous., 1911). In the mid-1960s, Jennifer Harvey and Werner Kirsten isolated 
two viruses – Harvey murine sarcoma virus and Kirsten murine sarcoma virus 
that induced tumours in rats (Harvey., 1964; Kirsten and Mayer., 1967). Further 
studies on these cancer-causing viruses were carried out by Scolnick and 
colleagues in 1973, which led to the identification of genetic elements 
responsible for oncogenic transformation. These were then referred to as SRC 
oncogenes (Scolnick et al., 1973). Now these are known as RAS oncogenes 
due to the ability of these retroviruses to cause rat sarcomas (RAS), which is 
an acronym for the current gene name RAS. Due to difference in transforming 
properties of RAS retroviruses, discoverers' names were used to distinguish 
each of them: Harvey (HRAS) and Kirsten (KRAS) viral RAS genes (Malumbres 
and Barbacid., 2003; Cox and Der., 2010) . In 1981 using the DNA transfection 
technique established by Weinberg (Krontiris and Cooper, 1981), Krontiris and 
Cooper isolated DNA from two bladder cancer cell lines and observed 
transforming activity in NIH 3T3 mouse cell lines (Shih et al., 1979; Der et al., 
1982). Following this, three groups in 1982 discovered that transforming genes 
identified in NIH 3T3 cell lines were similar to Harvey and Kirsten sarcoma 
viruses. Additionally, they found that the mechanism of Ras oncogene 
activation was due to single base missense mutation at residue 12 and less 
frequently at residue 13 and 61 (Reddy et al., 1982; Tabin et al., 1982; Capon 
et al., 1983) (Mageean., 2014). By 1983, a third transforming human RAS gene, 
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was discovered in neuroblastoma cells and was reported to have weak DNA 
sequence homology to HRAS and KRAS and was designated as NRAS 
(Shimizu et al., 1983). It was also found to be structurally related to HRas and 
KRas. The following section (Section 1) covers Ras superfamily of GTPases, 
including Ras synthesis, processing, and maturation. Section 2 covers the 
biochemistry of Ras signalling, including the mechanism of GTPase activation 
and elaborate on the role of Ras in cancer. 
 
  1.1.2 Ras superfamily of small GTPases 
           More than 150 members of Ras-related small Guanosine Triphosphatases 
(GTPases) have been identified in the cell so far, which share a conserved 
protein structure and function. GTPases function as binary molecular switches 
that get activated by binding to GTP and deactivated by hydrolysis of GTP to 
GDP (Wennerberg et al., 2005). The Ras superfamily of proteins can be 
classified into five major subfamilies based on their sequence and functional 






                              
 
Figure 1.1 Ras superfamily of small GTPases. Ras superfamily consists of 
five significant subfamilies of GTPases that perform a wide variety of cellular 
functions. These include Ras, Rho, Rab, Ran, and Arf. Best characterised and 
studied proteins in each subfamily have been mentioned along with their role in 
maintaining essential functions in the cell.  
 
 
All these families have a common core structure, a G domain, which comprises 
five alpha-helices (α1-α5) and six beta sheets (β1-β6) (Heider et al., 2010). The 
G domain’s basic structure consists of five highly conserved G motifs (G1-G5) 
(Figure 1.2). The G1 motif (GxxxxGKS/T) encodes the phosphate-binding loop 
(P-loop). The G2 motif (xTx) contains an invariant threonine residue that 
mediates hydrogen bonding interactions with the γ phosphate of GTP and 
coordinates with Mg2+ ion in the GTP-bound state. The G3 motif (DxxG) 
consists of invariant aspartic acid and glycine residues that stabilise Mg2+ 
binding and hydrogen bonding with γ phosphate. Finally, the G4 (N/TKxD) and 
G5 (xAx) motifs contain residues important for guanine nucleotide-binding 





Figure 1.2 Schematic representation of functional domains in Ras 
structure. A. Blue coloured boxes indicate regions participating in GTP and 
effector binding as represented by G motifs core effector domains. Switch I and 
switch II regions and membrane targeting CAAX (yellow) motif for post-
translational modifications are also shown. B. The regions indicated in A are 
highlighted on KRas structure (PDB: 4OBE). This KRas structure lacks the C 
terminal CAAX motif. GDP is coloured as per elements present, magnesium in 
yellow, the switch I and switch II regions are highlighted in yellow and red, 
respectively. Images were generated in PyMOL. 
 
           1.1.2.1 Ras protein subfamily (36 members) 
 
Ras subfamily members show high conservation within G1, G3, G4, and G5 
motifs. Ras subfamily contains 36 genes that encode 39 Ras proteins (20-29 
kDa) in the human genome (Colicelli., 2004; Karnoub and Weinberg., 
2008).The key members of the family include HRAS, KRAS, NRAS, Related 
Ras viral oncogene homolog (RRAS), Rap GTP binding protein (RAP), Ras-
related protein (RAL), Ras homolog enriched in brain (RHEB) and Ras-like 
protein in tissues (RIT). The functional differences between these members are 
mostly quantitative in effector protein engagement and post-translational 
modifications. Ras proteins (HRas, KRas, and NRas)   have been subjected to 
intense research scrutiny because of their crucial role in human cancers 
(Wennerberg et al., 2005). Ras proteins are membrane-bound intracellular 
GTPases activated in response to extracellular ligands that bind to cell surface 
receptors (Details in section 2.1) (Repasky et al., 2004). The most 
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characterised cell surface receptors involved in activation of Ras protein are 
epidermal growth factor receptor (EGFR), and G protein-coupled receptors 
(GPCR). 
1.1.2.2 Rho protein subfamily (23 members) 
 
The Ras homologous (Rho) subfamily of proteins is closely related to the Ras 
subfamily. The members of this subfamily show vital conservation among their 
G1-G5 motif. However, most members of this subfamily have insert sequences 
that are not found in any other Ras superfamily (Colicelli., 2004). Out of 23 
members identified Rho A, Ras-related C3 botulinum toxin substrate 1 (Rac1), 
and cell division control 42 (CDC42) proteins are the most studied. The role of 
Rho A, Rac1, and Cdc42 in maintaining the assembly of filamentous actins has 
been verified in animal models such as yeast, flies, and worms. Rho GTPases, 
besides playing a crucial role in the actin cytoskeleton, are involved in the 
regulation of cell polarity, vesicular transport, cell cycle progression, 
microtubule dynamics, and membrane transport pathways (Etienne-
Manneville and Hall., 2002). 
1.1.2.3 Rab and Ran protein subfamily (71 members) 
 
 Ras-like proteins in the brain (Rab) subfamily comprises of the largest branch 
of the Ras superfamily with 61 members. The majority of Rab GTPases are 
products of gene duplications since many Rab GTPases have 75-95% 
sequence similarity with overlapping functions with variation in the carboxy-
terminal end, which plays a vital role in subcellular targeting (Stenmark and 
Olkkonen., 2001). Rab GTPases are involved in the controlling all aspects of 
intracellular vesicular transport and trafficking of proteins between different 
organelles using endocytic and secretory pathways. They also facilitate vesicle 
formation, movement, and fusion. For example, Rab1 is located in the 
membrane compartment of the endoplasmic reticulum (ER) and Golgi 
apparatus. It is involved in biosynthesis/transport of proteins and lipids between 
ER and Golgi apparatus (Zerial and McBride., 2001).  
Ras-like nuclear protein (Ran) is the most abundant small GTPase in the cell. 
Like other GTPases, which act as molecular switch activated Ran GTP is 
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present in high concentration in the nucleus due to the concentration gradient 
created due to specific location of Ran regulators within the cell. This 
concentration gradient created by Ran GTPases helps regulate the nuclear 
import and export of RNA and proteins. Besides regulating nucleocytoplasmic 
transport, Ran GTPases are also involved in the formation of nuclear envelop 
around chromatin after mitosis is finished (Quimby and Dasso., 2003). 
1.1.2.4 Arf protein subfamily (30 members) 
 
Similar in function to Rab proteins, the ADP ribosylation factor (Arf) subfamily 
of proteins is regulators of the trafficking of intracellular proteins. For example, 
Arf1 regulates the assembly of vesicle coat proteins like coat protein complex I 
(COP1) and clathrin-coated vesicles. These coat proteins help in the precise 
sorting of lipids and proteins between cisternae of the Golgi apparatus and the 
recruitment of proteins to membranes (Memon., 2004).  
           1.1.3 Ras synthesis, processing, and maturation 
Ras proteins are synthesised in the cytosol by polysomes as globular 
hydrophilic proteins. Ras proteins are subjected to series of post-translational 
modifications (PTM) to enable them to associate with cell membranes, a key 
feature required for their biological activity (Willumsen et al., 1984; Ahearn, I. et 
al., 2018  ). This PTM takes place at the C terminal region of Ras and ends with 
a CAAX sequence where C is cysteine, and A is usually aliphatic, and X is any 
amino acid (Figure 1.3). The CAAX motif undergoes sequential modification by 
three enzymes. The unmodified CAAX motif serves as a substrate for 
prenylation by one of the two cytosolic prenyltransferases, farnesyltransferase 
(FTase) or geranylgeranyltransferase I (GGTase) (Ahearn, I.M. et al., 2011). 
These enzymes add a 15 or 20 carbon polyisoprene lipid to the sulfhydryl group 
of the cysteine. If the amino acid in the X position of CAAX sequence is a serine 
or methionine as in the case of all Ras proteins, then the protein is the primary 
substrate for FTase. If the X position is replaced by L, then they are modified 
by GGTase (Ahearn, I. et al., 2018). After farnesylation modified Ras proteins, 
accumulate on the cytoplasmic face of the endoplasmic reticulum. The modified 
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Ras proteins are then processed by an enzyme called Ras converting enzyme 
  
Figure 1.3 Ras plasma membrane targeting via post-translational 
modifications. Firstly, all Ras isoforms are farnesylated at cysteine residue of 
the CAAX motif with the help of farnesyl transferase, following which CAAX 
protease cleaves the terminal AAX peptide. The final step is the CAAX 
processing involves enzyme ICMT which methyl esterifies α carboxyl group 
(Dharmaiah et al., 2016). Finally, all Ras isoforms except KRas4B are 
palmitoylated at cysteine residue close to the carboxyl-terminal end. KRas4B 
isoform associates itself with the plasma membrane via electrostatic 
interactions due to a cluster of positively charged lysine residues (Hancock et 
al., 1990; Haza., 2019).Image was generated in Biorender.com. 
 
(RCE-I), an endopeptidase that removes AAX amino acids converting 
prenylcysteine into new C terminus (Figure 1.3) (Ahearn,et al., 2011). C 
terminal prenylcysteines then become substrates for final CAAX processing 
enzyme isoprenyl cysteine methyltransferase (ICMT). It methyl esterifies the α 
carboxyl group, thereby neutralising the negative charge at C terminus. The 
end result of CAAX processing is to remodel the hydrophilic C terminus and 
render it into hydrophobic one so that it has an affinity for membranes (Ahearn,  
et al., 2011).  
While these CAAX modifications are necessary to render a hydrophobic C 
terminal end, they would not lead to the stable binding of Ras to the plasma 
membrane since they require a membrane-targeting signal adjacent to the 
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CAAX motif (Bar-Sagi., 2001). In HRas, NRas, and KRas4A, the signals involve 
palmitoylation, once or twice, at cysteine residues upstream of the CAAX motif 
by Ras palmitoyltransferase. However, in the case of KRas4B, the polybasic 
lysine domain enables it to interact with anionic phospholipids to support 
membrane association electrostatically. This property allows KRas4B to forgo 
palmitoylation and bypass the Golgi to reach the plasma membrane (Mageean., 
2014; Silvius et al., 2006). The prenyl binding protein phosphodiesterase-δ 
(PDEδ) has shown to be specific to KRas4B isoform and binds to prenylated 
hyper variable region, thereby preventing the binding to endomembranes, 
which in turn enhances the distribution throughout the cell membranes 





















2.1 Ras signalling: Mechanism of GTPase activation and regulation 
 
    2.1.1 Ras regulated signalling pathways 
Once Ras stably associates to the plasma membrane, it can activate more than 
20 signalling pathways (Chavan et al., 2015). Mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway is one of the 
major signalling pathways that play a central role in cell proliferation, cell 
differentiation, and apoptosis (Figure 1.4). It is activated by growth factors, 
hormones, and cytokines binding to cell surface receptors, resulting in auto-
phosphorylation of receptor tyrosine kinases (RTKs) (Schulze et al., 2005). 
Phosphorylated tyrosine kinases provide a platform for the recruitment of 
adaptor proteins such as growth factor receptor binding 2 (GRB2), which is best 
known to link EGFR tyrosine kinases to activation of Ras and downstream 
targets. GRB2 consists of Src-homology 2 (SH2) domains flanked by two Src 
homology 3 (SH3) domains (Zarich et al., 2006). The SH2 domain interacts with 
phosphotyrosine containing motifs on the receptors, and the SH3 domains 
interact with proline-rich regions of the guanine nucleotide exchange factor 
(GEF) son of sevenless (SOS). GEFs catalyse the release of GDP and GTP-
loading, which is the rate-limiting step in Ras activation. GTP-bound Ras 
recruits Raf to the plasma membrane and enables it to phosphorylate its 
substrates Mek1 and Mek2 (Kern et al., 2011). These dual-specificity kinases 
subsequently activate extracellular signal-regulated kinases (ERK-1/2), 
enabling them to phosphorylate a wide variety of substrates that execute 
processes related to cell cycle progression, differentiation, protein translation 
and apoptosis (Cseh et al., 2014).  
 
Ras also displays a high affinity with a wide range of effectors, which are 
involved in regulating a variety of cellular processes (Figure 1.4) (Ponting and 
Benjamin., 1996). Ras proteins primarily bind to effectors via residues 32-41, 
which are present in the switch I region. Ras effector proteins are characterised 
by the putative Ras binding domain (RBD) (Rajalingam et al., 2007). Ras 
interacts with RBD and forms Ras-RBD complexes through complementary 
charge interactions. Currently, there are more than ten different Ras effectors 
10 
 
(Rajalingam et al., 2007). Apart from Raf, PI3K, RalGDS, and p120GAP, the 
growing family of Ras effector proteins includes Rin1, Team, Af6, Nore1, PLCε, 
and PKCζ. 
          
Figure 1.4 Ras regulated signaling pathways. Cartoon depicting an overview 
of significant Ras regulated signalling pathways. Active Ras (membrane and 
GTP bound) stimulates a network of downstream signalling pathways with 
MAPK and PI3K signalling pathways being the two best-characterised 
pathways. The first Ras effector pathway to be characterized is the Ras-Raf-
MAPK pathway (green). Ras becomes activated when ligands (growth factors, 
hormones, etc.)  bind to RTKs with the help of adaptor proteins (GRB2) and 
GEFs (SOS1) (Dhillon et al., 2007). Activated Ras binds to the Raf family of 
serine/threonine kinases (ARaf, BRaf, CRaf), by recruiting to the plasma 
membrane. Active Raf then phosphorylates MEK1/2, which in turn, activates 
ERK1/2 (Roberts and Der, 2007; Wortzel and Seger, 2011). Activated ERK 
phosphorylates several cytoplasmic (RSK) and nuclear (Fos, Jun) substrates 
including regulatory and transcription factors (ELK1) which in turn activate a 
variety of cellular processes such as cell growth, differentiation and apoptosis 
(Wortzel and Seger, 2011). Scaffold proteins such as kinase suppressor of Ras 
(KSR) play an essential role in the spatiotemporal regulation of the MAPK 
pathway by recruiting the kinases MEK and ERK to Raf (Nguyen et al., 2002). 
Ras effector family is PI3K signalling pathway (blue), which have essential 
cellular functions such as cell survival, cell growth and migration. Active PI3K  
catalyze the conversion of phosphatidylinositol 4.5 bisphosphate (PIP2) into 
phosphatidylinositol 3,4.5 trisphosphate (PIP3). PIP3 binds to Akt protein 
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(Figure 1.4 legend continued) stimulating its kinase activity, resulting in 
phosphorylation of proteins involved in cell cycle entry and cell survival 
(Hemmings and Restuccia., 2012). Other Ras effector pathways include 
RalGDS, Rho and TIAM1 play an essential role in cytoskeleton reorganisation 
and cell migration. Image was generated in Biorender.com. 
 
 
2.1.2 Mechanism of Ras GTPase activation 
Ras becomes activated when GDP-GTP exchange occurs, causing a 
conformational change in Ras that is critical to its function as a molecular switch 
in signalling pathways (Milburn et al., 1990). The comparison of the GDP- and 
GTP-bound structures of Ras has identified two nucleotide sensitive regions 
referred to Ras switch I (residues 30-40) and switch II (residues 60-76) regions 
(Figure 1.5). In case of  GTP bound Ras, the active site Mg2+  coordinates with 
β and γ phosphates of GTP and side chains of switch I residues T35 and S17 
(Hall et al., 2002). The residues in the switch I particularly T35 and G60 in switch 
II are involved in stabilization of Mg2+ bound GTP and form hydrogen bonds 
with γ phosphate in the active state (Figure 1.5) (Rudack et al., 2012b). Upon 
GTP hydrolysis, γ phosphate is released and the residues within switch I and 











                                      
   
 
Figure 1.5 Ras GTPase activation. Switch I and switch II regions are coloured 
red and blue respectively, the side chain residues that undergo large 
conformational changes as shown in stick representation. Ras GDP (PDB: 
4OBE) is activated when GEFs like SOS1, Ras GRP is involved in GDP 
release. When GTP binds to Ras (PDB: 6GOD), residues Y32, T35 of switch I 
(blue) forms hydrogen bonds with γ phosphate of GTP and G60 of switch II 
(red) resulting in activation of a molecular switch. Ras-GTP is inactivated by 
GTP hydrolysis stimulated by GAP proteins (NF1, p120GAP) and return into an 
inactive state as represented by open conformation of KRas-GDP. Images were 
generated via PyMOL. 
 
2.1.3 Guanine nucleotide exchange factors and GTPase activating 
proteins 
Even though Ras proteins possess intrinsic GTPase activity, the function of Ras 
to act as a molecular switch is highly regulated by the coordinated action of 
GEFs and GAPs (Rajalingam et al., 2007). Due to tenfold higher cellular 
concentration of GTP over GDP, GEFs promote the formation of GTP-Ras 
complex (Hall et al., 2002). Ras GEFs like SOS1 and 2 have a CDC25 
homology domain which is specific to Ras followed by Ras exchange motif 
(REM). They are flanked at N terminal with histone binding domain and DH-PH 
motif at C terminal with a proline-rich region  (Figure 1.6 A) (Boriack-Sjodin et 
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al., 1998) (Bos et al., 2007). These flanking domains are involved in the 
activation of GEF by upstream signals. The catalytic domains of GEFs are 
structurally unrelated, yet they all utilise similar principle to modify the 
nucleotide-binding pocket, to facilitate the release of GDP. For example, 
CDC25 domain of SOS covers a large area in the switch II region of Ras. It 
uses α helical hairpin to perturb the interactions between the phosphate groups 
of the nucleotide and the magnesium ion in the nucleotide-binding pocket, this 
allows the GDP to be released and GTP to bind to the pocket (Figure 1.6 B) 
(Boriack-Sjodin et al., 1998).  
 
Since the intrinsic GTP hydrolysis reaction of Ras is prolonged, Ras GAPs can 
accelerate the intrinsic GTPase activity of Ras by several orders of magnitude. 
For example, p120GAP inserts a catalytic arginine residue (called the arginine 
finger) into Ras nucleotide-binding pocket. It alters the position of Q61, thereby 
stabilising its position and neutralising negative charge at γ phosphate (Figure 
1.6 C). Following which Q61 positions the water molecule for a nucleophilic 
attack where GTP is cleaved into GDP and Pi. This mechanism of catalysis of 
GAP induced GTP hydrolysis is being supported by biophysical studies (Bos et 
al., 2007; Resat et al., 2001; Maertens and Cichowski, 2014; Rudack et al., 
2012a).Due to low intrinsic guanine nucleotide exchange and GTP hydrolysis 
activities, Ras signalling is ordinarily transient. Therefore prolonged Ras 
signalling due to Ras mutations, inactivation of GAPs or aberrant GEF 
















Figure 1.6 Functional domains and structural analysis of SOS1 and 
p120GAP. A. Domain structures of SOS1 and p120GAP. SOS1 contains Rem 
domain (green) and Cdc25 homolog domains (grey) that includes helical hairpin 
motif (HH; blue). Created with Biorender.com B. Binding of Ras (green) to the 
allosteric site of SOS results in the activation of SOS through the coordinated 
rotation of the helical hairpin (blue) and the Rem domain (cyan). The figure 
shows the structures of uncomplexed SOS (PDB: 2II0) and Ras-bound SOS 
(PDB: 2IJE) - adapted from Kuriyan et al., 2006. C. This figure illustrates native 
Ras (cyan) in complex with GAP poised for catalytic reaction (PDB: 1WQ1). 
The arginine finger (R789) is highlighted in red. Q61 (green) of Ras forms a 
hydrogen bond to R789. G12 residue located just below the arginine finger, 
when it becomes mutated, it prevents hydrolysis through a steric clash 















2.1.4 Isoform-specific Ras signalling 
The four Ras isoforms have a high degree of sequence homology in the G 
domain (~80%), with most of the variation being observed in hypervariable 
regions in C terminal end. Despite having a usual cohort of regulators and 
effectors, Ras isoforms have different mutation frequencies and display a bias 
towards certain cancers. This suggests isoform-specific function (Hood et al., 
2019). One of the primary reasons for the isoform-specific function is thought to 
lie in different trafficking and subcellular localisation of Ras isoforms. The 
hypervariable regions in Ras are post-translationally modified to facilitate 
membrane binding and correct trafficking (Aran and Prior., 2013). Each isoform 
has a distinct set of modifications and targeting motifs that result in overlapping 
but distinctive localisations (Aran and Prior., 2013). Another reason for isoform-
specific signalling is due to the specific orientation of G domain (residues 1-166) 
of Ras upon binding to GTP with respect to membranes (Newlaczyl et al., 2014). 
The differences in presentation of effector binding region due to this reorientation 
vary between different isoforms, and Ras effectors such as Raf and PI3K are 
sensitive to this change. Raf binding is favoured by conformation adopted by 
KRas, while PI3K favours the conformation adopted by HRas (Newlaczyl et al., 
2014). Additional factors such as relative expression differences of the different 
Ras isoforms will influence competition for effector and regulator binding, which 
will result in variations in signalling responses (Johnson et al., 2017). For 
example, the KRAS gene is poorly expressed as compared to HRAS due to a 
higher presence of rare codons. Rare codons can stall protein translation and 
conversion of rare codons to common codons can result in increased KRas 
expression. But since high Ras expression can lead to cellular senescence, it 
was proposed that rare codons in KRas due to codon bias limit the expression of 










3.1 Role of Ras in cancer  
 
Cancer is characterised by the uncontrolled division of abnormal cells due to 
loss of cellular regulation in the body. In most cases, cancers arise due to 
genetic damage caused by exposure to carcinogens such as tobacco smoke, 
UV radiation and certain chemicals (Carney., 1990; Chia et al., 1991). Mutations 
in two broad segments of genes: proto-oncogenes and tumour suppressor 
genes have been implicated in the early onset of cancer. Proto-oncogenes are 
normal genes involved in cell replication, growth and survival, which when 
altered due to mutations become oncogenes and resulting in hyperactive 
proteins involved in growth promotion. (Hanahan and Weinberg., 2000; 
Hanahan and Weinberg., 2011). Tumour suppressor genes monitor DNA 
damage and help in repairing damage to DNA before the cell divides. They 
prevent the expression of genes required for progression to S phase of the cell 
cycle. Mutations in these genes can result in uncontrolled cell growth.  
 
Ras proteins are encoded by proto-oncogenes that are frequently mutated in 
human cancers, with an average mutation incidence of 25% in all human 
cancers (Hobbs et al., 2016; Hobbs and Der., 2019). Mutant Ras proteins 
promote growth factor independent cell cycle entry. Ras proteins are involved 
in the regulation of various phases in the cell cycle, especially the G1 phase. 
Cyclin D1, cyclin-dependent kinase 4 (CDK4), p16 and tumour suppressor Rb 
are G1 phase regulatory proteins that have shown high expression due to HRas 
mutation. Cells harbouring oncogenic Ras and Rb can proliferate in the 
absence of mitogen and loss of cyclin-dependent kinase inhibitors like p16 and 
p21 makes them anchorage-independent and avoid contact inhibition creating 
a favourable environment for Ras-mediated tumorigenesis (Sathyan et al., 








3.1.1 Incidence and spectrum of Ras mutations in cancer 
Mutational damage in tumour cells results in aberrant Ras signalling. The most 
obvious of these are activating point mutations in Ras, GAP deletion, growth 
factor receptor activation and mutation and amplification of Ras effectors 
(Hobbs et al., 2016).  The highest incidence of aberrant Ras signalling is due 
to single base missense mutations mostly occurring at codon 12, 13 and 61 
(Figure 1.7 A). These mutations all impair GAP-induced GTP  hydrolysis activity 
of Ras and therefore causing Ras to be in a permanent active GTP bound state 
(Prior et al., 2012). 
 
Out of 3 Ras proto-oncogenes, the KRas isoform is most mutated in human 
cancers. As per Catalog of Somatic Mutations in Cancer analysed, KRas is 
mutated in 75% of all human tumours analysed compared to 17% with NRas 
mutations and 7% with HRas (Prior et al., 2020). Mutations in KRas are found 
in 90% of pancreas, 35% of lung and 45% of colorectal cancers. But in the case 
of skin cancer NRas is mutated in 18% of all tumours analysed compared to 
6% with HRas and 3% with KRas (Tate et al., 2019). These patterns suggest 
that certain Ras mutations are more prevalent in particular cancer types. In 
support of this concept, experiments using genetically engineered mice showed 
that oncogenic KRasG12D promoted stem cell expansion and helped initiate 
tumours in the colon, but NRasG12D did not promote proliferation and confer 
resistance to apoptosis. This indicates phenotypic differences between Ras 
isoform mutants (Haigis et al., 2008). Similar to the isoform bias observed in 
certain specific cancers, there is a preference of each isoform for certain codon 
mutations. For example, 80% of KRas mutations occur at codon 12, and 60% 
of NRas mutations occur at codon 61. HRas mutations are split between 50% 
and 40% for codon 12 and 61, respectively (Figure 1.7 B) (Prior et al., 2012). 
In addition to isoform and codon specificity, Ras mutations have shown tissue-
specific preferences. For example, in pancreatic ductal adenocarcinoma 
(PDAC) and colorectal carcinomas KRasG12D (51%) is the dominant mutation. 
Conversely, KRasG12C is the most common mutation in non-small cell lung 
cancer (NSCLC) (44%) (Figure 1.7 C) (Serebriiskii et al., 2019). Collectively, 
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these studies suggest that there is a correlation between Ras isoform mutants 
with specific cancer types. 
        
 
Figure 1.7 Incidence and spectrum of Ras mutations in cancer A. Positions 
of oncogenic mutations at G12, G13 and Q61 on Ras-GTP (PDB: 6GOD). 
Residue G12 (red), G13 (blue) and Q61 (orange) are drawn explicitly with 
residues labels in boldface type. Ras-GTP Structure generated in PyMOL. B. 
Ras isoform-specific codon mutation bias showing KRas is typically mutated at 
codon 12, whereas NRas favours codon 61 and HRas displays intermediate 
behaviour. C. Analysis of individual cancer types reveals isoform-specific 
patterns of codon mutations even within the same tissue. Pie chart colours:  
















3.1.2 Biochemical and structural properties of Ras mutants.  
The above examples have established the fact that Ras biology is far more 
complicated and context dependent on type of isoform, codon mutations and 
protein expression. KRas mutations are more prevalent in particular cancer 
types, most likely due to a combination of factors ranging from protein 
expression levels, genetic topology and cellular context. Additionally, based on 
varied responses of patients with specific KRas mutations, it has been found 
that different KRas mutations have unique biochemical behaviours based on 
biochemical and structural data (Hunter et al., 2015). 
 
3.1.2.1 Biochemical analysis of Ras mutants 
 
In terms of biochemical analysis of KRas mutants, it has been found that the 
nucleotide exchange rates between KRas mutants and wild type have largely 
been identical. However, in the case of G13D mutant, it was observed that the  
GTP exchange rate was nine times faster than WT (0.018/s vs 0.002/s) and 
GDP exchange rate fourteen times faster than wild type (WT) (0.027/s vs 
0.002/s),  insinuating that the G13D mutant may be able auto-activate more 
frequently by spontaneously exchanging GDP for GTP (Hunter et al., 2015). 
This fast exchange kinetics observed for the G13D mutant could explain the 
more aggressive biology of G13D-associated tumours seen in some studies 
(Hunter et al., 2015).  
 
3.1.2.2 Structural insights into Ras mutants  
 
Crystal structures of four KRas mutants which include G12V, G12R, G13D, and 
Q61L have been solved to understand the effect of common KRas mutations 
on the protein structure (Hunter et al., 2015). Mutations have been found to 
have a minimal effect on the overall structure of the protein with global Root 
Mean Square Deviation (RMSD) of 0.115, 0.351, 0.146, and 0.677 Å for G12V, 
G12R, G13D, and Q61L, respectively when compared with the WT KRas 
(Hunter et al., 2015).  
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When Ras is bound to GTP, it exists in two different conformational states 
(state1 and state 2) in solution interconverting on a millisecond time scale. 
These conformational states have been verified using NMR spectroscopy.  
State 1 has a low affinity towards effectors and more towards GEF whereas 
state 2 closely resembles conformation when bound to effector binding domain 
of Ras effectors and has higher GTPase activity (Shima et al., 2010). In case 
of wild type HRas bound to non-hydrolysable GTP (GppNHp), state 1 exists in 
36±2% of the population. However, when mutated to  HRasG12V-GppNHp and 
HRasQ61L-GppNHp, there is a shift in equilibrium between the two states, as 
state 1 occupies 53% and 58% of the population respectively (Mageean., 2014; 
Spoerner et al., 2001). Additionally, mutation of residue 12 or 13 to valine or 
aspartic acid results in displacement of catalytic water molecule, leading to GAP 
insensitivity(Hobbs et al., 2016). Thus, the above-mentioned structural 
differences may account for biochemical differences between mutant Ras 
proteins.   
                                  
 
4.1 Ras as a therapeutic target  
 
4.1.1 Why has Ras been considered 'undruggable'? 
In the past decade, significant advances have been made in sequencing many 
cancer driver genes. Large scale genomic sequencing and development of 
databases such as Cancer Genome Atlas, has helped in understanding the 
molecular basis of cancer (Dang et al., 2017). Many kinases that drive tumour 
growth and development have largely been 'druggable' and have yielded 
significant clinical benefits. However, many known oncogenes such as Ras, 
Myc, p53 and phosphatases PP2A have been termed as ‘undruggable’ due to 
lack of deep binding pockets for small molecules to bind with high affinity and 
specificity. Due to structural and functional challenges in targeting these 
‘undruggable’ oncoproteins development of new drug discovery technologies 
have now become one of the critical challenges in cancer research  (Stephen 




Ras has become one of the intensively studied oncogenic targets in drug 
discovery (Hunter et al., 2015; Ostrem and Shokat., 2016; Haza., 2019). Direct 
targeting of mutant Ras has been challenging due to various reasons which 
include a lack of deep hydrophobic pockets to which small molecule can bind 
to, high intracellular concentration and picomolar affinity of GTP towards the 
nucleotide-binding pocket, and toxicity related issues arising due to possible 
inhibition of the wild-type Ras (Ostrem and Shokat., 2016). Despite intensive 
efforts by researchers to develop effective pharmacological inhibitors of the Ras 
oncoproteins, no inhibitors of Ras have reached the market, prompting the 
previously held perception that Ras proteins are “undruggable” (Cox et al., 
2014). A resurgence of interest in the targeting of Ras emerged from the 
National Cancer Institute (NCI) USA, leading to Ras initiative led by Frank 
McCormick in 2013. Its main mission is to fill critical knowledge gaps essential 
to target Ras cancer effectively and to and provide as a central resource for 
data on Ras biology, reagents and therapeutics (Cox et al., 2014).  
 
   4.1.2 Early approaches to target Ras  
4.1.2.1 GDP-GTP exchange inhibitors 
 
One of the first compounds reported SCH 54292 (IC50=0.7 µM) was found by 
NMR spectroscopy and molecular modelling, to bind to a hydrophobic pocket 
near the critical switch II region of the Ras protein without displacing GDP (Peri 
et al., 2005). New compounds were optimised in which the sugar of SCH-54292 
(Figure 1.8) was replaced with a bicyclic moiety based on molecular modelling. 
Two of these compounds (SCH 53239 and SCH 53870) have been shown to 
inhibit Ras-dependent cell growth (Taveras et al., 1997). However, all 
compounds from this series contain hydroxylamine which is critical for their 
activity but not an ideal functional group in drug molecule due to toxicity, poor 




                                                     
Figure 1.8 Chemical structure of low affinity inhibitor compound SCH 




4.1.2.2 Peptide-based Ras/SOS and Ras/Raf inhibitors 
 
Ras GTP/GDP cycle is regulated by both GAPs and GEFs that facilitate 
dissociation of GDP and binding of the more abundant GTP (Shima et al., 
2010). The most prominent RasGEF is SOS1, which has multiple binding sites 
for Ras (Winter et al., 2015). A new peptide was designed based on αH helix of 
SOS (HBS3 peptide), a region that forms contact with Ras in a cleft near switch 
I and switch II regions (Patgiri et al., 2011). This peptide binds to Ras with a 
Kd of 158 μM, and inhibits Ras activation, by interfering in Ras/SOS interaction 
and significantly reduces EGF induced ERK activation in vivo. Although the 
peptide was not very potent, further optimization of the helical peptide could 
lead to drug-like molecules (Patgiri et al., 2011). 
 
In 2012, a group from Genentech® identified a compound called DCAI (Figure 
1.9) via fragment-based screening on KRas4B which binds to the pocket 
between α2 helix and core β sheet ( β1- β3) of KRas (Maurer et al., 2012). SOS 
mediated nucleotide exchange and release was inhibited by DCAI with an 
IC50 = 340 μM and 155 μM respectively. DCAI also has been found to attenuate 
the EGF stimulated activation of Ras in HEK293 cell lines. In addition to the 
weak binding (1.1 ±0.5 mM), development of small molecule analogues of DCAI 
with considerable improvements in affinity has been a challenging task (Maurer 
et al., 2012).  
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Figure 1.9 Ras/SOS inhibitor DCAI compound (Chemical name 2-(4,6 
Dichloro-2-methyl-1H—indol-3-yl) ethanamine. [Ref- (Maurer et al., 2012)]. 
 
 
In another study, using computer docking, several small molecules were 
selected from a virtual library of compounds for their ability to inhibit Ras-GTP 
binding to Ras binding domain (RBD) of CRaf (Shima et al., 2013). Two 
compounds namely compound Kobe0065 and  Kobe2602 (Figure 1.10), were 
identified that inhibited Ras/Raf1  interaction with an inhibitory constant (Ki) of 
46 µM and 149 µM (Shima et al., 2013). These compounds reduced the amount 
of Raf1 binding to mutant HRasG12V, effectively indicating a reduction of cellular 
activity by Ras (Cox et al., 2014). Using NMR spectroscopy, these compounds 
were found to bind on the side of the α2 helix of Ras (Switch II region) at a 
similar but not identical pocket as the Genentech® compound- DCAI  (Cox et 
al., 2014). Although the compounds are not very potent, they can serve as a 
starting point for lead optimisation. However, suitable replacement of toxic 
semicarbazide (H2NNHC(=O)NH2) is yet to be found (Shima et al., 2013).  
                                 
 
 
Figure 1.10 Chemical structures of Ras-Raf interaction inhibitors. Kobe 





4.1.2.3 FTase inhibitors 
 
Given the necessity of Ras association with plasma membrane for its oncogenic 
activity, initial attempts were carried out to develop pharmacological inhibitors 
of Ras by focussing on inhibiting the enzyme farnesyltransferase (FTase) 
(details of PTMs of Ras CAAX motif explained in section 1.3). Initial preclinical 
studies with FTase inhibitors (FTIs) demonstrated blocking tumour growth both 
in vitro and in vivo (End et al., 2001). Nevertheless, clinical trials failed owing to 
lack of efficacy of FTIs due to surprising biochemistry underlying the PTM of the 
CAAX motif. Since HRas is dependent on COOH terminal lipidation mediated 
by FTase,  FTI treatment of KRas or NRas resulted in alternative lipidation of 
these proteins by geranylgeranyltransferases (GGTases) (O'Bryan., 2019). As 
a result, FTIs have proven ineffective in solid tumours, which predominantly 
harbour KRas mutations. Although FTIs have been combined with GGTase 
inhibitors, this approach suffers from dose-limiting toxicities that are likely due 




5.1 Renewed efforts to target Ras directly 
5.1.1 Inhibition of K-RasG12C  
Approaches to develop inhibitors targeting Ras effector binding regions and 
membrane localization partly failed due to lack of understanding of the complex 
nature of Ras biochemistry and signalling (Figure 1.9). Therefore targeting 
specific mutations of Ras could provide an approach in inhibiting oncogenic Ras 
function and prevent binding to the wild-type protein (Ryan and Corcoran., 
2018). While KRas mutations are present in up to 25% of cancers, the 
oncogenic variants of KRas have different prevalence rates in different cancers. 
One single type of KRas mutation called KRasG12C account for 44% of all KRas 
mutations (Ryan and Corcoran., 2018). KRasG12C is particularly prevalent in 




Ostrem, Shokat, and colleagues described a unique approach in targeting 
oncogenic mutant KRasG12C specifically, without having any effect on wild type 
KRas (Ostrem et al., 2013). Using a  strategy adopted by Earlanson (Erlanson 
and Hansen., 2004) to identify small molecule drug fragments via reversible 
site-directed ligand discovery (referred to as “tethering”), small molecules 
specific to mutant KRasG12C have been identified. The initial screen was carried 
out using a library of disulphide containing small molecules that react with a 
native cysteine residue (KRasG12C in this case) under reducing conditions 
(McCormick., 2019). Those fragments which weakly bind to KRasG12C and have 
disulphide bond intact during native MS are identified. These fragments were 
further analysed via X-ray crystallography and optimised to develop lead 
compounds. (McCormick., 2019). KRasG12C compound 6 identified a druggable 
pocket between central β sheet, α-2 and α-3 helix of KRas, referred to as  
SII-P.  
 
Compounds binding to this new allosteric SII-P inhibit Ras activation by binding 
to the GDP-bound form (inactive) of KRas and not the GTP (active) bound state. 
Since the intrinsic nucleotide exchange rate of KRasG12C  is quite high (the half-
life is 30 min) KRasG12C mutant cycles more frequently between GDP- and GTP-
bound states which allow the compounds to irreversibly bind to the GDP-bound 
form and trap KRasG12C in an inactive conformation (Patricelli et al., 2016). 
Further attempts to identify potent inhibitors of KRasG12C led to the development 
of ARS 853 and ARS 1620, which potently inhibits G12C in its GDP-bound form 
and inhibits the growth of NSCLC tumour models (Janes et al., 2018). ARS 
1620 has shown mutation-specific selectivity and activity by inhibiting the 
growth of patient-derived mouse xenografts harbouring the KRasG12C mutation 
and is also a useful pharmacological tool to understand KRas biology in-vivo 








  5.1.2 Pan-Ras inhibitors 
While KRasG12C inhibitors have shown promise in preclinical and early-stage 
clinical trials, these agents would be effective in small populations of patients 
with specific KRas mutations.  Direct targeting of Ras with pan-Ras inhibitors 
would enable targeting of Ras with multiple mutations. Using fragment-based 
drug discovery to design compounds that can bind to switch regions of 
KRasG12D, pan-Ras inhibitor compound 3144 (Figure 1.11) was synthesised 
(Welsch et al., 2017). Compound 3144 was tested on KRasG12D using 
biophysical assays such as microscale thermophoresis and protein NMR 
spectroscopy and binds to KRasG12D with micromolar affinity. Additionally, 
compound 3144 was found to cytostatic at some concentrations in MEF 
containing KRas (IC50= 3.8 µM). Furthermore, it displayed similar levels of 
lethality in a panel of 11 cancer cell lines with different Ras mutations. However, 
low efficacy was observed in mutant Ras tumour cell lines with concurrent 
downstream Raf and PI3K mutations (Welsch et al., 2017). Despite promising 
results of the Ras inhibitors discussed in sections 4 and 5, none of them has 
been approved as anticancer therapeutics. 
 
                                       
Figure  1.11 Pan Ras inhibitor. Compound 3144. Chemical Formula 









6.1 Novel approaches to target Ras using non-antibody binding proteins 
6.1.1 Artificial binding proteins  
Considering the high incidence and poor prognosis of Ras driven cancers, 
novel approaches for successful Ras inhibitors were required. Researchers 
started exploring the possibility of using anti-Ras antibodies as potential cancer 
therapeutics. Clark and colleagues  reported that antibodies that recognize 
mutant forms of Ras usually at codon 12 or less frequently at codon 61 directly 
reverse transformed the cancer cells driven by cognate mutant Ras proteins 
(Clark et al., 1985). However, the antibodies raised against peptide sequences 
corresponding to codon 12 substitutions were unable to bind since the P loop 
containing codon 12 is not present on the surface of native nucleotide bound 
form of  Ras protein  (Clark et al., 1985). Nevertheless, this early study showed 
the validity of using anti-Ras antibodies for the treatment of Ras-driven cancers, 
but their clinical application was hindered due to technical challenges. These 
include how to deliver the antibodies into cancer cells effectively, and how to 
maintain the structural integrity of antibodies whose multiple disulphide bonds 
would be cleaved in the reducing environment of cytosol (Dimitrov., 2012).  
To overcome the limitation of antibodies as mentioned above, engineered 
protein scaffolds were developed which combine the universal antigen 
recognition function of an antibody with a compact and structurally rigid protein 
core termed as 'scaffold' (Yu et al., 2017). Candidates for suitable protein 
scaffolds besides having a compact and structurally rigid core should be able 
to present surface loops of varying sequence and length. They should also have 
the ability to tolerate side chain replacement in the contiguous surface region, 
without significant change in folding properties(Simeon and Chen., 2018). By 
designing a  random library with mutagenesis focused at the loop region or 
permissible surface area, variants of the engineered scaffold proteins can be 
selected against a given target by phage display technology (Simeon and 
Chen., 2018).These antibody alternatives have practical benefits such as 
robustness, small size and ease of protein expression and can serve as reliable 
alternatives to conventional antibodies. Such engineered proteins are 
becoming increasingly prevalent in biotechnology and biomedical applications 
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(Simeon and Chen., 2018). Over 50 different engineered proteins have been 
developed in the last two decades, with some reaching clinical trials and a few 



















44 pmol/L Plasma Kallikrein Hereditary 
angioedema 
Dyax FDA approval in 2012 
 DX 890 
(Depelstat) 
1 pmol/L Neutrophil elastase Pulmonary fibrosis Dyax Phase II (NCT00455767) 
Knottin Ziconitide 
(Prialt) 
1 pmol/L N-type calcium 
channels 
Neuropathic pain Jazz pharamceuticals FDA approved in 2004 
 Linaclotide 
(Linzes) 






FDA approved in 2012 
Fynomer COVA322 0.9 pmol/L Chymase Plaque psoriasis Covagen Phase I/II (NCT02243787) 
DARPin MP0112 2pmol/L VEGF-A AMD,DME Molecular 
partners,Allergen 
Phase I/II (Campochiaro et.al 
2013) 




 MP0250 <1nmol/L VEGF,HGF Tumour suppressor Molecular partners, 
Allergen Phase I (Rodon et.a l 2015) 
 MP0274  HER2 Tumour suppressor Molecular partners, 
Allergen 
Phase I (Reichert et al. 2014) 
Adnectin CT 322 0.06 
nmol/L 
VEGF receptor Pancreatic cancer Bristol Meyers Squib Phase I, Phase II 
 BMS 962476 0.85 
nmol/L 
PCSK9 Hypercholesterolemia Bristol Meyers Squib Phase I 




Bristol Meyers Squib Phase I (NCT02145234 
Phase II 
Affibody ABY 025 76 pmol/L HER 2 Tumour imaging Affibody Phase I 






Intrabodies are typically single variable fragments (scFv) consisting of heavy 
(VH) and light chain (VL) variable domains linked via a flexible peptide linker 
(Figure 1.12) (Lobato and Rabbitts., 2004). There are, however few scFv that 
can work efficiently as intrabodies since scFv cannot form disulphide bonds, 
which are critical in the folding of almost all antibodies and thus often exhibit 
insolubility and instability. To overcome this limitation imposed by the cellular 
environment, intracellular antibody capture (IAC) technology was used 
(Tanaka and Rabbitts., 2003). It involves selecting intrabodies from diverse 
phage libraries expressing scFv, which are initially screened with antigen in 
vitro and then subsequently screened using in vivo antibody-antigen 
interaction assay in yeast cells (Tanaka and Rabbitts., 2003). scFvs have been 
extensively characterised as research and imaging tools and in therapeutic 
applications (Haylock et al., 2017). For example, a large panel of anti-TAU (a 
microtubule-associated protein involved in Alzheimer's and Parkinson's 
disease) intrabodies selected from a naïve human antibody library can provide 
as a useful imaging tool to study TAU function in degenerating neurons 
(Gallardo et al., 2019). 
 
Intrabodies were the first non-antibody scaffold proteins that have been 
isolated against oncogenic Ras. Using IAC technology, anti-Ras scFvs with 
improved solubility and binding function in-vivo were shown to inhibit 
oncogenic HRas G12V mediated transformation of NIH 3T3 cells (Tanaka et 
al., 2007). Further studies using IAC technology established that single 
variable domains (iDab) are highly efficient as intrabodies. iDab6 intrabody 
was isolated by screening the libraries in yeast using HRas G12V as a bait 
protein. iDab6 has shown to specifically bind to oncogenic HRas with 
mutations at either amino acid 12 or 61 and impaired Ras-dependent 
tumourigenesis in mouse models (Tanaka et al., 2007). The details of the 
intrabody binding site on GTP-bound HRas was obtained by X-ray 
crystallography. The complementary determining regions (CDRs) of VH 
domains of iDab6 intrabody interact with the switch I and switch II region of 
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GTP bound HRas. Most of the interactions between HRas and VH region of 
the antibody is via hydrogen bonds derived from the main and side chain of 
residues of CDRs. The ability of intrabody iDab6 to inhibit Ras-effector 
interactions was confirmed using biochemical assays using GST fusion protein 
pulldowns in the presence of increasing amounts of iDab6 (Tanaka et al., 
2007). In addition to using intrabodies as target validation in disease models, 
small molecules were developed that target the same location in Ras and 
inhibit Ras-effector interactions. Altogether, these findings demonstrated the 
use of an non-antibody binding proteins (nABPs) as an excellent approach to 
develop Ras inhibitors (Quevedo et al., 2018; Cruz-Migoni et al., 2019). 
                       
Figure 1.12 Co–crystal structure of HRas and intrabody iDab6 binder 
protein. iDab6-HRas protein complex (PDB: 5E95). Intrabody variable regions 
(red) from Variable heavy chain (VH) of intrabody competitively binds to the 
conformationally variable regions of Ras, where its signalling effector 
molecules interact. Intrabody iDab6 scaffold and variable regions are 
highlighted in cyan green and red, respectively. Ras is shown in blue with the 
switch I (30-40) and switch II (61-75) regions highlighted in yellow, and orange 
respectively. V.L. Images were generated in PyMOL. VH- variable heavy, VL- 













Affibodies are class of non-immunoglobulin binding proteins obtained via 
randomization of 13 solvent-accessible residues of a bacterial receptor 
domain Z, derived from staphylococcal protein A (Stahl et al., 2017). These 
contain three α helices, no disulphide bonds and are smallest synthetic binders 
(6 kDa) so far. Affibodies are selected via phage display libraries obtained by 
randomizing 13 residues on the first two α-helices of the three-helix 
bundle(Gebauer and Skerra., 2019). The potential of Affibodies for medical 
applications particularly as tracers in medical imaging as well as for receptor 
signal blocking and delivery of toxic payloads has been explored extensively 
(Frejd and Kim., 2017; Stahl et al., 2017). 
 
Affibody variants specific for HRas and Raf1 were selected successfully via 
phage display, which displayed micromolar and nanomolar affinities, 
respectively (Grimm et al., 2010). Affibody molecules specifically binding to H-
Ras or Raf1 (CRaf) were selected with a range of high nanomolar to low 
micromolar affinities (Kd) against both proteins. Affibody variants selected 
against HRas were shown to bind to a site that differed when HRas binds to 
Raf1. In contrast, affibody isolated against Raf1 was capable of inhibiting Ras-
Raf interaction in a dose-dependent manner in vitro. (Grimm et al., 2010). In 
conclusion, affibody molecules can be used as tools for molecular recognition 
in diagnostic and therapeutic applications and have expanded the available 












The Monobody scaffold is based on 10th type III domain of human fibronectin 
(Koide et al., 1998). The fibronectin structure has β sandwich fold similar to 
immunoglobulin domains, exhibiting exposed loops at one end (termed as BC, 
DE and FG) (Sha et al., 2017). These are similar to the CDR of antibody 
variable domains. Unlike conventional Ig domains, the monobody scaffold 
lacks the central disulphide bond that normally links β sheets. Monobodies 
were first generated via mutagenesis of the BC and FG loops; later, the DE 
loop was also included in mutagenesis (Figure 1.13) (Martin et al., 2018; Khan 
et al., 2020). 
In a quest to identify novel strategies to inhibit Ras, monobody NS1 was 
isolated that selectively interacts with HRas (Kd~15nM) and KRas (Kd~65 nM) 
but not NRas (Spencer-Smith et al., 2017). Moreover, NS1 potently inhibited 
KRas and HRas mediated signalling and oncogenic transformation both in 
vitro and in vivo, however, NS1 did not inhibit NRas or oncogenic proteins such 
as BRafV600E or MEK (Spencer-Smith et al., 2017). To understand the 
mechanism of inhibition of HRas mediated signalling by NS1, crystal structure 
of NS1 in complex with GDP loaded Ras was solved to 1.4 Å resolution.  NS1 
binds to the  α4,β6, α5 region of Ras distal to switch regions (Figure1.13). This 
α4- α5 region has been proposed as a dimerization interface in Ras proteins, 
which in turn, is required for activation of BRaf-CRaf heterodimerisation (Khan 
et al., 2019). Using electron microscopy (EM) spatial analysis as well as co-
immunoprecipitation assay, the NS1 intrabody was found to reduce KRas 
plasma membrane localization and at the same time inhibit Raf activation 
(Spencer-Smith et al., 2019). In summary, these findings established the 
importance of targeting α4- α5 dimerization interface as an approach to inhibit  
Ras-mediated signalling in vivo and provides an invaluable tool for studying 





                 
Figure 1.13 Co–crystal structure of HRas and monobody binder protein 
NS1 (PDB: 5E95). Monobody NS1 inhibits Ras by binding to an allosteric 
regulatory site. Monobody scaffold and variable regions are highlighted in cyan 
green and red, respectively. Ras is shown in blue with the switch I (30-40) and 
switch II (61-75) regions highlighted in yellow and orange, respectively. The 




Designed Ankyrin Repeat Proteins (DARPins) are a novel class of binding 
molecules consisting of ankyrin repeat proteins built from tightly packed 
repeats usually having 33 amino acid residues. (Binz et al., 2004). Each repeat 
consists of β turn followed by two antiparallel α helices. Ankyrin repeat (AR) 
domains usually consist of 4-6 repeats, which are stacked onto each other, 
leading to a solenoid-shape structure with a hydrophobic core and large 
solvent-accessible surface (Figure 1.14) (Pluckthun.,2015).These 
characteristics were used to exploit AR domains for construction of libraries 
comprising of novel binding molecules. DARPin libraries thus comprise fixed 
and variable positions. The fixed positions are conserved framework residues 
acting as a scaffold for the six variable positions per repeat module that can 
be potentially engaged in interactions with the target. Because of their 
robustness and extreme stability, binding molecules have been selected from 
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synthetic DARPin libraries (Theoretical diversity library is 5.2×1015 or 
3.8×1023 for two-module or three-module binders, respectively) via ribosome 
display or phage display. DARPins can be evolved to bind to various targets 
using ribosome display with dissociation constants (Kd) within the picomolar 
range (Boersma., 2018). As proof of concept, DARPins were selected to bind 
to ERK either in its nonphosphorylated (inactive) or doubly phosphorylated 
(active pERK) form (ERK2 Kd=6.6 nM and pERK2 Kd=117 nM). Using 
bioluminescence resonance transfer technology (BRET), the specificity of 
DARPins inside the cell was confirmed (Kummer et al., 2012). The potential of 
using DARPins as next-generation protein therapeutics is currently being 
evaluated in clinical trials, with VEGF A specific DARPin (Abicipar®) in phase 
III clinical trials for the treatment of advanced solid tumours and age-related 
macular degeneration (Rodrigues et al., 2018). 
DARPins have also been used to target Ras. K27 (Figure 1.14 A) and K55 
DARPins inhibit Ras and have shown to reduce both ERK and AKT activation. 
K27 preferentially binds to inactive GDP form of Ras (Kd=4 nM) whereas K55 
favoured Ras-GTP (Guillard et al., 2017). DARPin K27 competes with SOS 
binding to Switch I region, and leaves both switch I and bound GDP in near 
identical conformation to that of nonliganded GDP bound Ras. DARPin K55 
interacts with both switch I and II of GTP-bound KRas (G12V) and prevented 
interaction with Raf (Kd=167 nM) (Guillard et al., 2017). These two Ras 
inhibitory DARPins function by blocking different aspects of Ras functions, 
namely nucleotide exchange of GDP to GTP (K27) and blocking effector 
interaction (K55).  
  
Recently, Rabbitts and colleagues isolated two DARPins K13 and K19 that 
specifically inhibit the KRas isoform by binding to α3-α4 interface in the 
allosteric lobe (Figure 1.14 B). These DARPins blocked Ras dimerization as 
well as SOS mediated nucleotide exchange (Bery et al., 2019). Along with 
iDab6, NS1 monobody and Ras: Raf Affibodies, these findings further highlight 
the importance of Ras: Raf PPI for inhibition of Ras/effector interactions and 




Figure 1.14 Co-crystal structures of Ras and DARPin binder proteins   A. 
KRas and DARPin K27 complex (PDB: 52OS), with K27 DARPin binder 
inhibiting nucleotide exchange reaction of GDP to GTP by binding to a region 
overlapping with GEF SOS. B. KRas and DARPin K13 (PDB: 6H4H) showing 
inhibition by binding to an allosteric regulatory site away from switch regions 
of Ras. Ras is shown in blue with the switch I (30-40) and switch II (61-75) 
regions in yellow and orange respectively. DARPin scaffold and the variable 
regions of the DARPin binders are highlighted in cyan green and red, 



















 7.1 Affimer Reagents  
 
The non-antibody based protein scaffold used in this study is called an Affimer. 
Two types of Affimer scaffold have been generated, which are described in 
further detail below.  
7.1.1 Type I Affimer scaffold 
The type I scaffold is derived from human protease inhibitor Stefin A (Stadler 
et al., 2011) (Figure 1.14 A). It is 98 amino acid in length, single-chain protein, 
which interacts with its target via three distinct features,  the amino terminus 
and two hairpin structures, namely loop1 and 2. This protein was chosen 
because protease inhibitor proteins are highly stable and use exposed peptide 
loops to bind to their targets, making them promising randomised protein 
scaffolds. Binding of stefin A to cathepsins (cysteine protease) was abolished 
by insertion of randomised peptides into loop regions (herein termed variable 
regions). This scaffold was termed Stefin A Quadropole Mutant –Tracy (SQT) 
(Stadler et al., 2011). The X-ray crystal structure of Stefin A, demonstrating 
the fold of Type I scaffold can be observed in Figure 1.15 A. Yeast-two hybrid 
libraries were constructed using this scaffold with insertions of randomised 
peptides either 10 amino acids in length in a variable region I (VR1) or 12 
amino acids in length in variable region 2 (VR2). These libraries comprising 
107 unique sequences were screened to identify specific binders to the  POZ 
domain of B cell lymphoma protein (BCL6), and a peptide derived from 
penicillin-binding protein 2 (PBP2) which is specific to methicillin-resistant 
Staphylococcus aureus (Stadler et al., 2011). The SQT scaffold can also 
present peptides for interaction within human cells. The insertion of the Noxa 
BH3 alpha-helix into the SQT scaffold allows for specific interaction with anti-
apoptotic protein Mcl-1 in human skin cancer cells. These results show that 
the SQT variant (Type-I Affimer scaffold) derived from Stefin-A is a robust and 
versatile scaffold that can present binding peptides for target interactions and 






Figure 1.15 Structure of the Affimer scaffolds. Crystal structures of A. 
Affimer Type I (PDB 1NB5) scaffold based on human protease inhibitor Stefin 
A and B. Affimer type II (PDB 4N6U) scaffold based on plant-based 
phytocystatin sequence with variable regions indicated in red. Images 
generated in PyMOL. 
             
 
7.1.2 Type II Affimer  
The type II scaffold design, originally termed an Adhiron, is related in structure 
to Type I scaffold (Figure 1.15 B) (Tiede et al., 2014). It is based on the 
consensus sequence of 57 plant-derived phytocystatins. It was chosen for its 
small size (12kDa), high thermodynamic stability, high-affinity target binding 
as well as lack of disulphide and glycosylation sites. This scaffold encodes a 
four-strand β sheet core and central α helix and two randomised nine amino 
acid loop regions for specific molecular recognition (Carter., 2011; Tiede et al., 
2014). An Affimer type II phage library of 1.3x1010 clones was created by the 
insertion of random amino acid codons in the two variable regions (Tiede et 
al., 2014). Since initial proof of concept studies, which isolated highly specific 
Affimers against yeast SUMO protein (Tiede et al., 2014) more than 350 
successful screens have been carried out by Bioscreening Technology Group 
(BSTG) at University of Leeds, to allow identification of Affimers against 
biological targets particularly those of clinical interest. The extent to which 
Affimers can be used in applications such as dissection of intracellular 
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pathways, inhibition of extracellular receptor function, in vivo imaging, 
modulation of ion channel function, super-resolution microscopy, diagnostics 
and in drug discovery has been evaluated (Tiede et al., 2014; Tiede et al., 
2017). For example, enzyme inhibitor switch sensors were developed by 
insertion of Affimer binding proteins, which disrupt the enzyme-inhibitor 
complex. These sensors are rapid wash free and sensitive assays in areas 
like therapeutic drug monitoring, health diagnostics and plant pathogen 
detection and can be provided as a platform for point-of-care and in-field 
diagnostics (Adamson et al., 2019). In addition, Affimer against glypican-3 
(GPC-3), a promising new tumour marker for hepatocellular carcinoma (HCC) 
has been isolated by phage display. Affimer specific for GPC3 has been 
combined with monoclonal antibody to develop a new sandwich 
chemiluminescence assay (CLIA). This newly developed CLIA test has been 
shown to have high specificity and can be used as a sensitive 
immunodiagnostic kit to detect GPC3 in the serum of HCC patients (Xie et al., 
2017). All the above examples demonstrate the use of Affimers as promising 
tools for label-free detection of biomarkers, offering improved specificity and 
affinity, as compared to traditional antibody diagnostic kits.  
 
Affimers have been used as highly selective protein-based inhibitors that bind 
to FcγRIIIa, a subtype of immunoglobulin receptor family present in natural 
killer (NK) cells and macrophages. These receptors are a valid therapeutic 
target for the treatment of autoimmunity. The FcγRIIIa specific Affimer 
provides the ability to block IgG binding and abrogate FcγRIIIa mediated 
downstream effector function in macrophages (Robinson et al., 2018). 
Additionally, Affimers have also been used to gain insights into the interaction 
between HIF1α and p300, which play an important role in tumour metabolism 
by inhibiting the interaction with low micromolar IC50  in the range 1-5 µM. This 
highlights the use of Affimers as tools to understand and modulate protein-





Isoform-specific Affimers have been isolated against PI3Kα, a heterodimeric 
protein comprising of p110 catalytic subunit and p85 regulatory subunit. This 
protein is a key molecule in the activation of the PI3K-Akt pathway and is 
mediated by oncogenic Ras. There are currently five variants of p85 regulatory 
subunit (p85α, p85β, p85γ, p55α, p50α) out of which p85α is highly expressed. 
Despite a high degree of sequence homology among the variants, a number 
of p85α specific Affimers have been isolated  by screening it  against the N 
terminal SH2 domain of p85 α. These binders were then cross reacted against  
p85β and p55α subunits.  None of these Affimers bound to C terminal p85/p55 
SH2 domains, indicating the ability of Affimers to bind to particular isoform of 
heterodimeric protein (Tiede et al., 2017). All the above findings, therefore, 
demonstrated Affimers as valuable tools to study intracellular signalling. 
 


























The overall aim of the project is to investigate the suitability of Affimer reagents 
as molecular biology tools to study Ras structure and function. Affimer 
reagents targeting Ras have been isolated previously, and preliminary 
experiments demonstrated the ability of these reagents to modulate Ras 
activity. This project aims to characterise the selected Affimers as a new tool 
to identify druggable binding sites in Ras. Firstly biochemical characterisation 
of KRas specific Affimer  followed by structural characterisation of the Affimer-
KRas protein complex was carried out to understand the mode of action of 
inhibition of KRas. This biochemical and structural understanding of Affimer 
action on Ras function could be used to inform small molecule drug design 
and development of novel anti-Ras therapeutics. If successful, this strategy 
can be applied to screen unique non-antibody binding proteins against other 
























                                   Materials and Methods  
 
2.1 Materials  
 
2.1.1 General reagents  
All reagents were supplied by Sigma Aldrich (Gillingham, Dorset, U.K) unless 
otherwise stated. 
2.1.2 Bacterial strain genotypes 
BL21 StarTM (DE3) E.coli cells were purchased from Invitrogen (Life 
Technologies, M.A, U.S.A) and were used for protein production. XL-1 Blue 
supercompetent E. coli cells were purchased from Stratagene (Agilent 
Technologies, CA, U.S.A) and were used for genetic engineering work and 
replication of plasmid DNA. The genotypes of each strain are shown in Table 
2.1. 
Table 2.1 Genotypes of bacterial strains used for this project. 
E. coli strain  Genotype  
BL21(DE3) ompT gal dcm lon hsdSB(rB–mB–) λ (DE3 
[lacI lacUV5-T7p07 ind1 sam7 nin5]) [malB+] K-
12(λS) 
XL1-Blue  endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 
F'[Tn10 proAB+ lacIq Δ(lacZ)M15] 
 
2.1.3 Primers used for sub-cloning  
Primers used for sub-cloning (sequences are shown in Table 2.2) and site-
directed mutagenesis (sequences are shown in Table 2.3) were obtained from 
Sigma-Aldrich (Gillingham, Dorset, U.K). Primers were used in the 
amplification of Ras or Affimer DNA from parent vectors by polymerase chain 
reaction (PCR), for sub-cloning into destination vectors. For both Ras and 
Affimer, donor and recipient vectors is pET-11a (5677 bp). Plasmid pGST-thr-
RAF1-RBD was purchased from Addgene (Cambridge, MA, U.S.A). The 
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recipient vector for this plasmid is pDest 521 (6770 bp). Vector maps can be 
viewed in Appendix A.  
 
Table 2.2 List and sequence of primers used for subcloning. 
Primer name  Primer sequence (5’-3’) 
KRas-forward CGC GCT AGC ATG ACC GAA TAT TAA ACT GGT GG 
KRas-reverse CGT TGG CGG CCG CTT ATT TAG TTT GCG AAT 
TTC ACG 
KRas 6 His forward GCT AGC ATG ACC GAA TAT AAA CTG GTG G 
 
KRas 6 His reverse GCA TAT GCG GCC GCG CTT TAT GTT TGC GAA 
TTT CAC G 
 
Affimer- His forward ATG GAT CCG CCA CCA TGG CCG CTA CCG GTG 
TTC GTG 
Affimer -His reverse GTT TCG CCA ACC ACC GGA CCA ATA CTT CTA 
CTG CTA CTG TTC GTA GTA GTA GTA GTA ATC 
CCA TTC GCC GGC GAT TAC G 
Affimer VR1 forward 
(P1) 
ATG GCT AGC AAC TCC CTG GAA ATC GAA G 
SOE forward primer 
(P2) 
CCT GGA AGC TAA AGA CGG T  
SOE reverse primer 
(P3) 
CAC CGT CTT TAG CTT CCA GG  
T7 Reverse primer 
(P4) 
GCT AGT TAT TGC TCA GCG G 
KRas M66A forward GGA AGA ATA TAG CGC CGC CCG TGA TCA ATA 
CAT GC 




GTT TTT CTG CCG AAT AAA CAA GCC ACC GTC 
GTC AAC GTT CG 
RAF1-RBD R67A 
reverse  
CGA ACG TTG ACG ACG GTG GCT TGT TTA TTC 
GGC AGA AAA AC 
RAF1-RBD R67E 
forward 
GTT TTT CTG CCG AAT AAA CAA GAG ACC GTC 




CGA ACG TTG ACG ACG GTC TCT TGT TTA TTC 
GGC AGA AAA AC  
KRas H95Q forward  GAA GAT ATC CAT CAG TAC CGT GAA CAG 
KRas H95Q reverse CTG TTC ACG GTA CTG ATG GAT ATC TTC 
KRas H95L forward GAA GAT ATC CAT CTC TAC CGT GAA CAG 






Table 2.3 List and sequences of alanine mutant primers used for sub-
cloning. 
Primer name Primer sequence 5 ´– 3 ´ 
K3-VR1.1 
forward 
GTT GTT AAA GCG AAA GAA CAG GCT TCT ATC GAC 
ATC TGG TAC GAC 
K3-VR1.1 
reverse 
GTC GTA CCA GAT GTC GAT AGA AGC CTG TTC TTT 
CGC TTT AAC AAC 
K3-VR1.2 
forward 








GTT AAA GCG AAA GAA CAG CAT TCT GCT GAC ATC 
TGG TAC GAC TTC ACC ATG 
K3-VR1.3 
reverse 
CAT GGT GAA GTC GTA CCA GAT GTC AGC AGA ATG 
CTG TTC TTT CGC TTT AAC 
K3-VR1.4 
forward 
CGA AAG AAC AGC ATT CTA TCG CTA TCT GGT ACG 
ACT TCA CCA T 
K3-VR1.4 
reverse 
ATG GTG AAG TCG TAC CAG ATA GCG ATA GAA   
TGC TGT TCT TTC G 
K3-VR1.5 
forward 
CGA AAG AAC AGC ATT CTA TCG ACG CTT GGT ACG 
ACT TCA CCA TGT ACT A 
K3-VR1.5 
reverse 
TAG TAC ATG GTG AAG TCG TAC CAA GCG TCG ATA 
GAA TGC TGT TCT TTC G 
K3-VR1.6 
forward 
AGA ACA GCA TTC TAT CGA CAT CGC TTA CGA CTT 
CAC CAT GTA CTA CC 
K3-VR1.6 
reverse 
GGT AGT ACA TGG TGA AGT CGT AAG CGA TGT 
CGA TAG AAT GCT GTT CT 
K3-VR1.7 
forward 
CAG CAT TCT ATC GAC ATC TGG GCT GAC TTC ACC 





CAG GTA GTA CAT GGT GAA GTC AGC CCA GAT 
GTC GAT AGA ATG CTG 
K3-VR1.8 
forward 
ATT CTA TCG ACA TCT GGT ACG CTT TCA CCA TGT 
ACT ACC TGA C 
K3-VR1.8 
reverse 
GTC AGG TAG TAC ATG GTG AAA GCG TAC CAG 
ATG TCG ATA GAA T 
K3-VR1.9 
forward 
TCT ATC GAC ATC TGG TAC GAC GCT ACC ATG TAC 
TAC CTG ACC CTG 
K3-VR1.9 
reverse 
CAG GGT CAG GTA GTA CAT GGT AGC GTC GTA 
CCA GAT GTC GAT AGA 
K3-VR2.1 
forward 
CTG TAC GAA GCG AAA GTT TGG GTT AAG GCT CTG 
AAC AAC AGT CAT ACC TAT AAA AAC 
K3-VR2.1 
reverse 
GTT TTT ATA GGT ATG ACT GTT GTT CAG AGC CTT 
AAC CCA AAC TTT CGC TTCGTA CAG 
K3-VR2.2 
forward 
GTA CGA AGC GAA AGT TTG GGT TAA GAA AGC TAA 
CAA CAG TCA TAC CTA TAA AAA CTT C 
K3-VR2.2 
reverse 
GAA GTT TTT ATA GGT ATG ACT GTT GTT AGC TTT 
CTT AAC CCA AAC TTT CGC TTCGTAC 
K3-VR2.3 
forward 
CGA AGC GAA AGT TTG GGT TAA GAA ACT GGC TAA 
CAG TCA TAC CTA TAA AAA CTT CAA AG 
K3-VR2.3 
reverse 
CTT TGA AGT TTT TAT AGG TAT GAC TGT TAG CCA  
GTT TCT TAA CCC AAA CTT TCG CTT CG 
K3-VR2.4 
forward 
AGC GAA AGT TTG GGT TAA GAA ACT  GAA CGC  
TAG TCA TAC CTA TAA AAA CTT CAA AGA AC 
K3-VR2.4 
reverse 
GTT CTT TGA AGT TTT TAT AGG TAT GAC TAG CGT 
TCA GTT TCT TAA CCC AAA CTT TCG CT 
K3-VR2.5 
forward 
AGT TTG GGT TAA GAA ACT GAA CAA CGC TCA TAC 
CTA TAA AAA CTT CAA AGA AC 
K3-VR2.5 
reverse 
GTT CTT TGA AGT TTT TAT AGG TAT GAG CGT TGT 





CGA AAG TTT GGG TTA AGA AAC TGA ACA ACA GTG 
CTA CCT ATA AAA ACT TCA AAG 
K3-VR2.6 
reverse 
CTT TGA AGT  TTT TAT AGG TAG CAC TGT TGT TCA 
GTT TCT TAA CCC AAA CTT TCG 
K3-VR2.7 
forward 
GGT TAA GAA ACT GAA CAA CAG TCA TGC TTA TAA 
AAA CTT CAA AGA ACT GCA GG 
K3-VR2.7 
reverse 
CCT GCA GTT CTT TGA AGT TTT TAT AAG CAT GAC 
TGT TGT TCA GTT TCT TAA CC 
K3-VR2.8 
forward 
AAG AAA CTG AAC AAC AGT CAT ACC GCT AAA AAC 
TTC AAA GAA CTG CAG GAG 
K3-VR2.8 
reverse 
CTC CTG CAG TTC TTT GAA GTT TTT AGC GGT ATG 
ACT GTT GTT CAG TTT CTT 
K3-VR2.9 
forward 
AAG AAA CTG AAC AAC AGT CAT ACC TAT GCT AAC 
TTC AAA GAA CTG CAG GAG TTC AA 
K3-VR2.9 
reverse 
TTG AAC TCC TGC AGT TCT TTG AAG TTA GCA TAG 
GTA TGA CTG TTG TTC AGT TTC TT 
 
 
Table 2.4 Details of antibody concentration, dilution factor and source. 
(IB: Immunoblot). 




































2.1.4 Common buffers and solutions   
• Tris buffered saline (1X TBS)- 50 mM Tris-Cl, 150 mM NaCl pH 7.6    
• TBS- Tween (TBS-T): 1X TBS + 0.1 %Tween-20   
• Phosphate buffered saline (1X): 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2 HPO4, 2mM KH2PO4, pH 7.4.  
• Affimer Lysis buffer: 50 mM NaH2PO4, 300 mM NaCl, 20 mM 
Imidazole pH 7.4   
• Affimer wash buffer: 50 mM NaH2PO4, 500 mM NaCl, 20 mM 
Imidazole pH 7.4  
• Affimer elution buffer: 50 mM NaH2PO4, 500 mM NaCl, 300 mM 
Imidazole, 10% w/v glycerol pH 7.4  
• Nucleotide exchange buffer: 20 mM Tris-Cl, 50 mM NaCl,0.5 mM 
MgCl2 pH 7.5 
• GST fused protein lysis buffer:  125 mM Tris-Cl, 150 mM NaCl, 1mM 
DTT, 1% w/v Triton X-100 pH 7.4    
• GST fused protein wash buffer:  125 mM Tris-Cl, 150 mM NaCl, 1mM 
DTT pH 7.4.  
• GST fused protein elution buffer: 125 mM Tris-Cl, 150 mM NaCl, 1mM 
DTT, 1% w/v Triton X-100, 50 mM reduced glutathione pH 7.4 
• Assay buffer: 125 mM Tris-Cl,150 mM NaCl,5 mM MgCl2,0.1% w/v 
Tween 20, 1 mM DTT (add DTT fresh before use) pH8.0   
• Blocking buffer: Casein blocking buffer 10X (Sigma-Aldrich), diluted 
2X in PBST 
 
 
2.1.6 Bacterial cell culture reagents   
• LB media (Lennox-L-Broth base) (Invitrogen Life Technologies): 86.2 
mM NaCl, 10g/L peptone, 5g/L yeast extract.   
• 2TY media: 24 g/L yeast extract; 16g/L tryptone, 5g NaCl.  
• LB agar (Lennox L agar) (Invitrogen Life Technologies): 10g/L 
SELECT peptone 140; 5g/L SELECT yeast extract, 5g/L sodium 
chloride, 12g/L SELECT agar.  
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• SOC media: 0.4% w/v glucose, 20 g/L tryptone, 5g/L yeast extract, 0.5 
g/L NaCl.   
  
2.1.7 SDS PAGE and western blot reagents   
• Separating gel buffer: 1.5 M Tris-Cl; 0.4% w/v SDS; pH 8.9. Filter 
sterilised through 0.22μm filter.  
• Stacking gel buffer: 0.4M Tris-Cl; 0.4% w/v SDS; pH 6.7. Filter 
sterilised through 0.22μm filter.  
• SDS PAGE running buffer: 25 mM Tris-Cl; 0.19 M glycine; 0.1% w/v 
SDS; pH 8.3.  
• SDS PAGE sample buffer (4X): 8% w/v SDS; 0.2 M Tris-HCl (pH 7); 
20% glycerol; 1% bromophenol blue (BDH laboratories); 20% v/v β-
mercaptoethanol added before use.  
• Coomassie blue stain: 45% v/v methanol; 7% v/v acetic acid; 0.25% 
w/v Coomassie Brilliant Blue R-250 (Sigma-Aldrich).  
• Destain solution: 25% v/v methanol; 7.5% v/v acetic acid.  
• Transfer buffer (Bio-Rad): 25 mM Tris-Cl; 0.19 M glycine; 20% v/v 
methanol; pH8.3.   
• Stripping buffer: 0.2 M glycine; 0,1% w/v SDS; 1% w/v Tween-20; pH 
2.2.  
• Transfer buffer (Bio-Rad): 100 mM Tris-Cl, 121 mM Glycine, 20% v/v 
methanol. 
• Tris Buffer saline -Tween 20 (TBS-T):  10 mM Tris-Cl, 150 mM NaCl, 









2.2.1 DNA protocols and molecular sub-cloning  
2.2.1.1 Polymerase Chain Reaction (PCR)  
 
The DNA sequences used during sub-cloning into various expression vectors 
were amplified by polymerase chain reaction (PCR). The reactions were 
performed in 200 μl PCR tubes, using a G-StormTM GS2 thermal cycler. 
Reactions were carried out with Phusion® High-Fidelity DNA polymerase (New 
England Biolabs; NEB, M.A, U.S.A) using the components supplied with the 
DNA polymerase. Reaction components and thermocycling conditions are 
detailed in Table 2.5 and Table 2.6. Following thermocycling, the template 
methylated DNA was digested by 10 U Dpn I (NEB) for 1 h at 37 °C. The PCR 
product was then purified using a NucleoSpin® Gel and PCR Clean-up kit 
(Macherey-Nagel), according to the manufacturer’s instructions (see section 
2.2.1.5).  
 
Table 2.5- Composition of thermal cycling reaction mixture 
Component  25 µl Reaction Final concentration 
Sterile water  13.8 µl  
5X Phusion HF buffer  5 µl 1X 
dNTP mix 25 mM  0.2 µl 200 µM each 
DMSO 0.75 µl 3 % v/v 
Forward primer 10 µM  2 µl 0.8 µM 
Reverse primer   10 µM 2 µl 0.8 µM 
Phusion DNA 
polymerase 
0.25 µl 0.02 units/µl 










Table 2.6 – Condition of thermal cycling reaction. 
Cycling step Temperature Time Cycles 
Initial 
denaturation  
98 °C 30 seconds  1 
Denaturation  98° C 20 seconds   
Annealing  54° C 20 seconds  30 
Extension  72° C 20 seconds   
Final extension  72° C 10 min  1 
Hold   4 ° C Hold  1 
 
2.2.1.2 Agarose gel electrophoresis  
 
Nine microliters of the PCR amplified and Dpn I digested DNA was mixed with 
1 μl of the 10x DNA loading dye (30 % w/v glycerol, 0.2 % w/v Orange G, H2O, 
final concentration 1x) and 5 μl of samples were loaded onto a 2 % w/v 
agarose gel in Tris-acetate-EDTA (TAE) buffer (40 mM Tris-Cl; 20 mM acetic 
acid, 1 mM EDTA, pH 8.0), containing 1X SYBR® Safe DNA Gel Stain. Quick-
Load® Purple 2-log DNA Ladder (NEB) was loaded in the first well. 
Electrophoresis was carried out in Mini-Sub® Cell GT apparatus (Bio-Rad, 
Hertfordshire, U.K) in TAE buffer at 100 V. DNA bands were visualised under 
UV light and imaged using an AmershamTM Imager 600 (GE Healthcare, 
Buckinghamshire). After the electrophoresis, DNA bands were excised from 
the gel using a scalpel. Extraction of the DNA was performed using a 
NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel, Leicestershire, U.K) 
(see section 2.2.1.5).   
 
2.2.1.3 Restriction digestion  
 
The restriction digestion reactions were carried out in a total reaction volume 
of 50 μl containing 10 U restriction enzyme(s), 1 – 5 μg DNA and 1X 
CutSmart® Buffer (NEB) in nuclease-free water. The resulting fragments were 
purified using a NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel, 
Leicestershire, U.K) (see section 2.2.1.5).  
The recipient vector pET-11a was dephosphorylated to remove 5 ´ phosphate 
and prevent self-ligation. Dephosphorylation was carried out using Antarctic 
Phosphatase (heat-labile alkaline phosphatase) in a total reaction volume of 
60 μl, containing 5 U Antarctic Phosphatase (NEB), 5 μg vector DNA and 1X 
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Antarctic Phosphatase Reaction Buffer (NEB) in nuclease-free water. After 
incubation for 15 min at 37 °C, Antarctic Phosphatase was heat-inactivated by 
incubation at 65 °C for 5 min. 
 
2.2.1.4 DNA ligation  
 
Ligation reactions were performed in a total volume of 20 μl, containing 25 ng 
vector DNA, 75 ng insert DNA, 1 U T4 DNA Ligase (Roche Basel, Switzerland) 
and 1X T4 DNA Ligase Buffer (Roche), in nuclease-free water. Ligation 
reactions were incubated at 4 °C overnight, followed by transformation of XL-
1 Blue super competent E. coli cells.  
 
2.2.1.5 DNA extraction and purification  
 
DNA fragments were purified from enzymatic reactions such as PCR as well 
as agarose gels. DNA fragment from agarose gel was excised, and the weight 
of the gel slice was determined. For each 1g agarose gel, 1 ml of binding buffer 
NTI from NucleoSpin® Gel and PCR Clean-up kit was added. The sample was 
incubated for 10-20 min at 50ºC and vortexed until the gel slice was completely 
dissolved. NucleoSpin Gel and PCR clean up midi column were placed in 15 
ml collection tube, and the sample was loaded. The column was centrifuged 
for 1min at 3000 x g for DNA to bind to the column. 4 ml of wash buffer NT3 
was added to wash the silica membrane in the column and centrifuged again 
for 1 min at 3000 x g. After repeating this step, the column was spanned again 
for 10 min at 3000 x g to dry the silica membrane completely. DNA was eluted 
by placing the column in new 15 ml centrifuge tube, and 200 µl of nuclease-
free water (NEB) was added and incubated at 70 ºC for 5 min and centrifuged 
for 2 min at 3000 x g.  
 
2.2.1.6 Transformation of E. coli bacterial strains with DNA  
 
The appropriate competent cells for each construct were thawed at 4º C.  
10 ng of DNA was aliquoted to a microcentrifuge tube and pre-chilled on ice, 
following which 10 μl of competent cells (per transformation) was added. The 
cell/DNA mixture was mixed and incubated at 4º C for 30 min, followed by heat 
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shock in a 42⁰ C water bath for 45 seconds. Samples were then incubated for 
further 2 min on ice, before the addition of 190 μl of SOC media. The mixture 
was incubated at 37°C for 1 h with shaking at 230 rpm. 100 μl of the 
transformation mixture was plated onto Lennox L agar plate containing 100 
μg/ml carbenicillin (LB-carb plate) and incubated overnight at 37°C.  
 
2.2.1.7 Purification of plasmid DNA 
  
The sub-cloned plasmid DNA was purified by QIAprep® Spin Miniprep Kit for 
the use of the plasmid in bacterial production. A single bacterial colony from 
LB-carbenicillin plate was inoculated into 5 ml of Lennox broth (LB media) 
containing 100 μg/ml carbenicillin (LB carb media) and incubated overnight at 
37°C and 230 rpm. For minipreps, the overnight cultures were centrifuged at 
4816 x g for 10 min at 4° C. Pelleted bacterial cells were resuspended in 250 
µl buffer P1 (re-suspension buffer) and transferred to a microcentrifuge tube. 
250 µl of buffer P2 (lysis buffer) was added and mixed thoroughly by inverting 
the tube 4-6 times until the solution becomes clear. 350 µl of buffer N3 
(neutralisation buffer) was added as soon as possible and mixed thoroughly 
by inverting the tube 4-6 times. Following which the tube was centrifuged for 
10 min at 13000 rpm. 800 µl of supernatant from the tube was then added to 
QIAprep® Spin column by pipetting and centrifuged for 1000 x g for 1 min. The 
column was washed with 0.5 ml PB buffer and centrifuged at the same 
specification mentioned above. The column was finally washed with 0.75 ml 
of Buffer PE twice and eluted by adding 25 or 50 µl of nuclease-free water. 
 
2.2.1.8 Determination of DNA concentration  
 
The concentration of purified DNA was measured by a NanoDropTM Lite 
spectrophotometer. The instrument was blanked with nuclease-free water 
before taking measurements of the DNA samples. The absorbance at 260 nm 
has been used to calculate the DNA concentration using the Beer-Lambert 
Law (Beer., 1852; Lambert., 1760) (A260 = εcl, where ε is the extinction 





2.2.1.9 DNA sequencing  
 
Sub-cloning was confirmed by DNA sequencing. The purified plasmid DNA 
was diluted to 100 ng/μl, and sequencing was performed by Genewiz (Essex, 
U.K) using the primers detailed in Table 2.7. 
Table 2.7- Primers used for DNA sequencing of plasmids 
Plasmid Primer name  Primer DNA sequence (5’-3’) 
pET-11a  T7 TAATACGACTCACTATAGGG 
pGEX 6P-2  5GEX GGGCTGGCAAGCCACGTTTGGTG 
  
2.2.1.10 Construction of K3 VR1 and K3 VR2 mutants  
 
To generate Affimer K3∆VR1 and K3∆VR2, residues of VR1 and 2 were 
replaced with three residues of alanine from the control Affimer variable 
regions using splice overlap extension. Affimer K3 variable region (VR) 1 was 
amplified using Phusion DNA polymerase with 1µl of Affimer K3 DNA, Affimer 
K3 VR1 forward and reverse primers (Table 2.2) and reaction components 
outlined in Table 2.5. The same approach used for control Affimer VR2 DNA 
sequence but using control Affimer DNA and Affimer VR2 forward and reverse 
primers instead. The PCR products were purified by PCR purification kit and 
subjected to splice overlap extension (as detailed in sec.2.2.1.1, but without 
any primers used), to anneal the fragments together. This was followed by 
PCR with Affimer forward and reverse primers using Phusion DNA 
polymerase. The same approach was followed for obtaining K3∆VR2 mutants. 
The spliced product was digested with NheI and NotI overnight at 37°C. The 
spliced product was purified and subcloned in pET-11a vector digested with 
Nhe-I and Not-I. DNA was ligated as per section 2.2.14 and transformed in XL-
1 blue supercompetent cells for culturing and extracting DNA by miniprep. The 







2.2.1.11 Alanine scanning by site directed mutagenesis 
 
Primers were designed using primer design guidelines as per QuikChange site 
directed mutagenesis kit by Agilent® (C.A, U.S.A). Variable regions of Affimer 
K3 were substituted to alanine (shown in Table 2.3). The PCR reactions 
contained 1 KOD polymerase buffer, 0.2 mM dNTP, 2 mM MgSO4, 0.3 µM of 
forward and reverse primers, 10 ng DNA template and 1 U KOD Hot start DNA 
polymerase in a total volume of 50 µl. The reaction mixtures were then 
subjected to thermal cycling parameters as per Table 2.8. Following thermal 
cycling, PCR products were digested with DpnI for 1 h at 37°C. XL-1 blue 
supercompetent cells were transformed with Dpn-I treated samples as 
outlined in section 2.2.1.5. Sub cloned plasmid DNA was extracted using a 
QIAprep spin miniprep kit. Mutagenesis was confirmed by sequencing 
(Genewiz, Essex, U.K).  
  
 
Table 2.8- Cycling conditions for site directed mutagenesis protocol. 
 
Cycle step Temperature Time Cycles 
Initial 
denaturation  
98°C 2 min 1 
Denaturation  98°C 20 seconds  
Annealing  68°C 10 seconds 30 
Extension  70°C 3.5 min  




2.2.1.12 Site directed mutagenesis of KRas and RAF1-RBD 
 
The same method was followed, as mentioned in section 2.2.1.10 with the 
exception being KRasM66A, RAF1RBD R67A and R67E primers were used 






2.2.2 Protein analysis methods  
2.2.2.1 Protein concentration determination 
 
The concentration of purified protein was measured using Nanodrop™ Lite 
spectrophotometer. The instrument was blanked using appropriate sample 
buffer before reading the absorbance of the sample. The sample protein 
concentration was determined by measuring absorbance at 280 nm using 
Beer-Lambert Law (A280=ɛ.c. l where ɛ= extinction coefficient, c= protein 
concentration in mg/ml and l= path length in cm.). The extinction coefficient 
was calculated from the protein sequence using ExPASy ProtParam software 
(Wilkins et al., 1999). 
Additionally, protein concentration was determined using Bicinchoninic acid 
(BCA) assay. A Pierce™ BCA kit was used, as per manufacturer’s instruction 
in microplate format, in which sample to working reagent ratio is 1:8 (working 
range 20-2000 µg/ml). 
 
 2.2.2.2 SDS-PAGE 
 
Purified proteins or whole cell lysates were resuspended in 4X SDS sample 
buffer and incubated at 95°C for 5 min. Samples were loaded on 15% w/v 
SDS-Polyacrylamide resolving gel and 7.5% w/v stacking gel and run at 150 
V for 60 min in SDS running buffer. PageRuler™ pre-stained protein ladder 
(10-180 kDa) was used as molecular weight marker. Gels were stained for 15 
min in Coomassie brilliant blue and de-stained overnight using a destaining 
solution. Coomassie brilliant blue gels were imaged using an Amersham™ 





Proteins subjected to SDS-PAGE were transferred to a nitrocellulose 
membrane in 1X transfer buffer using Turbo Trans blot (Bio-Rad). Membranes 
were incubated in 5% w/v skimmed milk (Sigma) in TBS-T for 1 h on a rocker 
at room temperature. Membranes were then incubated with primary antibodies 
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(Table 2.4) in 5% w/v skimmed milk powder overnight at 4°C and washed three 
times with TBS-T for 15 min each time before incubation with HRP conjugated 
secondary antibodies (Table 2.4) for 1 h. The membranes were then washed 
three times in TBS-T followed by detection using Immunoblot forte Western 
HRP substrate (Millipore, Watford, U.K). Images were taken in Amersham™ 
Imager 600 (GE Healthcare). Quantification of proteins was performed using 
densitometry on Image J and normalised using Alanine Affimer as a loading 
control for Ras/Raf binding assays. 
 




Affimers sequences were subcloned in the pET-11a vector and expressed in 
E. coli BL21 star™ DE3 cell line. After transformation, a single bacterial colony 
was used to inoculate a 7 ml LB carbenicillin (100 µg/ml) media and grown at 
37ºC and 230 rpm. Following which, 5 ml of the overnight culture was added 
to 50 or 400 ml of LB-carbenicillin media and grown at 37° C, 230 rpm until O. 
D600nm reached 0.6~0.8. Protein expression was induced by adding 0.1mM 
IPTG to the cultures and incubated at 25° C on shaking incubator at 150 rpm. 
Cells were harvested by centrifugation at 4816 x g for 20 min. For 400 ml cell 
culture, cells were lysed in a buffer containing 50 mM Na2HPO4, 150 mM NaCl, 
20 mM Imidazole, 10% w/v glycerol pH 7.4 supplemented with 0.1 mg/ml 
lysozyme, 0.1% w/v Triton X-100, 1X Halt protease inhibitor cocktail and 
10U/ml Benzonase for 20 min at 4°C. The lysate was heat denatured at 50°C 
for 20 min, followed by centrifugation at 4816 x g for 20 min and 12,000 x g for 
further 20 min. The clear soluble lysate was incubated with 400 µl of Ni2+-NTA 
resin assuming the binding capacity of the beads was 40 mg/ml of purified 
protein, based on expected protein yields and resin binding capacity. Excess 
Affimer was removed by extensive washing with 50 mM Na2HPO4, 300 mM 
NaCl and 20 mM Imidazole pH 7.4. His tagged Affimers were eluted with 50 




Proteins were dialysed overnight at 4°C in 1X PBS and 10% w/v glycerol using 
Slide- A-Lyser™ cassettes, 7K MWCO. Protein concentration was measured 
at A280 using Nanodrop® lite spectrophotometer and calculated using Beer-
Lambert Law. Protein purity was analysed by Coomassie Staining and 15% 
w/v SDS-PAGE. All Affimer sequences used in this project is shown in 
Appendix B. 
 
2.2.3.2 KRas/KRas His tag 
 
Plasmids encoding N-terminally His-tagged and C-terminally biotin acceptor 
protein (BAP)-tagged KRas was synthesised by GenScript. Piscataway (USA) 
was used to design KRas with no tag (KRas WT) and with 6 times histidine tag 
(KRas 6-His). The KRas WT DNA sequence was amplified by PCR (as 
detailed in section 2.2.1.1) with KRas forward and reverse primers in case of 
KRas with no tag and KRas 6His forward and reverse primers for KRas 6-His 
(Table 2.2). The PCR products were digested with NheI and NotI restriction 
enzymes at 37˚C overnight (as described in section 2.2.1.3). The digested 
products were purified using Qiagen Gel and PCR Clean up kit (Qiagen) and 
ligated into pET-11a vector, which was also digested with NheI and NotI 
restriction enzymes (as detailed in section 2.2.1.4). These recombinant 
plasmids were produced in E. coli BL21 StarTM DE3 cell line. A single bacterial 
colony from LB-carbenicillin plate was used to inoculate a 7 ml LB-carbenicillin 
culture overnight at 37ºC and 230 rpm. Then 500 ml LB- carbenicillin media 
was inoculated with 5 ml of overnight culture and grown at 37°C and 230 rpm 
to an OD600 between 0.6–0.8. 0.1 mM IPTG was added to the culture and 
further grown overnight at 25 °C and 150 rpm. The cells were harvested by 
centrifugation at 4816 x g for 15 min. Cells were lysed in 50 mM Tris-Cl, 150 
mM NaCl, 20 mM Imidazole, 5 mM MgCl2, 5% w/v Glycerol, pH 7.5 
supplemented with 0.1 mg/ml lysozyme, 0.1% w/v Triton X-100, 1x Halt 
protease inhibitor cocktail and 10 U/ml Benzonase for 20 min at 4 ⁰C. The 
lysates were clarified by centrifugation at 4,816 x g for 20 min,12,000 x g for a 
further 20 min, then incubated with 500 μl Ni2+-NTA resin at 4 ⁰C for 1 h. 
Unbound proteins were removed by washing with 50 mM Tris-Cl, 300 mM 
NaCl, 20 mM Imidazole, 5 mM MgCl2, 5% w/v Glycerol, pH 7.5. His-tagged 
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KRas protein was eluted with 50 mM Tris-Cl, 150 mM NaCl, 300 mM 
Imidazole, 5 mM MgCl2, 5% w/v Glycerol, pH 7.5 and was quantified using 
BCA assay. Protein purity was analysed by Coomassie staining on 15% w/v 
SDS-PAGE. KRas sequence is shown in Appendix B.  
2.2.3.3 SOScat 
 
Human SOS1 catalytic domains (SOS1cat) gene sequence (residues 564-
1059) with an N-terminal His-tag was subcloned in kanamycin resistant pET-
11a vector and expressed in E. coli BL21 StarTM DE3. 500 ml LB carbenicillin 
(100µg/ml) culture was induced with 0.5 mM IPTG and grown overnight at 25 
°C and 150 rpm. Cells were harvested by centrifugation at 4816 x g for 15 min 
at 4ºC. Cell pellets were lysed in 20 mM Tris-Cl pH 8, 300 mM NaCl, 20 mM 
imidazole, 5% w/v glycerol supplemented with 1% w/v Triton-x100, 1x halt 
protease inhibitor cocktail, 0.1 mg/ml lysozyme and 10 U/ml Benzonase 
nuclease. The cell lysate was centrifuged at 12,000 x g for 20 min, and the 
cleared supernatant was added to pre-washed Ni-NTA resin. SOScat was 
eluted using 20 mM Tris-Cl pH 8, 500 mM NaCl, 300 mM imidazole, 5% w/v 
glycerol and dialysed into 50 mM Tris-Cl pH 7.5, 100 mM NaCl. SOScat 
sequence is shown in Appendix B. 
 
2.2.3.4 Affimer-KRas complex  
 
The KRas wt DNA sequence (without His- and BAP-tag) from expression 
vector pET-11a was amplified by PCR (as detailed in section 2.2.1.1). The 
PCR products were digested with Nhe I and Not I restriction enzymes at 37˚C 
overnight (as described in section 2.2.1.3). The digested products were 
purified using Qiagen Gel, and PCR Clean up kit (Qiagen) (as detailed in 
section 2.2.1.5) and ligated with pET-11a vector which was also digested with 
Nhe I and Not I restriction enzymes (as detailed in section 2.2.1.4). Ligated 
DNA was transformed into XL-1 Blue super-competent cells (see 2.2.1.6), and 
DNA was extracted by using mini-preparation (refer to section 2.2.1.7). 
Extracted DNA was sent for sequencing to confirm successful ligation. The 
correctly sub-cloned DNA was transformed into E.coli BL21 StarTM DE3 cell 
line for protein production, as described in section 2.2.3.2. Affimer was 
59 
 
produced and purified, as outlined in section 2.2.3.1. Ten milligrams of purified 
Affimer was mixed with excess KRas lysate and incubated on a roller for 2-3 
h. Four hundred microliters of pre-washed Ni2+-NTA resin was added to 
Affimer-KRas lysate mixture and incubated on a roller overnight at 4 ⁰C. 
Unbound proteins were removed by washing in 50 mM Tris-Cl, 150 mM NaCl, 
5 mM MgCl2, 1 mM DTT, 20 mM Imidazole, 5% w/v glycerol, pH 7.5. Affimer-
KRas complex was eluted with 50 mM Tris-Cl, 150 mM NaCl, 5mM MgCl2, 
1mM DTT, 300 mM Imidazole, 5% w/v glycerol, pH 7.5. The eluted proteins 
were analysed by Coomassie staining on 15 % w/v SDS-PAGE. Affimer-KRas 
complex was further purified into 10mM Tris-Cl, 50 mM NaCl, 0.5mM TCEP, 
pH 8 by size exclusion chromatography, using HiPrep 16/60 Sephacryl S-100 
column (GE Healthcare). They were analysed by Coomassie staining on 15 % 
w/v SDS-PAGE. The purified complex was concentrated using Vivaspin 6 5K 
MWCO centrifugal concentrator (Sartorius) to 12 mg/ml as determined by the 
BCA protein assay. 
     
2.2.3.5 GST-thr-Raf1RBD protein expression  
 
The GST-tagged Ras binding domain (RBD) of Raf1 in pGEX vector 
(Addgene, M.A, U.S.A) was used to transform BL21 StarTM DE3 cells for 
protein production. A single bacterial colony from LB-carbenicillin plate was 
used to inoculate a 5 ml LB media with 100 μg/ml 
 carbenicillin overnight at 37ºC 230 rpm. Then 500 ml LB-carbenicillin media 
was inoculated with 5 ml of overnight culture and grown at 37°C and 230 rpm 
to an OD600 between 0.6–0.8.  0.5 mM IPTG was then added to the culture 
and further grown at 37°C at 230 rpm for 4 h. Cells were harvested by 
centrifugation at 4816 x g for 20 min. Cell pellets were lysed in 50 mM Tris-Cl, 
150 mM NaCl, 1 mM DTT, 1% w/v Triton X-100, pH 7.5 supplemented with 
1mg/ml lysozyme, 1x HaltTM protease inhibitor cocktail and 3U/ml Benzonase 
for 30-60 min at 4⁰C. The lysates were cleared by centrifugation at 4,816x g 
for 20 min then 12,000 x g for a further 20 min and the cleared cell lysates 





2.2.4 Ras nucleotide loading  
 
Before nucleotide loading, 60 μM Ras protein was desalted into nucleotide 
loading buffer (25 mM Tris-Cl, 50 mM NaCl, 0.5 mM MgCl2 pH 7.5) using a 
ZebaTM spin desalting column (Thermo Fisher) equilibrated with buffer 
according to the manufacturer’s instructions. MANT-GDP or GTP was added 
in 20-fold excess over Ras as well as 1 mM DTT and 5 mM EDTA in a final 
volume of 130 μl and incubated at 4 °C for 1 h. After incubation MgCl2 was 
added in a 2-fold excess over EDTA and incubated for a further 30 min at 4 
°C. Ras-mGDP or Ras-GTP was then desalted using a Zeba spin column into 
nucleotide exchange (NE) buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 10 
mM MgCl2). Nucleotide loading was confirmed by native mass-spectrometry 
(refer section 2.3.3). 
 
2.2.5 Guanine nucleotide exchange assay  
 
Nucleotide exchange buffer (section 2.1.4) was supplemented with 0.4 mM 
GTP and 0.5 μM SOScat for experiments involving KRas. The Affimers were 
diluted with this buffer to make 20 μM stock solutions and quantified using 
BCA assay. Following which serial dilutions of the Affimers was carried out by 
diluting each new concentration of Affimer 2-fold with nucleotide exchange 
buffer supplemented with SOScat and GTP. A 1 μM stock of the KRas bound 
to fluorescent GDP analogue MANT-GDP (mGDP) protein was made by 
diluting the stock KRas-mGDP (20 μM) in nucleotide exchange buffer 
supplemented with 2 mM DTT. Solutions were incubated at 37°C for 10 min 
prior to the assay. The reaction was initiated by addition of Affimer/SOScat/GTP 
solution to Ras-mGDP/DTT containing solution. Changes in fluorescence of 
KRas-mGDP were measured by a fluorescence spectrometer (Tecan Spark) 
in a Corning black, flat-bottomed, non-binding 384 well plate using 340/450 
nm excitation/emission filter, every minute for 90 min. The data was then 
normalised to Ras mGDP-only control and fit a single exponential decay using 
Origin Pro software. The derived rates were normalised to Ras-Sos and Ras-
mGDP only samples and fit to Hill equation (y = START + (END – START) (xn 





2.2.6 Ras-Raf interaction assay 
  
Glutathione magnetic agarose beads (Thermo Scientific) were blocked with 2x 
blocking buffer (Sigma) overnight at 4⁰ C. Beads were then washed with 
Binding/Wash (B/W) buffer (125 mM Tris-Cl, 150 mM NaCl, 5 mM MgCl2, 1 
mM DTT, 0.1% w/v Tween-20, pH 8.0) and incubated with Raf-RBD-GST 
soluble cell lysate and GST lysate (negative control) for 1 h at room 
temperature on a roller. At the same time, 1 μg of KRas-GTP (in B/W buffer) 
was incubated with 60 μg/100 µl of Affimers (in PBS) or PBS (no Affimer 
control) for 1 h at room temperature on a roller. Beads were washed 3x with 
B/W buffer and mixed with KRas-Affimer solutions. The pulldown was 
performed on KingFisher FlexTM robotic platform, programmed to incubate 
Raf-RBD-GST bound beads with KRas-Affimers for 1 h at room temperature. 
This was followed by 4x washes with B/W buffer, 15 sec each and elution of 
pulled down proteins into SDS-PAGE sample buffer. Proteins were then 
analysed by western blot with anti-GST and anti-Ras antibodies (Table 2.4). 
 
 
2.2.7 Affimer-Ras interaction assay 
 
His Mag Sepharose™ Ni beads (GE healthcare) were blocked with 2X 
blocking buffer overnight at 4°C. Beads were incubated with 20 µg of Affimer 
K3/mutant K3 for 1 h at room temperature on a roller. After incubation beads 
were washed with Binding/Wash (B/W) buffer (125 mM Tris-Cl, 150 mM NaCl, 
5 mM MgCl2, 1 mM DTT, 0.1% w/v Tween-20, pH 8.0) 3X times and mixed 
with 100 µl of KRas lysate (no tag). The pulldown was performed on 
KingFisher FlexTM robotic platform, programmed to incubate Affimer bound 
beads with KRas WT / mutant KRas for 1 h at room temperature. This was 
followed by 4x washes with B/W buffer, 15 sec each and elution of pulled down 
proteins into SDS-PAGE sample buffer supplemented with 500 mM Imidazole. 
Proteins were then analysed by western blot with anti-Ras and anti-His 




2.2.8 Protein crystallisation  
2.2.8.1 Initial screening of Affimer K3-KRas 
 
Crystallisation experiments were initiated with commercial sparse matrix 
screens, JCSG Core I-IV (Qiagen, Manchester, U.K). Using the NT8 drop 
setter robot (Formulatrix, M.A, U.S.A), the Affimer-KRas complex in 10 mM 
Tris-Cl, 50 mM NaCl, 0.5 mM TCEP, pH 8 at a protein concentration of 12 
mg/ml was mixed in 1:1, 2:1 and 1:2 ratio of protein to a unique set of 
conditions from sparse matrix screens mentioned above. The sitting-drop 
vapour diffusion technique was utilised. The plates were sealed and stored at 
room temperature. Crystal formation was monitored with the Rock Imager 
(Formulatrix) using visible light. Also, the absorption of aromatic residues at 




2.2.8.2 Additional preliminary screening for Affimer K3-KRas  
 
Additional crystallisation experiments were carried out with commercial crystal 
screens, Crystal screen 1 and 2 (Hampton, CA, U.S.A) and Wizard Classic 3 
and 4 (Rigaku, WA, U.S.A). Using NT8 drop setter robot (Formulatrix), the 
Affimer-KRas complex in 10 mM Tris-Cl, 50 mM NaCl, 0.5 mM TCEP, pH 8 at 
a protein concentration of 24 mg/ml was mixed in 1:1, 2:1 and 1:2 ratio of 
protein to a unique set of conditions from sparse matrix screens mentioned 
above. The sitting-drop vapour diffusion technique was utilised. The plates 
were sealed and stored at room temperature. Crystal formation was monitored 
with the Rock Imager (Formulatrix) using visible light. In addition, the 
absorption of aromatic residues at 280nm (UV) was employed in order to 
differentiate protein crystals from salt crystals. Crystals were obtained in 2 M 
(NH4)2SO4 pH5.6, 0.2 M K Na Tartrate and 0.1 M Trisodium citrate. Crystals 







2.2.8.3 Crystal diffraction and structure determination 
 
X-ray diffraction data were collected using beamline ID30A-1 at the European 
synchrotron radiation facility, on a wavelength of 0.966 Å and at 100 K. The 
structure of KRas-K3 complex was solved by molecular replacement using 
Protein Data Bank (PDB) codes 4OBE for the KRas and 4N6T for the Affimer 
with the program Phaser (McCoy., 2007). Structures were refined using 
REFMAC5 (Murshudov et al., 2011), followed by iterative cycles of a manual 
model building using COOT (Emsley and Cowtan., 2004). Data collection and 
refinement statistics are summarized in Table 2.9. Data collection, processing 





































Table 2.9 X-ray crystallographic data collection, processing and 
refinement statistics for Affimer K3-KRas complex. 
 
Data set AffimerK3-KRas 
Source ESRF ID30A-1 
Wavelength (Å) 0.966 
Resolution range (Å) * 54.09–2.06 (2.11–2.06) 
Space group P21 
Unit-cell parameters (Å) a=73.1, b=39.5, c=113.1 
 α=90.0,β=106.9,γ=90.0 
No. of observed reflections 113731 
No. of unique reflections 38740 
Redundancy 2.9 (3.0) 
Completeness (%) * 99.7 (99.9) 
< I/σ(I) >* 6.2 (1.3) 
Rmerge  0.09 
Rpim (%) ¥*                   6.3 (29.1) 
Resolution range for refinement (Å)  54.16-2.06 
R, Rfree 0.236, 0.278 
0.242, 0.284 
Rfree test set 1946 reflections (5.04%) 
Wilson B factor (Å2) 33.0 
Anisotropy 0.532 
L test for twinning  <|L|>=0.50, <|L|2>0.34 
Estimated twinning fraction 0.013 for h, -k,-h-l 
Average overall B factor (Å2) 46.0 
  F0 Fc correlation  0.94 
Total number of atoms 0.4298 
Ramachandran analysis, the 
percentage of residues in the 
regions of plot (%) ‡ 
 
Favoured region 95% 
Outliers 0.4% 
PDB code  6YXW 
  
 
Values given in parentheses correspond to those in the outermost shell of the 
resolution range.   
§ ( ) ( ) ( )   −= hkl ihkl i imerge hklIhklIhklIR /   
* Rp.i.m is the precision-indicating (multiplicity-weighted) Rmerge relative to I+ or 
I-.   
† Rfree was calculated with 5% of the reflections set aside randomly. 




2.3.1.4 Initial screening of Affimer K3 apo 
 
Crystallisation experiments were initiated with commercial sparse matrix 
screens, JCSG Core I-IV (Qiagen) and Morpheus screen (Molecular 
Dimensions, Sheffield, U.K). Using the NT8 drop setter robot (Formulatrix), the 
Affimer K3 in 10 mM Tris-Cl, 50 mM NaCl, 0.5 mM TCEP, pH 8 at a protein 
concentration of 80 mg/ml was mixed in 1:1, 2:1 and 1:2 ratio to a unique set 
of conditions from sparse matrix screens mentioned above. The sitting-drop 
vapour diffusion technique was utilised. The plates were sealed and stored at 
room temperature. Crystal formation was monitored with the Rock Imager 
(Formulatrix) using visible light. In addition, the absorption of aromatic residues 
at 280nm (UV) has been employed in order to differentiate protein crystals 
from salt crystals. Crystals were obtained in 0.1 M HEPES pH7.5 containing 
30% v/v PEG 300 and 0.2M MgCl2. Crystals were frozen in 75% w/v mother 
liquor and 25% w/v ethylene glycol. 
 
2.3.1.5 Crystal seeding of Affimer K3 apo 
 
Small, non-three-dimensional crystals are picked from initial JCSG screens.  
Seed stock is prepared by transferring a stack of crystals to micro seed bead 
tube, in which protein solution (20 mg/ml) used previously, for crystallisation 
screening is added. Once vortexed, three serial dilutions of seed stock were 
prepared in the protein solution. These serially diluted samples are used for 
crystal seeding using optimisation block (0.1 M Na phosphate citrate, 40% v/v 
PEG 300) prepared previously from JCSG screens. The plates were sealed 
and stored at room temperature. Crystal formation was monitored with the 
Rock Imager (Formulatrix) using visible light. In addition, the absorption of 
aromatic residues at 280 nm (UV) has been employed in order to differentiate 







2.3.1.6 Crystal diffraction and structure determination of K3 Affimer  
 
X-ray diffraction data were collected using beamline i24 at the Diamond 
synchrotron radiation facility, on a wavelength of 0.8 Å and at 100 K. The 
structure of K3 Affimer was solved by molecular replacement using Protein 
Data Bank (PDB) code 4N6T for the Affimer with the program Phaser (McCoy., 
2007). Structures were refined using REFMAC5 (Murshudov et al., 2011) 
followed by iterative cycles of the manual model building using COOT (Emsley 
and Cowtan., 2004). Data collection and refinement statistics are summarized 
in Table 2.9. Data collection, processing and structure determination were 
carried out by Dr Chi Trinh. 
 
2.3.1.7 Circular Dichroism (C.D) spectroscopy analysis  
 
Far UV spectra were performed on Chirascan circular dichroism (C.D) 
spectrophotometer (Applied Photophysics, Surrey, U.K) at 20° C, using 1 mm 
path length cuvette and a scan speed of 5 nm/min. The spectra (190-260 nm) 
were recorded using 200 µl protein solution (at a concentration of 
approximately 0.2 mg/ml) and averaged over 3 repeats with a buffer (20 mM 
sodium phosphate) baseline subtracted. Dichroweb software (Whitmore and 
Wallace., 2004) was used for C.D and deconvolution analysis.  
 
2.3.1.8 Native mass spectrometry   
 
The KRas protein samples with and without GppNHp (non-hydrolysable GTP) 
were sent to the mass spectrometry facility in the University of Leeds. To 
confirm the mass of the KRas protein in its native/folded state bound to 
GppNhp, 1 mg/ml of protein was buffer exchanged in 200 mM ammonium 
acetate pH 7.5 and analysed by nano-electrospray ionisation mass 
spectrometry. Quadrupole orbitrap mass spectrometer was used for 
transmission of high m/z ions (Q-Exactive Plus, ThermoScientific). Ions were 
generated with a nanospray voltage of 1.5 kV; these were passed through the 
heated capillary tube (250 °C) into the mass spectrometer. Ions were trapped 
briefly (4 µs) in the source region to aid desolvation with a desolvation voltage 
67 
 
of -150 V. Ions then passed through the multipoles and quadrupole which was 
operated at wide transmission window (m/z 350-5000) to the c-trap from where 
packets of ions were injected into the orbitrap cell for mass analysis. The 
instrument was operated by Tune software version 2.10 provided with the 
instrument. Mass calibration up to m/z ~12000 was performed using 2mg/ml 
CsI clusters in IPA: water. Data was processed using Xcalibur Qual Browser 











































                                          Chapter 3  
      Biochemical characterisation of Ras specific Affimer 
 
3.1 Introduction  
 
Ras is a small GTPase that acts as a molecular switch in a variety of signalling 
pathways and is involved in various functions including regulation of cell 
proliferation, differentiation and survival (Young et al., 2009). Ras oscillates 
between inactive GDP bound (Ras-GDP) and active GTP bound form of Ras 
(Ras-GTP). Ras-GTP interacts with multiple effector proteins including Raf 
and PI3 kinases, leading to activation of cell proliferation and survival (Prior et 
al., 2012). Aberrant Ras signalling due to mutation results in tumorigenesis. 
For instance, single base missense mutation mostly occurring at codon 12, 13 
and 61 results in impairment of GAP induced GTP hydrolysis of Ras. These 
mutations cause Ras to stabilise active GTP bound form leading to 
uncontrolled cell growth (Pei et al., 2018). Ras mutations occur in 30% of all 
human cancers and are well-established cancer drivers. There are three 
different isoforms of Ras namely, HRas, KRas and NRas and among them 
KRas is the most frequently mutated Ras isoform, accounting for 86% of all 
Ras mutations. Mutations in KRas are prevalent in cancers with high mortality 
rates which include pancreas (95% prevalence), colon (35% prevalence) and 
lung cancers (17% prevalence) (Omerovic et al., 2008; Stephen et al., 2014).  
Despite Ras being an attractive pharmacological target, there are challenges 
in inhibiting Ras using current small molecule-based drug discovery 
techniques (Ostrem and Shokat., 2016; Stephen et al., 2014; Dang et al., 
2017). The challenges include a lack of accessible pockets to which drug could 
bind with high affinity. Different strategies to directly inhibit Ras has met with 
recent success with the development of pharmacological agents that 
specifically target KRasG12C mutant protein. This has led to a first direct Ras 
inhibitor to enter phase I clinical trials (O'Bryan., 2019). KRasG12C mutation is 
present in 15% of all lung cancer and 32% of colon cancer patient samples 
(Sondka et al., 2018). However, G12C mutation accounts for only 11% of all 
KRas mutations. Development of small-molecule inhibitors against other KRas 
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mutations such as G12D (33.4%) and G12V (22.8%) using conventional 
screening have not been successful so far (O'Bryan., 2019). 
To identify druggable pockets in KRas for small molecules to bind to, Affimer 
reagents that bind to KRas have been isolated (see preliminary results). Here, 
biochemical characterisation of Affimer K3 via a range of techniques like 
nucleotide exchange assays, circular dichroism, co-immunoprecipitation 
indicated that both variable regions in Affimer K3 are essential for binding and 
inhibition of KRas. Mutation of two variable regions of K3 to alanine revealed 
that most residues present in only one of the variable region has been shown 
to be involved in inhibition of KRas activity, while the second variable region 
could be involved in stabilisation of intramolecular interactions of K3 Affimer 
and trapping KRas in an inactive conformation. Taken together, these results 
suggest that Affimer K3 can be used as a tool to identify druggable binding 
pocket in “difficult to drug” KRas oncoprotein.  
 
3.1.1 Preliminary results  
In order to identify KRas binding reagents, the Affimer phage library (1.3 x1010 
clones) (Tiede et al., 2014) was screened against WT KRas-GDP. After 
multiple rounds of panning, ninety-six randomly selected clones were isolated 
that bound to KRas irrespective of nucleotide state and were tested via phage 
ELISA (Figure 3.1). The majority of isolated Affimers displayed little or no 
binding to control (Streptavidin only). Out of ninety-six clones, seven unique 
Affimer sequences were identified. The amino acid sequences of variable 
regions of these seven unique Affimers and number of appearances (defined 
as a number of occurrences of the clone) is shown in Table 3.1. This, therefore, 
demonstrated that Affimer can bind to both active and inactive conformations 





  Figure 3.1 Phage ELISA for 96 Affimer clones isolated against KRas wild type. Bacteriophage 
expressing one Affimer clone was incubated with biotinylated wild type KRas GDP and GTP immobilised on 
streptavidin-coated plates. Plates were washed 3 times with 1xPBST, and the bound phage was detected 
with HRP conjugated anti-phage antibody and absorbance was measured at 620 nm. Streptavidin only wells 




Table 3.1 Amino acid sequences of variable regions and the number of 
appearances of seven unique Affimers against KRas wild type. 
 
Affimer Variable region   1 Variable region 2   Number of 
appearances 
K3 HSIDIWYDF KLNNSHTYK 80 
K6 HFTPWFQRN RIMVTDKMR 2 
K37 FFYLWLAPG AANSPMYHE 1 
K19 QYNPWFQTN VIHGTRWGN 5 
K68 YPNPWYQVN NMRVDMIVH 1 
K69 WHFDYQQYN RQLRMGSMN 1 
K91 WDFSAWWKY RNRYFKFPN 1 
 
To identify the ability of Affimers to inhibit nucleotide exchange reaction- a 
process involved in the activation of Ras, nucleotide exchange assay was 
carried out (Figure 3.2). This assay is useful for screening small molecular 
inhibitors for drug discovery and high throughput targeting of KRasG12C 
(Ostrem et al., 2013). For this assay, KRas was loaded with fluorescent N- 
Methylanthraniloyl guanosine-5’-diphosphate (MANTGDP/mGDP). 
MANTGDP binds to KRas in the presence of EDTA. EDTA chelates 
magnesium ions, which form coordination bonds with β and γ phosphate of 
GTP and with GTPase (Kanie and Jackson., 2018). KRas-mGDP was 
incubated with GEF SOScat, excess of unlabelled GTP and a fixed 
concentration of Affimer. SOScat catalysed nucleotide exchange was 
monitored by a decrease in fluorescence intensity of mGDP upon nucleotide 
release of mGDP from KRas. The reaction was monitored for 90 minutes, and 
data was normalised to Ras only control to account for well to well variability 







The observed results demonstrated the ability of seven unique Affimers (as 
shown in Table 3.1) to inhibit SOScat mediated nucleotide exchange reaction 
in a time-dependent manner. Affimer K3, K6 and K37 displayed the most 
potent inhibition of the reaction with fluorescence intensity (FI) between 1-0.95 
very close to WT KRas-mGDP control (black square dots) (this work was 
carried out by Kevin Tipping). While Affimer K19, K68 showed a modest effect 
with FI values between 0.7-0.75 and Affimer K69, K91 demonstrated the 
weakest inhibition with FI values at 0.4 very close to SOScat control (red circle 
dots) (Figure 3.3). This FI values suggests that three Affimer clones, namely 
K3, K6, K37, have the most potent inhibition of nucleotide exchange reaction 
due to consistently high fluorescence values similar to WT KRas-mGDP 
control over a 90-minute time interval.  These three Affimers were carried 








Figure 3.3 KRas binding Affimers inhibited SOS catalysed nucleotide 
exchange reaction. Wild type KRas protein, loaded with fluorescent 
nucleotide mGDP (Black squares) exhibits a constant high FI value of 1 and 
used as a positive control. Another control is a mixture of KRas-mGDP and 
SOScat (red circles), in which there is nucleotide release of mGDP and binding 
of GTP indicating a consistent decrease in FI value over time. Different KRas 
binding Affimer clones (coloured shapes) are evaluated with FI values 
between these two controls. FI values were measured every 60 seconds for 
90 minutes. Each Affimer inhibited nucleotide exchange reaction with different 
potencies (Haza., 2019).  
 
Since Ras isoforms have a high degree of sequence homology and activate a 
common set of upstream and downstream effectors (Castellano and 
Downward, 2011), WT HRas was tested with KRas binding Affimers in the 
nucleotide exchange assay. It was observed that Affimer K3, K6 and K37 were 
also capable of inhibiting nucleotide exchange of HRas. Affimer K6 and K37 
did not show any isoform specificity as evidenced by similar inhibitory 
potencies towards WT HRas as toward WT KRas (Table 3.2). Interestingly, 
significantly lower inhibition of HRas (IC50 ~ 2.6 µM) in comparison to KRas 
(IC50 ~ 145 nM) was observed with K3. This suggests that K3 displayed potent 
inhibition of KRas in an isoform-specific manner. 
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Table 3.2 – Calculated IC50 values of K6 and K37 Affimers for KRas and 
HRas WT. Values were calculated from Hill equation, to which data were 
fitted and represent the average of three biological repeats (n=3). Error bars 
± represent standard error of the mean (SEM).  
 
Affimer IC50 values (nM)   
 KRas WT HRas WT 
K3 144± 94 2585± 335 
K6 594 ± 271 389 ± 187 
K37 697 ± 158 626 ± 320 
 
To analyse the effect of Affimers on three most frequently mutated KRas 
mutations such as KRasG12D (35%), KRasG12V (24%) and KRasQ61H (13%), 
nucleotide exchange assay was carried out as previously described. Affimer 
K3 showed similar inhibitory potencies towards WT KRas and G12D and G12V 
mutants, but it is significantly less effective at inhibiting nucleotide exchange 
on Q61H mutant. Additionally, Affimer K3 showed higher IC50 values than K6 
and K37 Affimer to inhibit G12D and G12V mutants. This, therefore, indicated 
K3 not only displayed isoform specificity but also capable of inhibiting KRas 
mutants. Altogether, these findings have established the ability of Affimers to 
modulate Ras activation by nucleotide exchange. This work was carried out 
by Katarzyna Haza.  
Table 3.3 – Calculated IC50 values of K3, K6 and K37 Affimers for 
oncogenic KRas mutants. Values were calculated from Hill equation, to 
which data were fitted and represent the average of three biological repeats 
(n=3). Error bars represent ± SEM.  
 
Affimer IC50 value (nM)   
 KRas G12D KRas G12V KRas Q61H 
K3 144 ± 40 176 ± 115 3005 ± 865 
K6 185 ± 46 571 ± 148 532 ± 165 




3.2 Results  
   
To further characterise and understand binding and inhibition of KRas by K3 
Affimer, nucleotide exchange assay and a range of biophysical techniques 
were used.  
3.2.1 Affimer K3 inhibits SOScat mediated nucleotide exchange 
For examining the inhibitory function of Affimer on KRas, nucleotide exchange 
assay was carried out using KRas, SOScat and Affimer K3. Protein expression 
and purification of Affimer K3 and KRas was carried out in E. coli BL21 (DE3) 
StarTM competent cells and purified using Ni2+ ion affinity chromatography 
(Ni2+-NTA) as described in section 2.2.3.1 and 2.2.3.2. Eluted fractions were 
analysed by SDS-PAGE and Coomassie staining, which indicated purification 
of proteins with a molecular weight of 12 kDa for Affimer (Figure 3.4 A) and 21 
kDa (Figure 3.4 B) for KRas, respectively. In the case of Affimer, A280 nm was 
measured using a Nanodrop spectrophotometer (section 2.2.1.8) for each 
elution, and these values were used to calculate protein concentration using 
Beer-Lambert Law. For KRas, BCA assay was carried out to estimate the total 
protein concentration in elution buffer (refer section 2.1.4). The typical yields 
of purified proteins ranged from 20-30 mg/L culture for Affimer K3 and 1-5 




        
 
Figure 3.2 Diagram of nucleotide exchange assay. KRas (blue), loaded 
with fluorescent MANTGDP/mGDP (yellow) was incubated with GEF SOS and 
excess of unlabelled GTP (green). Over 90-minute time interval, nucleotide 
exchange was monitored as evidenced by a decrease in fluorescence intensity 
upon nucleotide release of mGDP from KRas, followed by binding to GTP. 
 
However, in case of SOScat, conditions for protein production were different 
from Affimer and KRas and is described in section 2.2.1.6. The recombinant 
proteins were purified from bacterial cell lysates using nickel ion affinity 
chromatography. Eluted fractions were analysed by SDS PAGE and 
Coomassie staining, which indicated purification of proteins with a molecular 
weight of 59.2 kDa for SOScat (Figure 3.4 C). For determination of SOScat 
protein concentration, a BCA assay was carried out. The typical yields of 




Figure 3.4 Production and purification of Ras, Affimer K3 and SOS for 
nucleotide exchange assay A. Following IPTG induced expression in E. coli 
BL21 StarTM DE3 cells, Affimer K3 (12 kDa) was purified by His-tag affinity 
chromatography and eluted proteins were identified by coomasie staining, 
which indicated 95% or more purity of the samples. B. Following IPTG induced 
expression in BL21 StarTM DE3 cells, the whole-cell lysate was analysed by 
Coomassie staining, which demonstrated efficient expression of KRas (20.5 
kDa) C. SOS1 catalytic domain (SOScat) (59.2 kDa) was produced and purified 
as mentioned in A. and analysed by Coomassie staining, which indicated 
efficient purity for downstream assays. 
 
To understand the effectiveness of Affimer K3 as a potent inhibitor of 
nucleotide exchange of WT KRas, a range of Affimer K3 concentration from 5 
nM to 10 µM was titrated against 1 µM KRas. Dose-dependent inhibition of 
nucleotide exchange reaction was observed with the highest Affimer 
concentration displaying the highest level of inhibition.  From the obtained 
dose-response curve, the concentration of Affimer K3 required for 50% 
inhibition of the reaction was calculated to be 200± 6 nM (Figure 3.5). The 
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value calculated by Katarzyna Haza was 144±94 nM for K3 WT (Table 3.2). 
However, the variability within the sample is high i.e. +94 nM.  
                
             
Figure 3.5 Affimer K3 inhibits nucleotide exchange on wild type KRas. 
Dose-response curved for Affimer K3 demonstrating inhibition of nucleotide 
exchange of wild type KRas. The initial nucleotide exchange reaction was 
plotted against Affimer concentrations of 5 nm-10 µM and fitted to Hill model, 
which was used to calculate IC50 values. The result is representative of three 
biological replicates (n=3). IC50 of K3 Affimer was found to be 200 ± 6 nM.  
 
3.2.2 Affimer K3 inhibits the interaction of Ras with Ras binding domain 
of CRaf 
One of the strategies to block Ras function involves inhibiting Ras-effector 
interactions with a number of previously reported Ras inhibitors demonstrating 
impairment of this interaction (Keeton et al., 2017). Therefore, the capabilities 
of Affimers to inhibit Ras-Raf interaction were also investigated. This was done 
by pulldown assay as described in section 2.2.3.4, with recombinant Ras 
binding domain (RBD) of CRaf (McGee et al., 2018). Since K3, K6, and K37 
Affimers have been identified as the potent inhibition of nucleotide exchange 
reaction; these were further investigated for Ras-Raf inhibition.  
79 
 
Before the Ras-Raf inhibition assay, KRas was loaded with GppNhp (a poorly 
hydrolysable GTP analogue), and its binding to KRas was verified using native 
mass spectrometry (refer section 2.3.3) (Leney and Heck., 2017). 
Deconvolution of native mass spectra of WT KRas (20536 Da) (Figure 3.6 A) 
and KRas loaded with GppNhp (21031 Da) was compared. The spectra show 
a mixture of both wild type as well as GppNhp bound KRas (Figure 3.6 B). 
There is a shift of 495 Da indicative of the molecular weight of GppNHp minus 
the phosphate group. To analyse the effect of Affimer K3, K6 and K37 on 
KRas-Raf interaction, immunoprecipitation assay was performed as described 
in section 2.2.6. Affimer containing alanine residues in the variable regions 
and Dynabeads™ only sample were used as controls (Figure 3.7 A).  
The ‘no Affimer’ and ‘alanine Affimer’ sample successfully pulled down KRas-
GTP with RBD-GST (Figure 3.7A). GST only sample was used as a negative 
control since Raf1-RBD has a GST tag. A band representing KRas was not 
present on the gel, indicating specific binding to RBD, and not to the GST tag. 
Pre-incubation of K3 with KRas blocked the KRas-RBD interaction almost 
completely, as demonstrated by a faint band on the gel in comparison to the 
amount of KRas-GTP obtained using alanine Affimer (Figure 3.7 B). Affimer 
K6 and K37 also significantly impaired this interaction, although much less 
extent than K3. These findings suggest that Affimer K3 has a dual mode of 
inhibition of KRas i.e. it inhibits nucleotide exchange to GTP and at the same 









             
Figure 3.6 Deconvolution of native mass spectra. Deconvolution of 
electrospray ionisation mass spectrometry (ESI-MS) showing the presence of 
A. KRas WT and B. GppNhp (non-hydrolysable GTP) bound to KRas. 
Highlighted red boxes show mass (Da) of WT Ras (M.W-20536 Da) and 
GppNhp bound Ras (M.W- 21031Da), indicating a shift in spectra when 
GppNhp is added to KRas. Asterisk (*) indicates bound sodium and 
magnesium adducts. Based on mass/charge (m/z) ratio, different symbols 
have been assigned to differentiate each peak with the lowest mass (kDa) 








Figure 3.7 Immunoprecipitation of KRas with GST Raf1RBD is inhibited 
by Ras binding Affimers. GST tagged Raf1RBD was added to KRas-GTP, 
which was pre-incubated with Affimers. RBD-GST was precipitated on 
glutathione Dynabeads and pulled down proteins were analysed by western 
blot with anti-Ras and anti-His antibodies. A. Western blot analysis of 
precipitated proteins were analysed using anti-Ras and GST antibodies both 
before (input) and after pulldown assay (output). Alanine Affimer is used as a 
control. Affimer K3, K6 and K37 significantly inhibited KRas-RBD interaction, 
as demonstrated by reduced pulldown of KRas-GTP in comparison to no 
Affimer sample. GST only was used as a negative control.  B. For densitometry 
analysis, relative KRas-GTP levels from the pulldown assay were normalised 
to levels of Alanine Affimer (control Affimer). Negligible or very low amounts of 
Ras are present for KRas, which is at a similar level to GST only control. 
Results are representative of three biological replicates (n=3). Error bars 
denote ±SEM. Error bars are ±SEM. p˂0.05 (*), p˂0.01 (**), p<0.001 (***) and 














3.2.3 Both variable regions of Affimer K3 are involved in binding and 
inhibition of KRas 
To investigate which variable region of K3 Affimer are essential for binding and 
inhibition of KRas, each variable region (VR1 and VR2) was replaced by three 
alanine residues, producing two variants of K3 - K3△VR1 and K3△VR2. These 
mutants have been created by a technique called splicing by overlap extension 
(SOE) as described in section  2.2.1.10 (Thornton., 2016). Four PCR products 
were used to make the constructs (Figure 3.8A). The first PCR product 
contained the K3 sequence encoding the VR1, the second PCR product 
contained alanine Affimer VR2 sequence. The third PCR product contained 
alanine VR1 sequence, while the fourth PCR product contained K3 VR2 
sequence. These PCR products of approximately 190 (PCRI/III) and 200 bp 
(PCR II/IV) length (Figure 3.8B), were then subjected to SOE as described in 
chapter 2.2.1.10, to splice the two fragments together (PCR I+II and III+IV). 
Agarose gel analysis indicated a single band in which two products of 390 bp 
in size were conformed, indicating successful splicing of two PCR fragments 
(Figure 3.8B). The product encoding K3△VR1 and of K3△VR2 was ligated in 
pET11a bacterial expression vector (refer section 2.2.1.6). The replacement 
of K3 △VR1 and △VR2 in each plasmid DNA was confirmed by sequencing.  
K3△VR1 and K3△VR2 mutant proteins were produced and purified as 
described in section 2.2.3.1 and ability to bind and inhibit KRas interactions 
were evaluated using pulldown assays (refer section 2.2.9). Either, wild type 
Affimer K3, K3△VR1 or K3△VR2 mutant proteins were immobilised on Pierce® 
Ni-NTA magnetic Agarose beads and incubated with soluble KRas protein (no 
tag). After washing the beads, the eluted Ras-Affimer complex were analysed 
by western blotting to visualise the presence of Ras using an anti-Ras antibody 
and Affimer using an anti-His antibody. The wild type K3 Affimer pulled down 
KRas as demonstrated by a thick band when stained with Ras antibody (Figure 
3.9). In contrast, no bands were observed for K3△VR1 and K3△VR2, 
therefore indicating no binding to KRas. Likewise, Alanine Affimer (control 
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Affimer) did not pull down KRas, indicating any pulled down proteins is due to 
specific interaction with KRas (Figure 3.9).  
             
 Figure 3.8 Cloning strategy to create mutants with deleted Affimer K3 
variable region 1or 2.  A. Schematic diagram outlining two templates – Full-
length K3 Affimer and Alanine Affimer with amplification of VR1 of K3 and 
Alanine Affimer VR2 and vice versa and splice overlap extension product of 
two PCR products I + IV and II+III.  Primers P1, P2, P3 and P4 sequences are 
mentioned in table 2.2 B. Agarose gel analysis of the four PCR products 
demonstrating four bands of approximately 190 and 200 bp in size. Splice 
overlap extension of I+IV and II+III generate two PCR clones encoding 
K3△VR1 and K3△VR2 mutants respectively of approximately 390 bp in size. 
This indicates successful splicing of the PCR products. PCR1= P1+P3, 
PCR2=P2+P4 using K3 Affimer sequence as template, PCR3= P1+P3, 







     
Figure 3.9 Binding studies of Affimer K3, K3△VR1 and K3△VR2 on KRas. 
A. 15% SDS-PAGE analysis of K3△VR1, K3△VR2, K3 and Alanine Affimer 
proteins prior to binding studies B. Pierce® Ni-NTA agarose magnetic beads 
were pre-incubated with 8x His tagged Affimer K3 and deleted VR1 and VR2 
mutants. The KRas-Affimer complex was precipitated and pulled down 
proteins were analysed by western blot with anti-Ras and anti-8x His 
antibodies. Results are representative of three biological replicates (n=3). 
 
 Next circular dichroism (CD) was carried out to check the stability and folding 
after substitution of variable regions to alanine residues (K3△VR1 and 
K3△VR2). Secondary structure of mutant Affimer K3 proteins, as well as wild 
type K3 protein used in the pulldown assays, were analysed by CD in far UV 
spectra (190-240 nm). CD spectra of individual mutant proteins and wild type 
when overlapped shows mean residue ellipticity (MRE) variation around 2±1 
% (Figure 3.10). MRE is a unit specific for proteins and accounts for molar 
ellipticity of individual amino acid residues instead of whole protein, allowing 
for easy comparison of proteins with different molecular weights (Greenfield., 
2006). This, therefore, indicates that structural integrity of Affimer mutants is 
stable even after substitution of alanine in each variable region.  
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Figure 3.10 Circular dichroism analysis of K3 WT, K3△VR1 and K3△VR2 
A. Circular dichroism spectra (far ultraviolet region [190-240 nm]) of purified 
K3 WT, K3△VR1 and K3△VR2 proteins (see Figure 3.9A) at 0.2 mg/ml 
concentration in 20mM sodium phosphate buffer solution. The molar ellipticity 
values of spectra showed similar ellipticity values indicating no change in the 
structural integrity of proteins. B. Deconvolution of CD spectra suggests 15-
16% α helix, antiparallel β sheets around 27-28%, which is similar to spectra 
observed with Adhiron scaffold. Overall variation in spectra between mutants 
and wild type K3 Ras was found to be around 2%. Results are representative 
of three biological replicates (n=3). Deconvolution and CD analysis were 




Next, the functional effect of VR1 and VR2 deletion of K3 was tested using the 
nucleotide exchange assay (as described in section 2.3.1). In this assay, 
Affimer protein concentration was calculated as per section 2.2.2 and 
confirmed by running 0.2 mg/ml of each Affimer protein on an SDS PAGE gel 
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(Figure 3.11 A). Incorrect protein concentrations can lead to a significant 
difference in the association rate constant (ka) and affinity (KD), which can 
eventually affect inhibitory concentration (IC50) (Pol, 2010). Fluorescence 
intensity (F.I) (a.u) of K3 and KRas mGDP was 1, indicating complete inhibition 
of nucleotide exchange activity. However, FI values for mutant K3△VR1 and 
K3△VR2 were around 0.65-0.7 at the same level as SOScat (Figure 3.11 B). 
The assays showed the inability of K3△VR1 and K3△VR2 to inhibit nucleotide 
exchange on KRas, even when the highest Affimer K3 concentration of 50 µM 
was used. Altogether, these findings established that both VR1 and VR2 of 
Affimer K3 are expected to  bind and inhibit KRas (Figure 3.8). 
 
Figure 3.11 Nucleotide exchange assay for K3WT, K3△VR1 and K3△VR2 
A. Protein expression and purification of K3 WT, K3△VR1 and K3△VR2 was 
carried out and was run on a 15% SDS-PAGE indicating correct protein 
concentration. B. Nucleotide exchange assay on WT Affimer K3 and K3△VR1 
and K3△VR2 with protein concentration ranging from 5 µM and maximum 50 
µM show that both VR1 and VR2 are essential for KRas binding. Results are 










3.2.4 Identification of Affimer K3 residues involved in binding and 
inhibition of KRas 
One of the major goals in understanding cellular processes is a detailed 
understanding of how protein-protein interactions work (De Las Rivas and 
Fontanillo., 2010). The three-dimensional protein structures provide 
information about their binding epitopes. However, they do not elucidate the 
functional roles of individual residues within the epitope that make energetic 
contributions to the binding interaction (Weiss et al., 2000). One strategy for 
the elucidation of functional epitopes to understand protein structure and 
function is site-directed mutagenesis. Alanine scanning mutagenesis is the 
most widely used technique in systematically mapping functional binding 
epitopes (Weiss et al., 2000). The substitution of variable regions to an alanine 
residue removes all the side chain atoms past the β carbon. The effects of 
individual alanine mutations can be used to infer the role of individual side 
chains  (Gauguin et al., 2008).    
QuikChange site-directed mutagenesis was used to replace each of the 
Affimer K3 variable residues to alanine, to determine the contributions to the 
binding interaction with KRas (Kunkel., 1985). The QuikChange method allows 
efficient site-directed substitution, deletion or insertion in a one-step procedure 
(Kunkel., 1985). The mutagenesis was performed as described in section 2.2.2 
by Dr Katarzyna Haza. Mutagenesis was confirmed by sequencing, which 
demonstrated successful substitution of each residue. 
Affimer K3 alanine mutants were produced and purified, as described in 





Figure 3.12 Expression and purification of K3 alanine mutants. Following 
IPTG induced production in BL21 StarTM DE3 cells K3 variable region 1 (VR1) 
alanine mutants and K3 variable region 2 (VR2) mutants were purified by His 
tag chromatography. These were eluted in imidazole buffer and dialysed in 1x 
PBS buffer and analysed by Coomassie staining, which indicated 90% or more 
purity of samples.  
 
 
To identify which residues are involved in binding and inhibition of KRas, Ras-
Affimer immunoprecipitation assay was performed. As visualised in Figure 
3.13 VR1 residues I40, D41, I42, W43, Y44 and D45 when mutated to alanine 
had the most significant effect on binding to KRas as seen by no presence of 
Ras on western blot. This, therefore, demonstrated that these residues are 
mostly involved in binding and inhibition of KRas. Mutations of residues L73 
and K80 to alanine had a moderate effect on binding to KRas, suggesting that 
these could be involved in facilitating the binding of Affimer K3 to KRas. These 
findings correlated with K3△VR1 and K3△VR2 mutants’ findings in section 





Figure 3.13 Effect of Affimer K3 variable regions alanine mutants on the 
ability to bind to KRas. A. After calculation of Affimer alanine mutant 
concentration, equal quantities of mutant proteins of K3VR1 were run on a gel 
to verify correct protein concentration. K3VR1 alanine residues have been 
labelled 1.1-1.9. For Ras-Affimer interaction assay, Pierce® Ni2+-NTA agarose 
magnetic beads were pre-incubated with Affimer K3 residues of VR1 
substituted to alanine with KRas (no-tag). The Ras-Affimer complex was 
precipitated and pulled down proteins were analysed by western blot with anti-
Ras and anti-His antibodies B. K3VR2. The same protocol was followed as 
mentioned in A except that Affimer K3 residues of VR2 were substituted with 
alanine. Results are representative of three biological replicates (n=3).  
 
To further identify the functional effect of residues in both VR1 and VR2 of 
Affimer K3, the alanine mutants were tested in the nucleotide exchange assay 
with wild type KRas as control Affimer (Figure 3.14). Complete inhibition of 
nucleotide exchange reaction is characterised by a low initial rate (V0). K3 WT 
has low V0 of 0.18 and reaction rate of alanine mutants >0.18 is indicative of 
inability to inhibit the exchange reaction. Mutations of residues L73 and K80 in 
VR2 significantly impaired the ability to inhibit the nucleotide exchange 
reaction. However, the most profound effects were observed with residues I40, 
D41, I42, W43, Y44 and D45, which completely abolished the inhibitory effect 
of Affimer K3 (Figure 3.14). This demonstrated that these residues are critical 
for effective inhibition of nucleotide exchange. Additionally, the functional 
effects of these residues correlated with the binding assay of Ras-Affimer 
complex, as demonstrated in Figure 3.13.  
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Figure 3.14 Functional effects of Affimer K3 variable regions alanine 
mutants on inhibition of nucleotide exchange to active GTP state. Affimer 
K3 wild type and alanine mutants were assayed at 10 µM in a nucleotide 
exchange reaction with wild type KRas-mGDP and initial reaction rates for 
each protein were plotted. The dashed line indicated the reaction rate of wild 
type Affimer K3. Results are representative of three biological replicates (n=3). 
Error bars are ±SEM. p˂0.05 (*), p˂0.01 (**), p˂0.0001 (****). 
 
 
3.3 Discussion  
 
Ras proteins are binary molecular switches and play a key role in regulating 
signal transduction. Ras mutations are oncogenic drivers of many human 
cancers, yet there are no approved Ras-targeted cancer therapies. The 
perceived ‘undruggability’ of Ras has led to tremendous interest in new 
targeting approaches. Affimers are a novel class of alternative binding proteins 
that behaves similarly to antibodies by binding with high affinity and specificity 
to its target molecule (Tiede et al., 2017). Affimer technology has been 
developed by our lab to isolate Affimer reagents against recombinant proteins, 
peptides and small molecules by phage display technology. The Affimer library 
(1.3 x 1010 clones) has been previously screened, and seven unique KRas-
binding clones have been isolated. In the preliminary experiments, these 
Affimers were shown to bind to KRas, irrespective of nucleotide bound form 
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(Figure 3.1). This mode of binding is similar to previously reported anti-Ras 
monobody NS1. The NS1 monobody binder was found to be insensitive to the 
nucleotide state of Ras and did not promote nucleotide release or block 
nucleotide exchange on HRas. Structural studies provided an explanation for 
this as NS1 monobody binds to an allosteric site away from switch I and II 
regions of Ras (Spencer-Smith et al., 2017). However, in contrast, KRas 
binding Affimers have shown to inhibit nucleotide exchange to active GTP 
bound state (Figure 3.3). This, therefore, indicates that Affimer tends to bind 
to a region distant to allosteric lobe where monobody NS1 binds. Structural 
studies involving X-ray crystallography of Affimer K3-KRas complex and 
comparison of binding site with another KRas binding Affimer K6 (discussed 
in detail in chapter 4) can provide conclusive answers.  
One of the strategies to inhibit the function of Ras is to prevent its activation 
by GEF SOS. This can be achieved by blocking nucleotide exchange to GTP 
and thereby reducing the amount of active Ras (Gysin et al., 2011). KRas 
labelled with fluorescently tagged GDP nucleotide (mGDP) have been used to 
measure the effects of nucleotide exchange. Out of seven KRas binding 
Affimers K3, K6 and K37 were identified as the most potent inhibitors, with IC50 
values ranging from 200 to 697 nm for wild type KRas (Table 3.2). Likewise, 
Affimers’ IC50 values were significantly better than stabilised peptides SAS-
SOS1 (IC50=5-15 µM) (Hillig et al., 2019) and HBS3 (25 µM). Notably, Affimers 
displayed 1000-fold better inhibitory potency than small-molecule Ras inhibitor 
DCAI (IC50=155 µM) and recently discovered pan-Ras inhibitor 3144 which 
has IC50 in low micromolar range 17.8 µM (Welch et al., 2017). However, 
DARPin K27 binding protein binds to KRas GDP and inhibits nucleotide 
exchange with IC50 of 2.4 nM. Other DARPins like K13 and K19 (Bery et al. 
2019) also inhibit nucleotide exchange with IC50 of 127 and 7.16 nM 
respectively. This could be due to large interaction surface area of DARPin, 
which covers the entire SI/SII pocket.  
Ras isoforms K, H and NRas are ubiquitously expressed and display 90% 
sequence identity. However, they play specific roles in physiological and 
pathological processes (Castellano and Santos., 2011). Therefore, isoform-
specific Ras inhibitors are highly desirable. Since 85% of Ras driven cancers 
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carry KRas mutations, much of the focus has been in the development of KRas 
specific inhibitors. Interestingly, Affimer K3 demonstrated isoform selectivity, 
as it displayed lower inhibitory activity towards HRas (IC50=2585 ± 335 nM) as 
compared to KRas (144±94 nM) (Haza et.al 2019). Additional experiments 
with the third isoform NRas would be beneficial to confirm isoform specificity 
of K3 Affimer. However, it could not be carried out due to issues in production 
of soluble NRas protein (data not shown). 
Recently many small molecule inhibitors have been developed that target 
KRasG12C mutant specifically (Khan et al., 2020). These small molecules 
covalently attached to KRas mutant cysteine residue, and do not bind to wild 
type KRas protein. However, Affimer K3 has shown to inhibit KRas G12D (IC50 
144 ± 40 nm) and G12V (IC50 176 ± 115 nm) as well as wild type KRas protein. 
Additionally, K3 Affimer has shown to have 20-fold lower inhibition for 
KRasQ61H mutant in comparison to G12D and G12V. This could be because 
G12 mutations are more predominant in KRas and HRas, while Q61 mutations 
are predominant in NRas (Cox et al., 2014). Above all, these findings signify 
that Affimer K3 can bind to both mutant and wild type KRas in vitro. 
 Another strategy to target Ras is to develop inhibitors that are capable of 
inhibiting the interaction of Ras proteins with their effectors, which drive and 
sustain malignant transformation and tumour growth (Keeton et al., 2017). 
While many Ras targeting scaffold proteins were shown to inhibit Ras-Raf 
interaction (Martin et al., 2018; McGee et al., 2018; Spencer-Smith et al., 2017; 
Tanaka et al., 2007), the ability to block nucleotide exchange simultaneously 
with Ras- effector binding has been reported in case of DARPin K13 and K19 
in-vivo. DARPin K13/K19 besides inhibiting Ras dimerization by binding to α-
3/α4 region of Ras, also perturb nucleotide exchange and Ras-effector 
interactions. K3 Affimer also inhibits nucleotide exchange as well as Ras 
effector interactions. Three of the seven KRas binding Affimers significantly 
impaired Ras-RBD-Raf1 binding with K3 displaying the most potent inhibition 
(Figure 3.3). Densitometry analysis revealed a 90-fold reduction in 
immunoprecipitated Ras when K3 is used for Ras-Raf inhibition as compared 
to 20-fold reduction when K6/K37 Affimer is used. This could be due to the 
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difference in binding modes and the extent of perturbation of Ras-Raf 
interaction.  
To identify which variable peptide regions of Affimer K3 are essential for 
binding and inhibition of KRas, variable regions (VR1 and VR2) of K3 were 
deleted, and mutants were created via overlap extension polymerase chain 
reaction. These mutants were analysed via Affimer-Ras immunoprecipitation 
assay. The assay showed that both deleted VR1 and VR2 are essential for 
binding and stabilisation of Ras-Affimer K3 complex (Figure 3.7).  
There is a possibility that deletion of variable regions VR1 and VR2 to generate 
K3∆VR1 and K3∆VR2 mutants used during pulldown assay above can affect 
Affimer scaffold protein folding. To verify the structural integrity of deleted loop 
mutants of Affimer K3, the secondary structure of the proteins was analysed 
via circular dichroism (CD) in the far UV spectrum. CD spectra provide an 
experimentally very convenient means of detecting structural changes in 
proteins, which can be examined in different spectral regions (S.M Kelly et al., 
2005). The secondary structure of Affimer was examined by CD and revealed 
a high ratio of β sheet to α helix and random coil (Teide et al., 2014). Mean 
residual ellipticity (MRE) spectrum of mutants and wild type Affimer K3 
overlapped completely with deconvolution software (Dichroweb®) estimating 
2% variation in total percentage of helical content of Affimer K3, alanine and 
mutants. This variation indicates little to no conformational change or 
misfolding of Affimer K3 protein scaffold.  
Mutation of each amino acid in variable regions of Affimer K3  to alanine via 
Affimer-Ras pulldown assay identified that the majority of VR1 amino acids are 
involved in binding to KRas (Figure 3.10). This finding correlated with 
nucleotide exchange activity of the alanine mutants, with residues I40, D41, 
I42, W43, Y44 and D45 when substituted to alanine, completely abolished the 
inhibitory effect of Affimer K3 (Figure 3.11). Also, L73 and K80 of VR2 might 
be involved in stabilising the Affimer K3 structure, since only first and last 
amino acids in VR2 are involved in binding to KRas and majority of residues 
are not involved in binding to KRas. The importance of VR2 is further 
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evidenced by nucleotide exchange activity of L73A and K80A with reaction 
rate (V0) two-fold higher than K3 WT. 
In conclusion, data presented in this chapter demonstrated KRas binding 
Affimers as potent inhibitors of nucleotide exchange activity, with K3 binder 
showing isoform specific selectivity towards wild type KRas and clinically 
relevant mutants like G12D and G12V. Moreover, dual inhibition of Ras 
activation and effector interaction showed K3 as the most potent inhibitor, with 
K3 VR1 involved in binding and inhibition of KRas. Overall, all these findings 
demonstrate the use of Affimers to target ‘difficult to drug’ KRas with ability to 





















                                             Chapter 4 
 Structural characterisation of Affimer-KRas complex 
 
4.1 Introduction  
 
The effectiveness of drug discovery process is dependent on the correct 
identification of targets involved in pathology of disease, followed by 
successful selection, optimisation and development of candidate drugs 
(Marsden et al., 2014). Antibodies have become an essential tool in drug 
discovery process and have been used for target identification, validation and 
in design of lead compounds (Rhodes and Trimmer, 2008) (Figure 4.1). This 
is because of specific binding characteristics which include specificity and 
affinity to the target protein, coupled with their amenability to protein 
engineering. The use of antibodies for target validation in the case of 
extracellular and cell surface targets have been well established (Naylor and 
Beech, 2013; Phillips and Signs, 2005). However, antibodies have limited 
access to intracellular targets due to their large size (>150 kDa) and the 
reducing environment of cytoplasm can lead to destabilization of disulphide 
bonds and aggregation (Marsden et al., 2014). This limitation has been 
addressed by using other antibody formats or alternative affinity tools for 
intracellular target validation. The examples of affinity tools include 
nanobodies, DARPins, monobodies etc. Nanobodies have been used to study 
the mechanism of adrenergic receptor agonist isoprenaline on β2 
adrenoreceptor, revealing the role of agonist in G protein activation in plasma 
membrane as well as early endosome formation (Irannejad et al., 2013). This 
example shows the application of antibody alternatives to fill the knowledge 




Figure 4.1 Timeline of drug discovery process and steps involved in 
identification of lead compound. Antibodies/antibody alternatives are key 
tools in research and are applied throughout drug discovery process. 
Adapted from (Marsden et al., 2014). 
 
With the rapid rise in rational drug design, biophysical techniques have been 
employed to study potential drug sites before lead optimisation and candidate 
selection. X-ray crystallography is an especially important biophysical 
technique that has been used for lead site identification. Using X-ray 
crystallography for de-novo drug design, several compounds have reached 
clinical trials that target disease-relevant signalling proteins such as  BCL-2 
(Navitoclax for treatment of myelofibrosis), MDM2 (KRT-232 for treatment of 
glioblastoma), and BET (OTX -015 for treatment of solid tumours/lymphoma) 
(Mabonga and Kappo, 2019). 
Engineered proteins have vast potential as leads for synthetic inhibitors of 
protein-protein interactions (Wuo and Arora, 2018; Miles, J. et al., 2020). 
These modulators of PPIs can be used as probes to understand cellular 
biology and can serve as starting points in drug discovery. Engineered proteins 
can be used as molecular recognition tools to identify interface residues or hot 
spots that contribute most of the binding energy. These hot spots are important 
targets for the development of small molecule inhibitors. The presence of 
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critical ionic residues in engineered proteins may aid in the development of 
inhibitors with high affinity and specificity (Wuo and Arora, 2018). Scaffold 
proteins that display smaller interaction interfaces such as anti-Ras monobody 
NS1 (interaction surface area of 568 Å2) or Affimers binding to SUMO proteins 
or Bcl family proteins (interface area in the range of 610-720 Å2) are likely to 
aid in small molecule inhibitor design (Hughes et al., 2017).  
Previously, we have isolated Affimers that bind to KRas, out of which Affimer 
K3 showed most potent inhibition of SOScat mediated nucleotide exchange. 
Further biochemical characterisation of Affimer K3 shows the involvement of 
both variable regions in binding and inhibition of KRas. To further understand 
molecular details of Affimer K3-KRas binding, the atomic structure of KRas 
bound to Affimer K3 was solved to resolution of 2.1Å. To screen for 
crystallisation conditions, a high concentration of Affimer K3 in complex with 
KRas protein was used to set up factorial crystallisation trials. Additionally, 
Affimer K3 only crystal structure was also solved to resolution of 1.8 Å in order 
to understand the dynamic nature of VR2 of K3.  
 
4.2 Results  
 
4.2.1 Generation of Affimer K3-KRas complex.  
X-ray crystallography was used to understand the mechanism of Affimer K3 
binding to KRas. A high-resolution atomic structure of Affimer K3 bound to 
KRas is needed. For this a stable and homogeneous complex of Affimer K3-
KRas is required. The initial step was to re-clone KRas without the biotin 
acceptor peptide (BAP) and 6x His affinity tags  since fusion tags are known 
to hinder crystal growth (Smyth et al., 2003). The KRas sequence was 
amplified using PCR from a bacterial expression plasmid and cloned into 
pET11a plasmid (see section 2.2.3.4) (Haza, K.Z et al., 2020). The successful 
cloning was confirmed by sequencing. KRas protein was then produced in  




Affimer K3 was first purified via Ni2+-NTA chromatography and then was 
incubated with excess of E. coli cell lysate containing KRas protein (no tag). 
Following incubation, AffimerK3-KRas complex was then captured by Ni2+-
NTA resin for purification (see section 2.2.3.4). After washing the resin, the 
purified protein complex was eluted and analysed by 15% w/v SDS-PAGE and 
stained using Coomassie blue. Two bands of approximately 18 and 12 kDa 
corresponding to KRas and Affimer K3 were observed, indicating efficient 
purification of Affimer K3-KRas complex (Figure 4.2).  
                  
Figure 4.2 Purification of Affimer K3-KRas complex. Purified Affimer K3 
protein (with 6x His tag) was mixed with KRas E. coli bacterial cell lysate and 
incubated overnight. The complex was purified by Ni2+-NTA chromatography. 
The eluted fractions E1-E6 were analysed by 15% SDS-PAGE and stained 
using Coomasie blue. Eluted fractions showed two strong bands at 18 and 12 
kDa indicating successful formation of KRas-Affimer K3 complex.  
 
The eluted complex was further purified by size exclusion chromatography to 
remove any impurities from the cell lysate and to separate any Affimer not in 
a complex with KRas; this also demonstrates that the purified proteins were in 
a stable complex. Protein samples from the peak region (40-65 ml) as seen in 
A280 elution trace, were collected in 2 ml fractions and analysed using 15% 
SDS-PAGE gel (Figure 4.3 A). Once again, two bands of approximate 
molecular weight of 18 and 12 kDa, corresponding to KRas and Affimer K3 
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were observed, confirming the purification of Affimer K3-KRas complex 
(Figure 4.3 B). The eluted fractions were pooled and concentrated to 24 mg/ml 
total protein concentration and quantified by bicinchoninic acid assay (BCA). 
 
 
Figure 4.3 Size exclusion chromatography (SEC) of Affimer K3-KRas 
complex obtained after Ni2+-NTA chromatography A. Following Ni2+-NTA 
chromatography of Affimer K3-KRas, SEC using Hiprep® Sephacryl 16/60 
column was carried out. Y axis of chromatogram is measure of intensity of 
absorbance in milli absorbance units (mAU) and X axis is indicated by elution 
volume (ml) B. Eluted fractions were analysed via 15 % w/v SDS-PAGE gel 
and Coomasie stained to verify the presence of purified K3-KRas complex.  
 
4.2.2 Crystallisation of Affimer K3-KRas complex 
Once a high concentration of homogenous, purified protein sample of Affimer 
K3-KRas was obtained, a set of screening conditions, called sparse matrix 
screens, was used for obtaining protein crystals. This is a high throughput 
crystallisation screening method that covers large areas of chemical space to 
hopefully obtain well diffracting crystals (Luft et al., 2011). The screening 
conditions are selected based on successful crystallisation attempts and 
published PDB entries (Jancarik and Kim, 1991). Crystallisation experiments 
for the AffimerK3-KRas protein complex were initiated using commercial 
sparse matrix screen JCSG screen I-IV. A total of 384 crystallisation conditions 
in the JCSG core suites offer a broad sampling of crystallisation space 
(Newman et al., 2005). Sitting drop vapour diffusion technique was employed 
as described in section 2.2.8.1. Crystal formation was monitored using an 
automated imaging system Rock Imager® (Formulatrix). Crystallisation 
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conditions were screened using different imaging methods such as visible 
light, ultraviolet (UV) light and second harmonic generation spectroscopy 
(SHG) imaging. In UV imaging, the absorption of light by aromatic residues at 
280 nm was employed to confirm the presence of protein crystals. Also, 
second-order nonlinear optical imaging of chiral crystals (SONICC) was used 
which is based on combination of second harmonic generation (SHG) and UV 
Two photon excited fluorescence (UV-TPEF). This technology helps identifies 
crystals present in precipitate and can detect nano and microcrystals < 1µM 
(Kissick et al., 2011). 
In the initial screening using JCSG screen I-IV, crystals of Affimer K3-KRas 
started appearing within 8-13 days in 2 conditions only (Figure 4.4). Protein 
crystals grew as a cluster of needle-shaped crystals. UV + SHG imaging 
demonstrated that observed particles are indeed protein crystals. In addition, 
crystals were picked and sent to the Diamond Light source facility to confirm 
that these were protein crystals. The diffraction pattern showed sharp spots 
near the centre in concentric circles, but it gave a very poor resolution of 7.3 
Å. 
 
Figure 4.4 Summary of initial crystallisation conditions obtained via 
JSCG screens. Screen plate names as well as well number in which crystals 
appeared are mentioned. The images of crystals in visible, UV and SHG 
imaging along with their conditions and duration of crystal appearance have 






4.2.3 Optimisation of initial crystal hit from JCSG screen II 
Since the initial crystals obtained showed poor diffraction, the conditions were 
optimised to obtain crystals of sufficient quality. Optimisation of crystal hit from 
JCSG screen II (0.05 M LiSO4, 0.1M Tris-Cl pH 7.0 and 50% v/v PEG 200) 
was carried out by varying pH of the buffer (pH 6.0-9.0) and precipitant 
concentration (40-55% v/v PEG 200) and keeping the salt concentration (0.1 
M Tris-Cl) constant. Unfortunately, no crystals were observed even after 
varying the original crystal conditions.  
4.2.4 Crystallisation using additional sparse matrix screens  
Since optimisation of conditions from JCSG screens did not yield any good 
quality protein crystals other random sparse matrix screens for crystallisation 
of Affimer K3-KRas protein complex were used. These include Wizard™ 
classic screen III and IV (Rigaku®), Salt Rx screen (Hampton®) and crystal 
screen HT (Hampton®). Wizard classic screens have been proven to be ideal 
starting points for biological macromolecules. The Wizard classic formulations 
include a large range of precipitants, buffer and salts covering a broad range 
of crystallisation space with pH range from pH 4.5 to pH 10.5. In the case of 
Wizard screen III and IV, crystals of Affimer K3-KRas started appearing in 5-8 
days in two different conditions (Figure 4.5). Since the crystals obtained were 
either needle shaped or microcrystals, optimisation of both the conditions of 
Wizard screens (See Figure 4.5) was carried out. Unfortunately, very few 
crystal hits with poor crystal quality was obtained. 
Crystal screen HT is a sparse matrix screen consisting of 48 unique reagents 
from two crystal screens 1 and 2 in deep-well block format (Jancarik and Kim, 
1991). In case of crystal screen HT, best crystal hit was obtained after 21 days 
in condition containing 2 M ammonium sulphate (precipitant), 0.1M Tri-sodium 
Citrate pH 5.6 (buffer) and 0.2 M potassium sodium tartrate (salt). These 
crystals (Figure 4.5) were around 20 µM-50 µM in diameter, which were large 
enough to diffract X-rays. These crystals were cryo-protected for data 
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collection in a solution containing 75% w/v mother liquor (liquid remaining after 
the solution has crystallised out) and 25% w/v ethylene glycol. 
No crystals were observed when using Salt Rx screen.  
 
Figure 4.5 Summary of crystallisation conditions for Affimer K3-KRas 
complex crystals. Screen plate names as well as well number in which 
crystals appeared are mentioned. The images of crystals in visible and UV 
imaging along with their conditions have been listed. Conditions obtained from 
crystal screen HT was selected because the crystal size was good enough for 
X-ray diffraction and data collection.  
 
4.2.5 Binding of Affimer K3 to KRas revealed a druggable SII/α-3 pocket  
X-ray diffraction data for KRas-K3 crystal obtained from the Crystal screen HT 
was collected at European Synchrotron Radiation Facility (ESRF) using 
ID30A-1 beamline. Data collection, processing and structure determination 
was performed as described in section 2.2.8.3 and was carried out by Dr Chi 
Trinh.  
The crystal structure of Affimer K3-KRas bound to wild type GDP was solved 
at 2.1Å resolution. The co-crystal structure revealed Affimer K3 interacting with 
switch II region (SII) (amino acids 60-76) of KRas (Figure 4.6). Affimer K3 
residues 40-45 in VR1 has shown to be crucial for interaction with KRas. This 
interaction was correlated with pulldown and nucleotide exchange assays 
carried out previously, in which residues I41, D42, I43, W44, Y45, and D46, 
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when mutated to alanine, did not bind and inhibit KRas (see section 3.2.4). 
Binding of Affimer K3 to KRas revealed a novel Ras conformation with large 
druggable pocket between switch II and α-3 helix. The hydrophobic pocket 
identified by K3 was found to have a total buried surface area of 790.6 Å2 
which was calculated using PDB-e-PISA [EMBL-EBI] server (Krissinel and 
Henrick, 2007).  
 
                      
Figure 4.6 Co-crystal structure of KRas with Affimer K3. K3 Affimer VR1 
(green) binds to pocket between Switch II (red) and α-3 helix (dark grey) of 
KRas (blue). Magnesium is shown as yellow sphere and GDP is shown as 
green sticks. Arrows indicated VR1 and VR2 of Affimer K3. Image was 
generated in PyMOL. 
 
With Affimer K3 VR1 bound to the SII region, the D42 residue of K3 brings the 
SII region close to the α-3 by generating a hydrogen bond between R68 of SII 
and Q99 of α-3. Affimer K3-KRas complex formation is further strengthened 
by hydrogen bonds between side chain oxygen of D46 residue in K3 Affimer 
with the main chain nitrogens of Q99 and R102 in α-3 (Figure 4.7 A). This is 
further complemented by OH group on the side chain of Y45 of K3 forming 
hydrogen bonds with side chain oxygen of E62 of SII. This hydrogen bonding 
network creates a large binding interface, in which residues of Affimer K3 
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namely I41 and I43 form hydrophobic interactions with V103, M72 and V9 of 
KRas respectively (Figure 4.7 C). The pocket created by hydrophobic 
interactions is further stabilised by W44 indole side chain orienting itself to form 
hydrogen bonds with H95 present in α-3 such that it is packed against residues 
of Q61, D92 and Y96 (Figure 4.7 B).  
 
Figure 4.7 Intermolecular interaction between Affimer K3-KRas A. Affimer 
K3 residues D42 and D46 (highlighted in green) bind strongly to R68 of SII α-
3 (red) and Q99 and R102 of α-3 (dark grey) bringing the two α helices in 
proximity. B. The intermolecular interactions mentioned in A is further 
strengthened by interaction by W44 side chain and Y45 (green) burying into 
hydrophobic pocket and forming hydrogen bond with H95 of α-3 (dark grey) 
and E62 of SII (red). C. Hydrophobic interactions between Affimer K3 residues 
and KRas. H-bonds are shown in yellow dashed lines.  
 
The interaction between K3 and KRas described above caused a significant 
conformational shift in the SII region of KRas. Most notably, SII α-2 helix 
moves 4.3 Å away from α-3 as compared to KRas WT GDP (PDB-40BE) 
(Figure 4.8 A). This conformational shift generates a new network of 
intramolecular hydrogen bonds in KRas. When K3 binds, the D42 of K3 Affimer 
binds to R68 of SII via a salt bridge interaction. This interaction shifts the R68 
105 
 
residue into an orientation necessary to create a hydrogen-bonding network 
between E37 of Switch-I (SI) and S65, A59 and G60 of SII. Additionally, the 
side chain of Y71 of the SII α-2 helix flips to form a hydrogen bond with D54 of 
the β3 strand (Figure 4.8 B) thereby stapling the SII region to the SI site. This 
hydrogen bond network has not been observed in WT KRas GDP (PDB: 
4OBE) or WT KRas GppNHp (PDB: 6GOD).  
   
    
Figure 4.8 Conformational shift and hydrogen bonding network 
facilitated by binding of K3. A. KRas WT (blue) (PDB: 4OBE) structure was 
fixed and overlaid with KRas-K3 Affimer complex (cyan). This overlay shows 
a conformational shift in Switch II when Affimer K3 binds between α-2 and α-
3 helix region of Ras B. Interaction of D42 residue of Affimer K3 (green) with 
R68 residue (red) in SII via salt bridge interaction. Hydrogen bonding network 
between E37 (blue) of SI and G60, S65 (red) of SII region. This hydrogen bond 
network has not been observed in KRas WT. H-bond is shown as yellow 

















4.2.6 Crystal structure of Affimer K3 reveals a dynamic VR2 loop 
We have previously observed that both VRs of Affimer K3 are involved in 
binding and inhibition of KRas (see section 3.2.3). It was observed that VR2 
residues L73 and K80 have shown to be involved in binding and inhibition of 
KRas (see section 3.2.4). However, in case of Affimer K3-KRas crystal 
structure, we observed that VR2 is not involved in binding to KRas. This could 
be attributed to the dynamic nature of VR2. Thus, to investigate the Affimer K3 
protein structure dynamics, crystallisation of Affimer K3 only was carried out.  
Protein expression of Affimer K3 was carried out as per section 2.2.3.1. The 
eluted Affimer was purified by nickel ion affinity and then size exclusion 
chromatography. Two narrow and one broad peak were seen in A280nm elution 
trace (Figure 4.9 A). The elution profile shows that Affimer K3 can exist in 
different oligomeric states i.e it could exists in dimer or trimeric or even higher 
oligomeric states when present in high concentrations. The eluted fractions 
from all three peaks were collected and analysed using 15 % w/v SDS-PAGE 
gel and stained using Coomasie. For peak 1 and 2, we observed trimer/dimer 
at 24 kDa and for peak 2 purified monomeric K3 protein was obtained (Figure 
4.9 B). The eluted fractions containing monomeric K3 was pooled and 









Figure 4.9 Elution profile of K3 Affimer. A. Analysis by Size exclusion 
chromatography of K3 Affimer shows three oligomeric states first is trimer or 
tetramer followed by dimer and monomeric form. Affimer K3 was eluted in 
fractions using Hiprep® 16/60 Sephacryl S-100 column (GE Healthcare®). 
Chromatography was carried out using 10 mM Tris, 50 mM NaCl pH 7.5 buffer 
with flow rate of 0.8 ml/min and the volume of protein injected was 1.5 ml B. 
Elution fractions from dimeric (red dashed box) and monomeric states of K3 
were run on 15%SDS-PAGE gel and Coomassie blue stained.  
 
 
After optimisation of Affimer K3 crystal conditions, single large three-
dimensional protein crystals were obtained. However, multiple lattices were 
observed in the crystals, therefore indexing failed. Subsequently, the protein 
concentration was increased to 80 mg/ml, which is the highest possible 
concentration of Affimer K3 obtained without precipitation of purified soluble 
protein solution. JCSG screens I-IV and Morpheus screen (Molecular 
dimensions®) were used. Morpheus screen contains 96 conditions covering a 
range of pH, PEGs and low molecular weight ligands which promote initial 
crystal formation and lattice stability (Gorrec, 2009). Sitting drop vapour 
diffusion technique was employed as described in section 2.2.8.1. Crystal 
formation was monitored using an automated imaging system Rock Imager® 
(Formulatrix). This time 6 promising crystal were obtained: 3 from the JCSG 
screens and 2 from the Morpheus screen within 3 days (Figure 4.10). Protein 
crystals from 3 crystal hits (total of 12 crystals) were collected immediately 
after 3 days and frozen in liquid nitrogen at -80º C. Crystals were sent to 
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Diamond synchrotron for data collection and structure determination 
(beamline-i24). 
 
Figure 4.10 Summary of crystal conditions of Affimer K3 only. Screen 
plate names as well as well number in which crystals of Affimer K3 appeared 
are mentioned. The visible images of protein crystals along with the conditions 
are shown.   
 
4.2.7 Crystal structure of Affimer K3  
X-ray diffraction data of K3 Affimer crystal obtained from JCSG screen II and 
screen III (30% v/v PEG 300, 0.1 M HEPES pH 7.5, 0.2 M MgCl2 and 40% v/v 
PEG 300,0.1 M Na cacodylate pH 6.5, 0.2 M Ca acetate) was collected at 
Diamond synchrotron using i24 beamline. Data collection, processing was 
carried out by Dr Chi Trinh.  
 Affimer K3 protein crystals diffracted to 1.8 Å resolution. The asymmetric unit 
consists of a dimer of Affimer K3 directed at each other (Figure 4.11 A). Both 
Affimer K3 molecules within the lattice showed little intermolecular interactions 
due to the crystal packing. The electron density around the VR2 was found to 
be relatively weak, with poor main chain connectivity density for residues 74-
83. This suggests that K3 Affimer VR2 is flexible. Average B factor of all atoms 
was found to be 46.0 Å2 (Figure 4.11 B). B factor is a term used to define the 
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extent of atomic oscillations that are possible around the equilibrium positions 
in the crystal structure (Carugo, 2018). For the known structures in the highest 
resolution range (0.0–1.5 Å), the average B-factor is only 25 Å2, while it is 80 
Å2, in the lowest resolution range (3.3–4.0 Å) (Carugo, 2018). In case of VR2, 
high B factor with average value of 54.42 Å2 was observed. This is indicated 
by putty tube representation with colour variation from blue to green (narrow 
tube, “cold”, low B factors) then orange to red (wider tube, “hot”, high B factors. 
In case of the K3 VR1, low B factor with an average value of 22 Å2 was 
observed. This was indicated by a narrow tube with blue to green colour 
variation (Figure 4.11B). Therefore, B factors establish that VR2 is more 





Figure 4.11 Crystal structure of Affimer K3. A. Asymmetric unit of Affimer 
K3 shows each Affimer directed at each other. Variable regions with missing 
VR2 shown in dotted lines B. Affimer K3 is shown in putty tube representation, 
with VR2 shows high B factors (64 Å2) as indicated by red and wide tube. VR1 
shows low B factors (22 Å2) with narrow tube and is blue in colour. KRas is 
shown in blue. 
 





There have been significant strides in development of antibody/antibody 
alternatives as tools to allow rapid identification and characterisation of small 
molecules with optimised functionality. This progress has been possible due to 
the availability of structural data provided by X-ray crystallography and other 
structural biology techniques such as NMR and cryo-EM. Many cancer drug 
targets which had been considered as ‘undruggable’ such as transcription 
factors like MYC and NFκB have had their protein structures solved and 
deposited in PDB database (Dang et al., 2017). This has led to development of 
inhibitors that are currently in clinical trials (Villanueva, 2019). The second 
major category of undruggable proteins is the Ras family of small GTPases. 
Despite 30 years of research, no drug has reached the market. The main 
reason was due to lack of druggable pockets for small molecules to bind with 
high affinity and specificity (Stephen et al., 2014). Findings from our lab have 
suggested that engineered binding proteins like Affimers can be used as tools 
to modulate PPI, identify druggable pockets and aid in the design of small-
molecule inhibitors (Haza et al., 2020; (Robinson et al., 2018) 
In this chapter, X-ray crystallography was used to solve the atomic structure of 
the KRas-AffimerK3 complex to understand the mechanism of inhibition of 
KRas. From the crystal screening and optimisation of Affimer K3-KRas it was 
observed that more crystals were produced when formulations contained low 
molecular weight PEG concentration or high molar concentrations (>2M) of 
ammonium sulphate or phosphate as precipitant. Once crystals of KRas-K3 
protein complex were obtained, atomic structure of protein complex was solved 
to 2.1 Å resolution. It was observed that Affimer K3 binds to SII region of KRas 
(60-75aa), establishing K3 Affimer as an allosteric inhibitor of Ras.  
When Affimer K3 binds to KRas, a hydrophobic pocket is revealed adjacent to 
SII and α-3. This pocket is created due to its molecular interactions with SII 
resulting in a conformation unfavourable for binding of the helical hairpin loop 
of SOS1. A similar hydrophobic pocket has also been observed using cyclic 
peptide KRpep2d, binding to KRasG12D mutant (see appendix C). However, the 
major difference is that K3 binding involves residue H95, which is a unique 
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residue in the G domain of KRas, whereas the isoform specificity of KRpep2d 
has not being studied (Sogabe et al., 2017). Additionally, the peptide has shown 
to be not sufficiently efficacious for in-vivo studies. The pocket revealed by 
Affimer K3 binding is previously unseen conformer of SII-P. This pocket has 
been termed the SII/α3 pocket as it coincides with cryptic groove identified 
computationally (Grant et al., 2011). This SII-P has been recognised by 
covalent KRasG12C inhibitors such as ARS-853 and 1620 which are currently in 
clinical trials (Janes et al., 2018; Ostrem et al., 2013).  
Gentile and colleagues used fragment-based drug discovery method, namely 
tethering, to identify disulphide-based fragment 2C07. Fragment 2C07 binds to 
both nucleotide states of KRas (GDP and GTP) and expands the SII-P into a 
new groove away from nucleotide termed the SII groove (SII-G) (Gentile et al., 
2017). SII-G is located between the central β sheet and α-2 and α-3 helices, 
the same cryptic groove to which Affimer K3 binds. The authors further noted 
that for non-covalent binding to SII-P, a substituted phenolic ring is required for 
coupling to a sub pocket formed by V9, R68, D69 and M72 (Gentile et al., 2017). 
Affimer K3 fulfils this requirement with the aromatic ring of W44 extending into 
this sub-pocket. Therefore, the SII/α-3 pocket shares this sub-pocket present in 
SII-G.  
Additionally, Lu et al. observed multiple conformations of switch II when ARS 
series of compounds bind to SII-P using hydrogen/deuterium exchange mass 
spectrometry (Lu, et al., 2017). This suggests that SII-P binders are capable of 
an engaging range of KRas conformations. Here, when K3 binds to KRas, the 
α-2 helix is distal from the α-3 helix, indicating an open conformation (Figure 
4.12 A). In the case of AMG510, a more closed conformation is observed, 
where the α-2 helix is semi-distal to the α-3 helix (Figure 4.12 C) (Lanman et 
al., 2020; Canon et al., 2019). Affimer K3 stabilised an open switch II 
conformation as compared to a closed conformation seen with AMG510. This 
binding of Affimer K3 to KRas facilitates a new network of hydrogen bonding 
interactions between SI/SII and SII/α3 helix that is not present in KRasG12C 
AMG510 structure (PDB: 6OIM). In case of ARS 1620, binding of the most 
potent ARS compound that targets KRasG12C leaves the helices proximal to 
each other as seen in KRas WT (Figure 4.12 B) (PDB 5V9U) (Janes et al., 
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2018). These differences suggest that there may be an extended pocket area 
for small molecules based on the K3 pharmacophore i.e. there is potentially 
more affinity and selectivity that could be built into small molecules. 
 
Figure 4.12 Comparison of surface shape and electrostatics of small 
molecules with K3 Affimer. Alteration in conformation of SII region (red) and 
α-3 helix (black) and corresponding alteration in electrostatics (bottom row) is 
shown A. Affimer K3 residues 41-45 when bound to KRas: GDP crystal 
structure indicate an open conformation (left panel). B. KRasG12C compound 
ARS 1620 when bound to KRasG12C (middle panel) shows a closed 
conformation where the α-2 helix is semi-distal to the α-3 helix C. AMG510 
compound when bound to KRasG12C (right panel) shows a half open 
conformation. Blue-positive potential, red-negative, white-neutral. 
 
 
The biochemical data in Chapter 3 provides evidence that both VR1 and VR2 
of Affimer K3 are involved in binding and inhibition of KRas (see section 3.2.4). 
But in the Affimer K3-KRas crystal structure, we observe that there are 
intramolecular interactions between VR2 residues K71 and K72 form hydrogen 
bonds with N75 and K80 residues of VR2 (Figure 4.13). These interactions 
could explain the importance of VR2 in stabilising KRas-Affimer K3 complex, 
as in absence of this interaction there is very weak to no binding of Affimer to 
Ras (see Figure 3.9). The molecular interactions between K3∆VR1/VR2 and 
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KRas WT can be further verified by using SPR. Additionally, VR2 has shown to 
have high B factor, indicating the flexible nature of VR2. Affimers have also 
been shown to bind to Ras intracellularly and inhibit downstream signalling, all 
three Affimers (K3, K6 and K37) showed inhibition of ERK1 phosphorylation 
using KRas expressing mouse embryonic fibroblasts (MEFs) (Haza, K.Z et al., 
2020). 
In conclusion, the data presented in this chapter demonstrates the use of non-
antibody binding scaffolds with a relatively small binding interface to identify 
novel conformers of target protein. Affimer proteins can identify druggable 
regions on protein surfaces as evidenced by modulation of BCL2 family of 
proteins (Miles, J.A. et al., 2019). In this study, Affimer K3 selects a unique 
conformation to reveal a large druggable pocket in KRas. This pocket has been 
previously identified by AMG 510 and ARS 1620, but K3 exhibits different 
surface electrostatics due to an open conformation of the SII region. It will be 
interesting to use this α3/SII pocket as a template for the development of novel 
Ras binding molecules. Additionally, the differences in the conformation when 
K3 binds to KRas indicates an extended pocket area for small molecules based 










                                
Figure 4.13 Intramolecular interactions of Affimer K3. Intramolecular 
interactions between residues of VR2 of Affimer K3 (green) are highlighted. H-
bond interactions between variable regions’ residues were generated in PyMOL 



























                           Chapter 5 
                 Understanding Affimer K3 specificity towards KRas 
 
 
5.1 Introduction  
 
The Ras family of small GTPases consisting of HRas, NRas, KRas4A and 
KRas4B have shown to have a high degree of amino acid sequence similarity 
with differences observed mostly in C terminal hypervariable regions 
(Watzinger et al., 1998). In case of Ras GTP binding domain (G domain), there 
are 17 residue positions in the allosteric lobe that differ in at least one of the 
isoforms. Most of these residues are clustered in the nucleotide binding pocket 
as well as helix3. Out of the 17 residues 9 are unique to NRas, 7 are unique to 
HRas and 5 are unique to KRas. Interestingly, only 2 amino acids differ in all 
three Ras isoforms, this include H95 in helix 3 and R122 in loop8. Therefore, 
there is a need to generate Ras isoform specific protein binders to understand 
Ras isoform and mutation specific signalling differences (Baker, 2015; Waters 
et al., 2017). Here in this project BSTG group isolated Affimers that specifically 
target the G domain of KRas, which represents 85% of all Ras family mutations 
(Moore et al., 2020). Affimer K3 inhibits SOS1 mediated nucleotide exchange 
and Ras/Raf interaction by binding between SII and α-3 helix of KRas 
(Chapter4). Structural analysis identified W44 side chain of K3 to form hydrogen 
bonding with H95 on α-3 helix. H95 and E107 are two unique residues in the 
KRas isoform. To evaluate the specificity of Affimer K3 towards KRas, as 
observed in biochemical and cellular data (Haza et al., 2020), site directed 
mutagenesis and pulldown assay was carried out in this chapter to verify the 







5.2 Results  
5.2.1 Affimer K3 preferentially binds to KRas isoform 
In Chapter 4, it was shown that the W 44 residue of Affimer K3 forms a hydrogen 
bond with H95-residue present in α-3 helix of KRas (Chapter 4, Figure 4.7). 
H95 is one of the unique residues present in KRas and not in HRas and NRas 
isoform. Therefore, we introduced mutations at position H95 by replacing His 
(H) with Q and L (found at residue 95 in HRas and NRas respectively). This 
was carried out using site directed mutagenesis. The plasmids DNA were sent 
for sequencing to verify whether they have point mutation (Figure 5.1).  
 
Figure 5.1 Site directed mutagenesis and sequence of KRas H95Q/L. A. 
Sequence alignment between KRas WT and KRas H95Q/L shows point 
mutation at 95 position to Gln and Leu. B. KRas was mutated to Q and L at H 
95 via site directed mutagenesis protocol using KRas WT sequence as a 
template (pET11a 5677bp). DNA was loaded on agarose gel to verify presence 







                     
Figure 5.2 15% SDS PAGE gel showing protein expression of KRas WT, 
H95Q, H95L and Affimer K3/Alanine. Protein separation was performed on 
15% Bis-Tris gel. Protein expression was carried in E. coli BL21 DE3 cell line. 
20.5 KDa = KRas, KRas H95Q, KRas H95L E. coli cell lysates. 12 KDa =Affimer 
K3, 10.7 KDa =Alanine Affimer and KRas WT/H95Q= 20.5 kDa.  
 
 
Once verified, mutated KRas cell lysates were produced in E. coli BL21 DE3 
cells. Affimer K3 and Alanine Affimer (both VR1 and VR2) were also expressed 
and purified using Ni2+-NTA chromatography (See Figure 5.2). To analyse the 
effect of protein interactions between K3 Affimer and the mutated H95Q and 
H95L KRas, co-immunoprecipitation assay was carried out. K6 Affimer was 
used as positive control in this assay, since K6 binds to pocket between Switch 
I and II region and does not form hydrogen bond with H95 KRas (Haza, et al., 
2020). Alanine Affimer was used as negative control for this assay since it does 
not bind to Ras (Figure 5.3 A). Prior to performing the assay Affimer K3, Alanine 
Affimer and K6 Affimer was purified and dialysed in PBS buffer (see section 
2.2.3.1). 20 µg of purified Affimers (K3, K6 and Alanine Affimer) was pre-
incubated with Ni2+-NTA magnetic agarose beads in separate tubes. These 
Affimers loaded beads were then added to KRas WT, H95Q and H95L proteins 
(without His-tag) present in E. coli cell lysate. For Affimer K3, a strong Ras band 
was observed for WT KRas, verifying the interaction between Affimer K3 and 
KRas (Figure 5.3B lane 9). For KRas H95Q (which represents HRas) there is 
60% reduction in density compared to KRas WT (Figure 5.2B, C. lane 8). For 
H95L (which represent NRas) there is no Ras band, indicating K3 does not bind 
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to NRas isoform in this assay (Figure 5.3 B Lane 7). Affimer K6 shows nearly 
equal immunoprecipitation of Ras for KRas WT, H95Q and H95L protein 
samples (Figure 5.3 B lane 4, 5 and 6). This assay shows the preferential 

































                                             
     
 
             
Figure 5.3 Immunoprecipitation of K3/K6 with KRas, KRas H95L and KRas 
H95Q. A. 1 µg of Affimer K3, K6 and Alanine Affimer was run on 15% SDS-
PAGE gel confirm concentration of Affimer. B. Pierce® Ni-NTA agarose 
magnetic beads were pre-incubated with 8x His tagged Affimer K3, K6 and 
Alanine Affimer. KRas WT/H95Q/H95L-Affimer complex was precipitated and 
pulled down proteins were analysed by western blot with anti-Ras and anti-His 
antibodies. Results are representative of three biological replicates (n=3). C. 
Densitometry analysis of Ras immunoprecipitated as fold KRas WT. Results 
are representative of three biological replicates (n=3). Error bars denote ±SEM. 








5.2.2 Structural analysis of Ras-Raf1RBD inhibition via Affimer K3 
Ras is activated by GDP/GTP nucleotide exchange with the aid of guanine 
nucleotide exchange factors such as SOS1, Ras GRF, Ras GEF, PLCE1 etc. 
It triggers range of signalling cascades through interactions with multiple 
effectors. This includes effectors like Raf, PI3K, Tiam1, Ral GDS and Nore1 
(Athuluri-Divakar et al., 2016). The well characterised Ras effectors such as 
Raf, PI3Kγ and Ral GDS share a common Ras binding domain (RBD) that binds 
to Ras. Structural analysis of various RBD shows a common ubiquitin like fold 
that consists of five stranded β sheets flanked by two α helices. The structures 
of Ras and Raf complexes show Raf RBD interact with Ras via residues in β2 
and C terminal end of α1 (Filchtinski et al., 2010). Efforts to develop small 
molecules that prevent Ras binding to effector proteins like Raf kinases have 
largely been unsuccessful. This is primarily because antiparallel β sheets that 
form the interface region between Ras and effector such as Raf, offer no 
pockets for small molecule to bind with high affinity (McCormick, 2018). In the 
previous chapters (Chapter 3 and 4). Affimer K3 when it binds to Switch II region 
of Ras, it causes a conformational shift in α-2 helix to reveal druggable binding 
pocket resulting in steric clash between M67 of Ras and R67 of RBD. This steric 
clash perturbs the salt bridge network that is formed between E37 of Ras and 
terminates at Raf RBD R100 (See Figure 5.4) (Fetics et al., 2015). If this steric 
clash is proven true, then this could explain the mechanism of inhibition of 
Ras/Raf inhibition when K3 binds to KRas. Point mutagenesis of these residues 
followed by pulldown assays was carried out in this chapter to verify the 










            
Figure 5.4 Structural overlay and comparison between HRas: Raf1RBD 
and KRas: Affimer K3. A. Crystal structure of HRas: Raf1RBD (PDB: 4G0N) 
shows E37 forming hydrogen bonds with R59 and R67 of Raf1RBD (as seen in 
dashed black lines). B. Crystal structure of HRas: Raf1RBD (blue) overlayed 
with KRas: Affimer K3 complex (green) shows shift in E37 and D38 (blue) side 
chain and perturbation of salt bridge network that begins with E37 and 
terminates at R100 of Raf1-RBD.Also shown is steric clash between M67 of α-
2 helix after Affimer K3 binds to KRas and R67 of Raf1-RBD. 
 
To verify steric clash between M67 side chain of α-3 and R67 of Raf RBD 
(Figure 5.4B), M67 KRas side chain was mutated to alanine (A) and R67 Raf 
RBD to alanine (A) or glutamic acid (E) using site-directed mutagenesis. This 
was done to see if mutating these residues might relieve the inhibition. After the 
sequence was verified the proteins were expressed and purified as described 




                           
Figure 5.5 SDS PAGE to verify protein expression of KRas WT and 
GSTRBD. After site directed mutagenesis of KRas WT to KRas M66A and GST 
RBD to GSTRBDR67A and R67E, protein expression in E. coli BL21 DE3 was 
carried out. KRas WT and mutant proteins were purified via Ni2+-NTA 
chromatography. GST RBD WT and mutant proteins were expressed and run 
on 15% Bis-Tris gel via SDS-PAGE and Coomassie stained for visualisation. 
KRas -20.5 kDa, GST Raf1RBD = 42 KDa. 
 
 
 Initially, KRas WT and KRas M67A was loaded with GppNHp and verified using 
native mass spectrometry (refer sec 2.3.3). Following which Affimer K3 was 
pre-incubated with KRas WT and KRas M67A protein present in two separate 
tubes and added to glutathione coated magnetic beads. After incubation for an 
hour, GST RBD Raf1 WT was added to the protein complex of Affimer K3-KRas 
WT and KRas M67A separately. The same process was repeated using GST 
RBD Raf1R67A and R67E mutant Raf E. coli cell lysate (see section 2.2.6 for 
more details). The beads were washed three times, and protein complex was 
eluted and run on 15% w/v SDS PAGE gel and the blot was stained using anti 
Ras, GST and 6x His antibodies. This pulldown assay was carried out to 
analyse the effect of Affimer K3 on interaction between KRas WT and KRas 
M67A R67A/E of RBDRaf1. No Ras band was observed on the blot for WT Ras-
Raf when Affimer K3 binds, indicating successful inhibition of Ras-Raf complex 
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(Figure 5.6 B lane 1). Also, when Raf R67 was mutated to glutamic acid (R67E), 
it relieved the inhibition in presence of Affimer K3 as observed by a Ras band 
in the output (Figure 5.6B lane 6). But when Alanine Affimer was used as control 
there is no band observed for Ras only as well as any RasM67A or RafR67A/E 
mutant lanes (Figure 5.6A lane 2-8), indicating failure to verify the presence of 
steric clash between M67 of Ras and R67 of Raf1RBD. This experiment was 
carried out only once and needs to be repeated.  
 
 
Figure 5.6 Co-immunoprecipitation assay showing effect of mutation on 
residues involved in Ras:Raf inhibition A. Prior to pulldown assay the 
samples was run on 15% SDS PAGE to verify the expression of the KRas and 
RAF1 RBD WT and point mutants. Following which K3 Affimer is incubated with 
KRas WT and M67A Ras and then allowed to interact with RafR67A and R67E 
with KRas and Raf1RBD as control and western blot of samples was carried 
out using Ras, GST antibodies for output and Ras and 6x His antibodies for 
input samples B. Same layout and western blotting was carried out using 







5.3 Discussion  
 
In this chapter it has been demonstrated that Affimer K3 shows preferential 
specificity for KRas as compared to HRas and no binding affinity towards NRas. 
Affimer K3 has shown to bind in a pocket between SII α-2 and α3 helix of Ras. 
W44 residue of Affimer K3 forms a hydrogen bond with H95 residue present in 
α-3 helix of KRas, which is only found in KRas, thereby confirming KRas 
selectivity. Recently KRas specific DARPin’s K13 and K19 have been isolated 
that can bind KRas at the allosteric lobe i.e. helix 3 loop7 and helix 4 region.  
However, the key difference is that DARPins that bind H95 do not probe SII/α3 
pocket and instead binds to other side of α-3 helix, and therefore not revealing 
the novel conformation. Affimer K3 has shown preferential specificity towards 
KRas as compared to HRas (60% less fold) and no binding to NRas and is 
correlated by nucleotide exchange assays (chapter 3). The SII/α3 pocket 
identified by K3 Affimer may help achieve the first non-covalent small molecule 
inhibitors of KRas. These small molecules may have similar properties to the 
E3-ligase fused DARPin K19 and can be used in affinity directed protein missile 
system (AdPROM) (Roth et al., 2020). This system has shown to selectively 
degrade KRas and inhibit AKT, ERK and MEK phosphorylation in cell lines 
expressing mutant KRas (this include cell lines namely MIA PaCa2, H358 etc). 
This is an exciting avenue to be explored in the future studies.  
The correct conformation of the switch II is important for Ras-Raf binding (Kiel 
et al., 2009). Upon Affimer K3 binding to KRas, it prevents the Switch II from 
adopting a correct conformation, preventing Ras: Raf RBD binding by shifting 
the α-2 helix of Ras. The positioning of the side chain of E37 and D38 of KRas 
changes when K3 Affimer binds and perturbs the H-bonding interactions with 
R59 and R89 of Raf1 respectively. The structural overlay with Ras: Raf1 RBD 
(PDB: 4G0N) with KRas: Affimer K3 shows a steric clash between M67Ras and 
R67 Raf1RBD which perturbs the salt bridge network. But in solution these side 
chains would move away and mutating to alanine would not make difference. 
Therefore, to verify the presence of steric clash, mutation of R67 to E was 
carried out helps relieve the inhibition. This was done based on the premise 
125 
 
that α-2helix dipole (with positive charge created at N terminus) helps repel the 
two arginine residues R59 and R67 of Raf1 away from Ras structure when K3 
Affimer is used. Although, there is evidence of steric clash, as seen in the crystal 
structure of KRas: Affimer K3 M67 Ras and R67 of Raf1RBD would move away 
in solution, hence mutating these residues would not have any effect. Instead 
mutating E37Ras-R59Raf or D38Ras-R89Raf to alanine would be beneficial to 
understand how these residues play a role in Ras-Raf interaction. 
In conclusion, data presented in this chapter demonstrates that Affimer K3 
shows preferential binding to KRas as compared to HRas and no binding to 
NRas. Overall, these findings demonstrate the benefits of Affimer technology 
to identify and study the effects of different isoforms of Ras for research, 


















         Chapter 6     
Discussion and future perspectives 
 
Ras proteins are small GTPases that act as binary molecular switch and are 
involved in regulation of various cellular functions such as cell proliferation, 
differentiation, migration, and apoptosis (Karnoub and Weinberg, 2008). Ras 
proteins are frequently mutated in human cancers, with an average mutation 
incidence of 25% in all human tumours (Hobbs et al., 2016). The highest 
incidence of aberrant Ras signalling is due to single base missense mutations 
mostly occurring at codon 12, 13 and 61. These mutations impair GAP-induced 
GTP hydrolysis activity of Ras and therefore causing Ras to be in permanent 
active GTP bound state, which lead to uncontrolled cell growth (Prior et al., 
2012) (Figure 6.1).  
 
Figure 6.1 Comparison of normal, oncogenic Ras signalling and inhibition 
of oncogenic KRas with help of Affimer K3. Affimer K3 has shown to have 
dual mode of function-it inhibits SOScat (GEF) mediated nucleotide exchange 
as well as Ras-Raf interaction. Affimer K3, K6 and K37 has shown to bind to 
intracellular Ras and inhibit downstream signalling. Inset- Affimer K3 binding 
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(Figure 6.1 legend continued) between switch II and α 3 region of KRas. 
Adapted from “Vemuravenib in oncogenic BRaf signalling pathway in 
melanoma” by Biorender.com (2020).  
 
 
Direct targeting of mutant Ras has been challenging due to two main reasons- 
firstly, due to lack of deep druggable pockets to which small molecule can bind. 
Secondly, it is due to high picomolar affinity of GTP towards the nucleotide-
binding pocket making it difficult to develop effective competitive inhibitors 
(Ostrem and Shokat., 2016; Stephen et al., 2014; Dang et al., 2017). But 
recently there has been success in development of allele specific covalent 
inhibitors that selectively target KRASG12C, which is the most commonly found 
mutation present in non-small cell lung tumours (Mullard, 2019; McCormick., 
2019; Canon et al., 2019; Janes et al., 2018). The inherent reactive nature of 
cysteine present at codon 12 of KRasG12C has been leveraged to develop 
covalent small molecule inhibitors. These covalent compounds bind KRas in 
GDP bound state and blocked nucleotide exchange and KRasG12C association 
with Raf (Moore et al., 2020). Covalent inhibitors of KRasG12C have shown to 
bind exclusively to GDP bound state at the allosteric pocket behind Switch II 
(SII-P) (Ostrem and Shokat., 2016). However, resistant mutations could arise 
in KRasG12C that could influence intrinsic GTPase activity or GDP/GTP 
exchange. Recently, small molecule compound namely 2C07 has been 
discovered that bind to both nucleotide states of Ras. 2C07 compound bind to 
a new Switch II groove (SII-G) adjacent to SII-P (Lu, J. et al., 2017; Gentile et 
al., 2017). Analysis of B factors from deposited GppNHp structure of HRasG12C 
and NMR studies suggests that switch-II region is dynamic in nature and Ras 
transitions between multiple conformational states to accommodate effector 
binding and GTPase activities. Targeting both GTP and GDP bound states 
opens the possibility of inhibiting oncogenic Ras mutants which exists 
predominantly in GTP bound state (Gentile et al., 2017).  
We have used phage display technology to identify seven unique Affimer 
proteins that bind to KRas irrespective of its nucleotide state. Three of the seven 
Affimers namely K3, K6 and K37 Affimers were identified as the most potent 
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inhibitors of SOScat mediated nucleotide exchange. Affimer K3 was the most 
potent inhibitor with IC50 value of 200 nM± 6 nM compared to K6 (594±271 nM) 
and K37 (697±158 nM) when using WT KRas. Further characterization of K3 
binder revealed that K3 exhibits dual mode of inhibition i.e. it inhibits nucleotide 
exchange as well as Ras/Raf interaction (chapter3) (Figure 6.1). The critical 
residues in K3 involved in binding and inhibition of KRas were identified using 
alanine scanning mutagenesis. Crystal structure of Affimer K3 binding to KRas 
showed that K3 Affimer selects a novel Ras conformation to reveal a druggable 
pocket between SII and α3 helix (chapter 4). Recently Gentile and colleagues 
have found that for non-covalent binding to SII-P, a substituted phenolic ring is 
required for insertion within the sub pocket formed by V9, R68, D69 and M72 
(Gentile et al., 2017). Here we observed that Affimer K3 also has the aromatic 
ring of W44 extending into this sub-pocket. Aromatic ring of W44 has also 
shown to engage with His-95 residue, which may explain the specificity of K3 
for KRas as demonstrated in our pulldown (chapter 5) and cellular assays 
(Haza, K.Z et al., 2020). The SII/α-3 pocket identified by K3 shares this key sub-
pocket with the SII-P.  
Taken together these findings show that Affimers can be used to inhibit KRas 
by identifying cryptic binding pockets that are not present in the unbound 
structure. Furthermore, this also highlights the use of Affimer technology to 
select novel conformers of various target proteins to reveal druggable regions. 
6.1 Use of Affimers to inhibit KRas function 
 
In recent years, there has resurgence of research to directly target Ras, due to 
advances in drug discovery technologies such as fragment based lead 
discovery (FBLD) and disulphide-tethering technology (Sun et al., 2014). These 
technologies have helped to identify two pockets on surface of Ras that are 
amenable to drug discovery (O'Bryan., 2019). First is pocket between switch I 
and switch II of KRas (referred as SI/SII pocket) and second is SII-pocket, 
positioned above switch II loop. Researchers at Genentech (Maurer et al., 
2012), Vanderbilt University (Sun et al., 2012) and the Rabbits group (Quevedo 
et al., 2018; Cruz-Migoni et al., 2019) identified small molecules that bind to 
SI/SII pocket. SI/SII pocket has been shown to be involved in interaction with 
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GEFs, GAPs and downstream effectors. Using Affimer technology, out of seven 
unique Affimer binders, Affimer K6 was shown to bind to both active and 
inactive forms of Ras with low nanomolar affinities and inhibit SOScat mediated 
nucleotide exchange reaction (Kd=1.36±0.87 nM for GDP and Kd=7.88nM for 
GppNHp) (Haza, Katarzyna Z et al., 2020; Kessler et al., 2019). All small 
molecules which have been shown to bind to SI/SII pocket (see appendix C) 
such as DCAI, compound 13 and Abd-7 have an aromatic ring inserting into 
SI/SII pocket (Sun et al., 2012; Maurer et al., 2012).This aromatic ring has 
shown to be easily reproduced by W43 side chain of Affimer K6, thereby 
highlighting the structural similarities of SI/SII molecules with K6 
pharmacophore. Affimer K3 has also shown to inhibit SOScat mediated 
nucleotide exchange as it locks KRas in inactive conformation by stapling the 
switch regions through induced hydrogen bonding involving E37 of switch I and 
S65, A59 and G60 of switch II (chapter 4 Figure 4.8). Also, both K3 and K6 
have shown to bind to endogenous Ras and have resulted in significant 
reduction in p-ERK levels (Haza, K.Z et al., 2020). However, the degree to 
which Affimers inhibit activation of Ras by other GEFs such as Ras-GRP, GRF 
has not being studied. Nevertheless, SOScat is most widely studied GEF for Ras 
activation and logical target for exchange assays. Thus, Affimer K3 and K6 can 
be used as useful in-vitro tool to study Ras signalling.  
 
6.2 Identification of cryptic binding sites in Ras using Affimer K3  
 
Besides using Affimers to study Ras signalling, Affimer K3 has been used to 
identify cryptic binding site between SII and alpha 3 helix. These cryptic sites 
can provide druggable targets and require a ligand to form a pocket that can be 
identified in ligand bound and not in unbound structure of protein (Vajda et al., 
2018). Affimer K3 when it binds to KRas, caused a conformational shift in α-2 
SII region to reveal a novel Ras conformation with druggable SII/α-3 pocket 
(Chapter 4). This conformational shift generates a new network of 
intramolecular hydrogen bonds in KRas that has not being observed in 
unbounded WT KRas GDP or KRas GppNHp. However, The SII/α3 pocket has 
been previously being identified using cyclic peptide KRpep-2d in mutant 
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KRasG12D (Sogabe et al., 2017). But K3 engages with KRas specific residue 
namely His-95, to which KRpep-2d does not bind. Additionally, Affimer K3 
induces intramolecular hydrogen bonding between Q61 and Y96 without the 
involvement of residue 12, whereas KRpep-2d requires an Asp to induce similar 
bonding network. This specificity has been demonstrated in our pulldown 
(chapter 5) and cellular assays (Haza, K.Z et al., 2020). All these finding show 
that Affimer K3 binds to SII/α3 pocket in unique conformation different from 
peptides and small molecules. In addition to molecular dynamics, reliable 
cryptic site prediction can be improved by using highly specific binding proteins 
with small interaction surfaces (Beglov et al., 2018). Therefore, Affimers can be 
used as tools to identify cryptic binding pockets in ‘difficult to drug/undruggable’ 
protein targets. 
  
6.3 Continuation of the project and future applications  
 
Data obtained in this thesis can be expanded and improved upon in several 
ways. Firstly, Affimer K3 has shown to inhibit Ras-RBDRaf1 interaction via 
pulldown assay (Chapter 3 Fig 3.7). RBD has ubiquitin fold and is principle 
interface of interaction with GTP-Ras. But a cysteine rich domain (CRD) is 
required for full activation of Raf kinase (Okada et al., 1999). Therefore, further 
research by using live cell imaging experiments involving fluorescent proteins 
fused to the Ras binding domain and cysteine rich domain would provide an 
additional line of evidence of the effect of Affimers on regulation of Raf kinase 
activity. Techniques such as nano-bioluminescence resonance energy transfer 
(BRET) can be used to study the effect of Affimers on Ras-effectors such as 
PI3K and RalGDS. BRET is biophysical technique used to monitor proximity 
between proteins /molecules within live cells (Dale et al., 2019). The information 
will provide more insights on other signalling pathways besides MAPK pathway, 
involved in cell proliferation and differentiation. 
 
Also, both variable regions of Affimer K3 have shown binding and inhibition of 
Ras via pulldown assays (Chapter 3 Fig 3.9 and 3.10). Additional experiments 
to know the affinity of each deleted loop mutants via SPR or ITC can provide 
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additional insights on the binding of K3VR2. This is important to understand 
why L73 and K80 residues of loop2 are involved in binding (Fig 3.13). If SPR 
shows weak binding in case of K3△VR1 then this data can correlate with 
pulldown and CD studies. The effect of Affimers (K3, K6 and K37) on WT Ras 
and oncogenic Ras mutants can be further studied using electron microscopy 
(EM) spatial analysis using plasma membrane (PM) sheets to study the effect 
on PM localisation and nanoclustering. This is important since Ras proteins 
assemble into nanoclusters transiently and are sites for Ras effector 
recruitment and activation (Zhou and Hancock, 2015).  
 
Structural characterisation has shown that Affimer K3 identifies a SII/α3 pocket 
in KRas using X-ray crystallography. Since X-ray crystallography is static 
snapshot, nuclear magnetic resonance (NMR) (Schulze-Sunninghausen et al., 
2014) can provide supporting evidence to show the presence of SII/α3 pocket 
when K3 Affimer binds. Affimer K3 has shown to have preferential selectivity 
towards KRas over HRas and no binding to NRas isoform as evidenced by 
pulldown (chapter 5) and nucleotide exchange studies. Further experiments 
using BRET assay to see effect of mutating H95 residue to Q/L using Affimer 
K3 could add important information to this project.  
 
Affimer K3 derived small molecule series obtained can be further characterised 
by obtaining KRas-compound co-crystal structures. This can be followed by 
studies of these compounds on cell proliferation, apoptosis and Ras-effector 
interactions. Obtaining KRas-K3 derived compounds crystal structures could 
inform structure-based optimisation of compounds to achieve better potency or 
new series like that observed using intracellular antibodies binding to KRas. 
Additionally, the effect of these compounds on cancer cell growth and 
proliferation could provide interesting insights on how the small molecules 
function.  
 Another strategy that can be employed for continuation of this project is not 
direct inhibition of KRas, but targeted degradation of KRas through ubiquitin 
proteasome system. Sapkota and colleagues have developed an affinity 
directed protein missile system (AdPROM) for targeted degradation of 
endogenous KRas using VHL-GFP-nanobody fusion (Roth et al., 2020). Affimer 
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K3 can be used by substituting the nanobody binder in AdPROM system and 
can be used to verify degradation of endogenous KRas or HRas.  
 
6.3.1 Affimers as therapeutics   
 
Apart from their use as pharmacological research tools, Affimers being utilised 
as therapeutics themselves is a future possibility. Biologics consisting of 
monoclonal antibodies have become the fastest growing class of cancer 
therapeutics. There are currently about 30 monoclonal antibodies approved by 
FDA for treatment of cancer (Lu, R.M. et al., 2020). However, while majority of 
these monoclonal antibodies in the market have been used against extracellular 
targets, the main limitation is that due to their large size (>150 kDa), it is unable 
to cross the cell membrane (Walker et al., 2017). Thus, leaving the intracellular 
targets out of their reach (Tsomaia, 2015). Since proteins are in general not cell 
permeable, intracellular applications needs to be accomplished by novel 
delivery technologies. Several strategies already exist to overcome this 
problem, and these include use of liposome based nanocarriers, engineered 
modular transport systems and fusion of antibodies with protein transduction 
domains (Slastnikova et al., 2018). For example, DARPins have been used to 
deliver into cytoplasm through engineered modular transport system involving 
Pseudomonas exotoxin A derived mechanism for translocation (Verdurmen et 
al., 2015). Despite these advances, intracellular delivery of proteins remains a 
challenging task for any new biologic therapy. Another hurdle to overcome 
concerns the immunogenicity of biologics. Administration of biotherapeutics 
carries a risk of production of anti-drug antibodies (ADAs), which in turn could 
impact the pharmacological properties of the therapeutic or trigger adverse side 
effects (Boehncke and Brembilla, 2018). Both Type I and Type II Affimer 
scaffolds did not induce a significant immunogenic response in an industry 
standard in-vitro immune cell assay namely peripheral blood mononuclear cells 
(PBMC) assay (Avacta Life Sciences, 2017). This, therefore, indicated that 
Affimer reagents do not possess fundamental immunogenicity problems and 








Mutation in RAS genes have been found to present in 30% of all human 
cancers. Out of three RAS isoforms, KRAS is most frequently altered 
oncogene. Therapeutic strategies to target Ras mutant cancers have so far not 
being successful. A key aspect of this challenge is direct inhibition of Ras which 
has proven to be difficult leading to researchers terming Ras as ‘undruggable’ 
cancer target. In this thesis I have shown that Affimer technology has been used 
to identify binding pockets on KRas in very short timeframe, which scientific 
community has taken 30 years using traditional medicinal chemistry 
techniques.  
The key findings of this study are: 
1. Affimer K3 was shown to inhibit SOScat most potently with IC50 of 200 nM 
and inhibit Ras-RBDRaf1 interaction in-vitro.  
2. Both variable regions of Affimer K3 have shown to be involved in binding 
and inhibition of KRas.  
3. Crystal structure of Affimer K3-KRas protein complex was solved to 2.1 
Å resolution. Affimer K3 selects a novel Ras conformer to reveal a 
druggable SII/α3 pocket.  
4. Affimer K3 was shown to have preferential specificity to KRas isoform as 
it engages with His-95 residue which is present only in KRas and not in 
HRas and NRas.  
Thus, Affimer K3 can be used to provide further insights into understanding 
KRas biology which will be of interest to cancer researchers. 
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Appendix A  
Vector Maps  
 
 
Figure 1- Vector map of pBSTG phagemid vector (Tiede et., al 2014) 




















Figure 2- Vector map of pET11a Affimer containing expression vector (Tiede et. al., 










































Figure 4- Vector map of pET11a KRas8x His containing expression vector 




















Figure 5- Vector map of pET28c containing expression vector in which SOScat 6xHis 














       Appendix-B  
             Protein sequences of all proteins used in this thesis  










K3 Affimer  MASNSLEIEELARFAVDEHNKKENALLEFVRVVKAKEQHSIDIWYDFTMYYLTLEAKDGGKKK
LYEAKVWVKKLNNSHTYKNFKELQEFKPVGDAAAAHHHHHHHH 
 

























AACTTCGCGCGTAAAACCTTT TTG AAG CTG GGT ATC CAT CGT GAC 
 
Bold- Variable regions  
Yellow- His tag  









           
 Appendix C 
             Additional protein-based inhibitors binding to Ras 
                       
 KRpep-2d peptide  
 
  Fig 1. Comparison of KRpep2d peptide which binds between SII and α 3 helix 
region of KRas and Affimer K3. Affimer K3 shows different binding conformation as 





Fig 2. Comparison of Affimer K3 (green) and K6 Affimer (cyan). K3 Affimer binds 
between Switch II and α 3 helix. K6 Affimer binds between Switch I and Switch II region 
of KRas.  
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